{"gname":"The Rockefeller University","grp_id":"2","rels":[{"rel_title":"Cervicovaginal metabolites mediate the relationship between vaginal microbiota and risk for Chlamydia trachomatis infection","rel_doi":"10.64898\/2026.11.16.26368223","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.16.26368223","rel_abs":"Background: Chlamydia trachomatis (CT) remains the most prevalent bacterial sexually transmitted infection and a cause of adverse reproductive outcomes. Epidemiologic studies describe bacterial vaginosis (BV) as a major risk factor for CT infection. Emerging data suggest that BV-associated bacteria and their metabolites contribute to CT susceptibility. Here, we measured the role of specific bacteria in incident CT and evaluated a hypothesized causal role between the vaginal microbiota, its metabolites, and CT risk. Methods: We conducted a nested case-control study of Kenyan women who engage in transactional sex from the Mombasa Cohort who acquired CT versus those who did not, and compared their vaginal microbiome and metabolome at the visit preceding CT acquisition. We determined CT infection and total bacterial load using qPCRs. 16S rRNA sequencing was used to characterize the genital microbiome, and BV status was determined using Nugent-Hillier and Amsel scoring criteria. Metabolites were measured using targeted liquid chromatography-mass spectrometry from a subset of women. Findings: Women with BV, high vaginal microbial diversity, and community state types III and IV were significantly more likely to have CT at their next visit. CT infection itself did not alter vaginal microbial diversity. More specifically, both concentrations and relative abundances of Lactobacillus crispatus and several BV-associated bacteria (Sneathia sanguinegens, Umbribacter vaginalis, Prevotella amnii, Hoylesella\/Prevotella timonensis, and Ureaplasma urealyticum) were predictive of CT outcomes. Vaginal metabolites differed between cases and controls pre-CT, including Tyramine, reduced and oxidized Glutathione, and sucrose. In a mediation analysis, the vaginal metabolome significantly mediated the relationship between the microbiome and CT infection. Interpretation: We show for the first time that the association between BV and CT risk is mediated by differences in the metabolome. Identification of the mechanisms underlying increased CT risk with BV can inform interventions to reduce infections in high-risk women. Funding: US NIH (R01AI13214401-A1)","rel_num_authors":14,"rel_authors":[{"author_name":"Smritee Dabee","author_inst":"Seattle Childrens Research Institute, Seattle, WA, USA"},{"author_name":"Mor Tsamir-Rimon","author_inst":"Department of Human Genetics and Computational Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"author_name":"Omolara Akingba","author_inst":"Department of Global Health, University of Washington, Seattle, WA, USA"},{"author_name":"John Kinuthia","author_inst":"Department of Research and Programs, Kenyatta National Hospital, Nairobi, Kenya"},{"author_name":"James W MacDonald","author_inst":"Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA"},{"author_name":"Theo K Bammler","author_inst":"Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA"},{"author_name":"Daniel Raftery","author_inst":"Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, USA"},{"author_name":"Kevin Hybiske","author_inst":"Department of Global Health, University of Washington, Seattle, WA, USA"},{"author_name":"Ken Tapia","author_inst":"Department of Epidemiology, University of Washington, Seattle, WA, USA"},{"author_name":"Walter Jaoko","author_inst":"Department of Medical Microbiology and Immunology, University of Nairobi, Nairobi, Kenya"},{"author_name":"Elhanan Borenstein","author_inst":"Department of Human Genetics and Computational Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"author_name":"Jennifer E Balkus","author_inst":"Department of Epidemiology, University of Washington, Seattle, WA, USA"},{"author_name":"R. Scott McClelland","author_inst":"Department of Global Health, University of Washington, Seattle, WA, USA"},{"author_name":"Heather B Jaspan","author_inst":"Seattle Childrens Research Institute, Seattle, WA, USA"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"The genetic architecture of wisdom and its relationship with health, personality, and cognition","rel_doi":"10.64898\/2026.11.10.26367758","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.10.26367758","rel_abs":"Wisdom is a personality trait composed of self-reflection, pro-social behaviors, emotional regulation, acceptance of divergent perspectives, decisiveness, social advising, and spirituality. Greater levels of wisdom are linked to better overall health, well-being, happiness, life satisfaction, and resilience. However, the underlying genetic architecture of wisdom remains unexplored. We assessed wisdom using responses to the SD-WISE-7 in 153,384 23andMe research-consented participants and conducted a multi-ancestry GWAS. We identified one genome-wide significant locus (rs2325631, p=1.41E-08) near MANEA on chromosome 6. Wisdom was heritable (h2SNP=0.03{+\/-}4.50E-03) and genetically correlated with numerous traits, including greater subjective well-being, openness, and risk tolerance, and lower neuroticism and loneliness. Crucially, wisdom was genetically distinct from intelligence and the cognitive component of educational attainment. Wisdom polygenic scores were associated with psychosocial outcomes, but not cognitive performance in All of Us. This study advances our understanding of wisdom as a heritable trait that could guide interventions to improve human health.","rel_num_authors":13,"rel_authors":[{"author_name":"Fabrizio Malatesta","author_inst":"Department of Psychiatry, University of California San Diego, La Jolla, CA, USA"},{"author_name":"Hayley Thorpe","author_inst":"Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada"},{"author_name":"Jean Gonzalez","author_inst":"Department of Psychiatry, University of California San Diego, La Jolla, CA, USA"},{"author_name":"John J Meredith","author_inst":"Department of Psychiatry, University of California San Diego, La Jolla, CA, USA"},{"author_name":"Laura Vilar-Rib\u00f3","author_inst":"Department of Psychiatry, University of California San Diego, La Jolla, CA, USA"},{"author_name":"Natasia Courchesne-Krak","author_inst":"Department of Psychiatry, University of California San Diego, La Jolla, CA, USA"},{"author_name":"Daniel Gustavson","author_inst":"Institute for Behavioral Genetics; Department of Psychology and Neuroscience, University of Colorado Boulder, CO, USA"},{"author_name":"- 23andMe Research Team","author_inst":"-"},{"author_name":"Vinh Tran","author_inst":"23andMe Research Institute, Palo Alto, CA, USA"},{"author_name":"Shubham Saini","author_inst":"23andMe Research Institute, Palo Alto, CA, USA"},{"author_name":"Emily M. Rios","author_inst":"23andMe Research Institute, Palo Alto, CA, USA"},{"author_name":"Abraham Palmer","author_inst":"Department of Psychiatry; Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA"},{"author_name":"Sandra Sanchez-Roige","author_inst":"Department of Psychiatry; Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Evaluation of System One Models on Biomedical Texts","rel_doi":"10.64898\/2026.11.15.26368126","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.15.26368126","rel_abs":"Objective To compare the performance and cost of System One models (SOMs) with general-purpose large language models (LLMs) on biomedical tasks and evaluate confidence-based routing. Materials and Methods We evaluated three SOMs and three LLMs across seven datasets and eight endpoints covering question answering, error detection, structured extraction, and clinical-note assessment. Outcomes included task-specific performance, recorded inference cost and latency, and confidence calibration. Calibration data determined routing schemes and confidence thresholds to evaluate test predictions, with cost-matched random referral as a comparator. Results Claude Opus 5.5 had the highest primary performance on all eight endpoints. The strongest SOM, Jev, had competitive performance with the evaluated LLMs and cost less than 1% of Opus on most datasets. Three selected SOM-to-LLM routes reduced costs by 30.0%-71.7% relative to the receiving LLM, with modest reductions in performance. On one benchmark, SOM-to-SOM routing achieved 91.1% accuracy, compared with 82.3% and 82.2% for the individual models. Discussion SOMs offered favorable performance-cost tradeoffs for most tasks. The magnitude of the advantages depended on task structure and prompting requirements. Confidence-based routing between SOMs and LLMs can leverage complementary model strengths and offers additional flexibility in performance-cost tradeoffs. The price advantages offered by SOMs can facilitate experimentation and development of workflows. This warrants further evaluation on closed datasets. Conclusion For biomedical tasks with predefined choices, SOMs represent a competitive stand-alone or first-stage approach.","rel_num_authors":6,"rel_authors":[{"author_name":"Anthony F Chen","author_inst":"Stanford"},{"author_name":"Albert Yang","author_inst":"Georgia Institute of Technology"},{"author_name":"Daniel R Guth","author_inst":"Stanford University"},{"author_name":"Frederic M Berl","author_inst":"Helarctos"},{"author_name":"Stephen C Guth","author_inst":"UC Law San Francisco"},{"author_name":"William Yuan","author_inst":"NYU Grossman School of Medicine"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Data-driven modeling of trigeminal nerve shape reveals pain-associated morphology in trigeminal neuralgia","rel_doi":"10.64898\/2026.11.11.26367487","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.11.26367487","rel_abs":"Although the leading theory for the cause of trigeminal neuralgia (TN) is neurovascular compression, compression alone does not fully explain which nerves are painful. Recent work has demonstrated that pain in TN is associated with morphological changes of the trigeminal nerve, which may be a result of specific forms of compression or other disease processes. These changes have so far been quantified by hand-crafted geometric measurements, which can miss higher-order characteristics of the anatomy that are difficult to visualize. In this study, we use a cohort of 479 patients with TN who underwent microvascular decompression and had high-resolution pre-operative MRI scans to determine whether data-driven 3D shape features of the trigeminal nerve capture pain-associated morphology better than predefined metrics. We find that a predictive model using our shape features can distinguish nerves implicated in pain from those without pain in a held-out test cohort with an area under the receiver operating characteristic curve (AUROC) of 0.719, compared with 0.626 for a model using existing hand-crafted measurements (p=0.005). Our study identifies candidate nerve morphology biomarkers of TN pain through data-driven shape analysis and demonstrates that these higher-order features relate better to symptoms of TN than conventional shape metrics.","rel_num_authors":10,"rel_authors":[{"author_name":"Michael E. Xie","author_inst":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD"},{"author_name":"Haoyuan Liang","author_inst":"Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD"},{"author_name":"Xihang Wang","author_inst":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD"},{"author_name":"Vivek Yedavalli","author_inst":"Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD"},{"author_name":"Christopher Jackson","author_inst":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD"},{"author_name":"Michael Lim","author_inst":"Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA"},{"author_name":"Judy Huang","author_inst":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD"},{"author_name":"Chetan Bettegowda","author_inst":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD"},{"author_name":"Peirong Liu","author_inst":"Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD"},{"author_name":"Risheng Xu","author_inst":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Safety of Bio-Interventional Uveoscleral Outflow Enhancement: Twelve-Month Post-Operative Results from 395 Eyes in the CREST Study","rel_doi":"10.64898\/2026.11.12.26367928","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.12.26367928","rel_abs":"PurposeTo characterize 12-month ocular safety of bio-interventional uveoscleral outflow enhancement in open-angle glaucoma (OAG).\n\nDesignProspective, multicenter real-world evidence study (CREST; NCT05506423).\n\nParticipantsAdults with OAG treated by bio-interventional uveoscleral outflow enhancement with acellular scleral allograft spacers (AlloFlo, Iantrek, Inc.), standalone or with phacoemulsification, reaching 12 months of follow-up.\n\nMethodsAdverse events were captured prospectively at each protocol-specified visit against pre-defined definitions; data were analyzed at the eye level.\n\nMain Outcome MeasuresPre-specified ocular safety endpoints: adverse events, clinically significant hypotony, sustained intraocular pressure (IOP) elevation [&ge;] 10 mmHg beyond 30 days, allograft migration, corneal endothelial decompensation, secondary incisional glaucoma surgery, and endothelial cell density.\n\nResultsOf 395 eyes (mean age 72.8 years; 52% female), 267 were combined with phacoemulsification (Cohort 1) and 128 standalone (Cohort 2). Medicated IOP decreased from 19.1 to 14.5 mmHg (p < 0.001) and medications from 1.9 to 1.2, with 42% medication-free. Sustained IOP elevation occurred in 34 eyes (8.6%), BCVA loss [&ge;] 2 lines in 15 (3.8%), hyphema > 2 mm in 6 (1.5%) and hypotony in 1 (0.3%). Two allograft spacers entered the anterior chamber in one eye and were successfully repositioned intraoperatively. Serious events occurred in 12 eyes (3.0%). In the N=91 eyes with paired specular microscopy data, endothelial cell density changed -6.5% (-8.7%, -4.4%). There were no reports of endothelial decompensation, endophthalmitis, or sympathetic ophthalmia.\n\nConclusionsThrough 12 months no endothelial decompensation, endophthalmitis or sympathetic ophthalmia occurred, and most events were self-limiting or medically managed. Endothelial cell loss tracked concurrent cataract surgery rather than the allograft, though that subgroup is small. Follow-up remains shorter than the interval over which an earlier supraciliary microstent diverged from controls.\n\nTrial RegistrationClinicalTrials.gov (NCT05506423.)","rel_num_authors":6,"rel_authors":[{"author_name":"Douglas Rhee","author_inst":"Case Western Reserve University School of Medicine"},{"author_name":"James Lewis","author_inst":"SightMd"},{"author_name":"Ticiana De Francesco","author_inst":"University of Utah John A. Moran Eye Center"},{"author_name":"Kiper Nelson","author_inst":"Southern Eye Center"},{"author_name":"Tsontcho Ianchulev","author_inst":"New York Eye and Ear of Mount Sinai"},{"author_name":"Steven R. Sarkisian Jr.","author_inst":"Oklahoma Eye Surgeons"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"CONSORTiUM-IO: A Phase 1 Study Evaluating VE800 Plus Nivolumab in Treatment of Select Refractory or Metastatic Cancers","rel_doi":"10.64898\/2026.11.13.26368051","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368051","rel_abs":"Microbiome modulation can augment responses to immunotherapy in advanced cancer. Early studies of anti-PD-1 therapies in combination with fecal microbiota transplantation (FMT) reported efficacy in immunotherapy-naive and -refractory settings. However, FMTs are variable in composition, difficult to scale, and risk the transfer of emerging pathogens. VE800 is a consortium of 11 strains of commensal bacteria derived from healthy donors and grown from clonal cell banks. VE800 increased anti-PD-1 efficacy in preclinical models of cancer. CONSORTiUM-IO was a first-in-human, open-label phase 1 study that evaluated safety and efficacy of VE800 with nivolumab in advanced PD-1-refractory melanoma, PD-1-naive gastric\/gastroesophageal junction (G\/GEJ) adenocarcinoma and PD-1-naive microsatellite-stable colorectal cancer (MSS CRC). VE800 plus nivolumab was well tolerated but offered no improvement over historic response rates. Exploratory analyses in patients with melanoma revealed that VE800 strain engraftment was associated with greater progression-free survival (PFS) and increased immune activation peripherally.","rel_num_authors":17,"rel_authors":[{"author_name":"Carolina Lyon De Ana","author_inst":"Glaxo Smith Klein"},{"author_name":"Rajita Menon","author_inst":"Vedanta Biosciences, Inc., Cambridge, MA, USA"},{"author_name":"Shakti K. Bhattarai","author_inst":"Program in Microbiome Dynamics, Department of Microbiology, University of Massachusetts Chan Medical School, Worcester, MA"},{"author_name":"Amanda L Prince","author_inst":"CSL Behring, Waltham, MA"},{"author_name":"Scott Buresh","author_inst":"Tokyo Chemical Industry, Portland, OR"},{"author_name":"Erica Darrah","author_inst":"Veeva Systems, Boston, MA"},{"author_name":"Jason M Norman","author_inst":"Vedanta Biosciences, Inc., Cambridge, MA, USA"},{"author_name":"Rose L Szabady","author_inst":"Ferring Pharmaceuticals, Parsippany, NJ"},{"author_name":"Dmitri Bobilev","author_inst":"Vedanta Biosciences, Inc., Cambridge, MA, USA"},{"author_name":"Bruce Roberts","author_inst":"Vedanta Biosciences, Inc., Cambridge, MA, USA"},{"author_name":"Judy S Wang","author_inst":"Florida Cancer Specialists\/Sarah Cannon Research Institute, Sarasota, FL"},{"author_name":"Vanni Bucci","author_inst":"UMass Medical School"},{"author_name":"Jeremiah J Faith","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Jeffrey L Silber","author_inst":"Vedanta Biosciences, Inc., Cambridge, MA, USA"},{"author_name":"Kenya Honda","author_inst":"RIKEN Center for Integrative Medical Sciences, Yokohama, Japan"},{"author_name":"Bernat Olle","author_inst":"Vedanta Biosciences, Inc., Cambridge, MA, USA"},{"author_name":"Diwakar Davar","author_inst":"UPMC Hillman Cancer Center, Pittsburgh, PA"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Hierarchical Graph Learning with Multimodal Distillation for Breast Cancer Survival Prediction","rel_doi":"10.64898\/2026.11.14.26368121","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368121","rel_abs":"Imaging mass cytometry (IMC) and DNA methylation can provide complementary information for breast cancer prognosis, yet these measurements may be unavailable for new patients. In this paper, we propose HEAL-Surv, a teacher-student framework that uses both modalities during training to predict five-year net disease-specific survival (DSS) from clinical variables and molecular profiles at inference. An additive Cox teacher integrates all four modalities, using a hierarchical IMC graph encoder to capture local cell relationships and coarser tissue organisation. The student learns from observed outcomes and cross-fitted teacher survival curves, giving more weight to targets that agree across random initialisations. In five-fold cross-validation on 423 METABRIC patients, the full teacher achieved a mean five-year Uno's concordance of 0.723. Removing any modality reduced mean concordance and increased mean Brier-based errors. Relative to the matched student trained on observed outcomes alone, distillation increased mean five-year Uno's concordance from 0.658 to 0.704, with higher integrated and five-year Brier scores. In a separate external evaluation, an IMC-clinical variant trained on METABRIC achieved a five-year Uno's concordance of 0.660 on 265 Basel patients without refitting. These findings support multimodal supervision for improving risk discrimination with fewer inference inputs, while external validation of the student remains necessary.","rel_num_authors":6,"rel_authors":[{"author_name":"Binh Minh Tran","author_inst":"The University of Sydney"},{"author_name":"Van An Nguyen","author_inst":"Hanoi Medical University"},{"author_name":"Quynh Anh Dang","author_inst":"Hanoi Medical University"},{"author_name":"Minh Hai Nguyen Ngoc","author_inst":"Hanoi Medical University Hospital"},{"author_name":"Hai Nam Tran","author_inst":"University of New South Wales"},{"author_name":"Dang Hung Tran","author_inst":"Hanoi University of Industry"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Hierarchical Graph Learning with Multimodal Distillation for Breast Cancer Survival Prediction","rel_doi":"10.64898\/2026.11.14.26368121","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368121","rel_abs":"Imaging mass cytometry (IMC) and DNA methylation can provide complementary information for breast cancer prognosis, yet these measurements may be unavailable for new patients. In this paper, we propose HEAL-Surv, a teacher-student framework that uses both modalities during training to predict five-year net disease-specific survival (DSS) from clinical variables and molecular profiles at inference. An additive Cox teacher integrates all four modalities, using a hierarchical IMC graph encoder to capture local cell relationships and coarser tissue organisation. The student learns from observed outcomes and cross-fitted teacher survival curves, giving more weight to targets that agree across random initialisations. In five-fold cross-validation on 423 METABRIC patients, the full teacher achieved a mean five-year Uno's concordance of 0.723. Removing any modality reduced mean concordance and increased mean Brier-based errors. Relative to the matched student trained on observed outcomes alone, distillation increased mean five-year Uno's concordance from 0.658 to 0.704, with higher integrated and five-year Brier scores. In a separate external evaluation, an IMC-clinical variant trained on METABRIC achieved a five-year Uno's concordance of 0.660 on 265 Basel patients without refitting. These findings support multimodal supervision for improving risk discrimination with fewer inference inputs, while external validation of the student remains necessary.","rel_num_authors":6,"rel_authors":[{"author_name":"Binh Minh Tran","author_inst":"The University of Sydney"},{"author_name":"Van An Nguyen","author_inst":"Hanoi Medical University"},{"author_name":"Quynh Anh Dang","author_inst":"Hanoi Medical University"},{"author_name":"Minh Hai Nguyen Ngoc","author_inst":"Hanoi Medical University Hospital"},{"author_name":"Hai Nam Tran","author_inst":"University of New South Wales"},{"author_name":"Dang Hung Tran","author_inst":"Hanoi University of Industry"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Deep learning of point-of-care lung ultrasound and clinical data for pulmonary tuberculosis triage in Uganda","rel_doi":"10.64898\/2026.11.14.26368125","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368125","rel_abs":"Rationale: Point of care lung ultrasound is portable and radiation free and could extend tuberculosis screening to settings without chest radiography, but no standardized criteria exist for interpreting it for tuberculosis. Objectives: To develop and internally evaluate deep learning models that classify pulmonary tuberculosis from lung ultrasound images, alone and combined with routine clinical variables, and to derive an abbreviated scanning protocol. Methods: In a prospective study in Kampala, Uganda (2023 to 2025), we enrolled people aged 13 years or older with microbiologically confirmed pulmonary tuberculosis, their household contacts, and symptomatic people with other respiratory conditions. One still frame from each of 12 lung ultrasound zones was analyzed with an attention-based multiple-instance learning network. We compared clinical-only (random forest), ultrasound only, and combined models and derived a 6 zone protocol from training set attention weights. Participants were allocated to training (n = 223), validation (n = 20), and held-out test (n = 73) sets. Results: Of 318 enrolled participants, 316 were analyzed (118 with and 198 without tuberculosis). In the test set, areas under the receiver operating characteristic curve were 0.88 (95% confidence interval, 0.80 to 0.95) for the clinical-only model; 0.93 (0.86 to 0.97) and 0.95 (0.89 to 0.99) for the 12 zone ultrasound-only and combined models; and 0.91 (0.83 to 0.97) and 0.93 (0.86 to 0.99) for the corresponding 6-zone models. At 90% sensitivity, specificity was 82.2% (34.9 to 97.8) for the 12-zone combined model and 91.1% (25.0 to 98.0) for the 6-zone combined model. Point estimates for all 12-zone models and the 6-zone combined model met the 2025 World Health Organization minimum accuracy targets for a high-sensitivity screening test ([&ge;]90% sensitivity, [&ge;]60% specificity). Conclusion: Lung ultrasound analyzed with attention-based deep learning and combined with clinical variables showed high internal discrimination for pulmonary tuberculosis, and a simplified 6-zone protocol retained most of this performance. External validation in intended-use screening populations is needed","rel_num_authors":13,"rel_authors":[{"author_name":"Akanksha Sharma","author_inst":"Emory University"},{"author_name":"Lydia Nakiyingi","author_inst":"Makerere University Infectious Diseases Institute"},{"author_name":"Elena Jovanovska Janeva","author_inst":"Rutgers university"},{"author_name":"Keith Guevarra","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Wycliff Nate","author_inst":"Makerere University, Infectious Diseases Institute, Kampala, Uganda"},{"author_name":"Eva Nabawanuka","author_inst":"Mulago National Referral Hospital, Department of Radiology, Kampala, Uganda"},{"author_name":"Raphael Shankman","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Rohan Dhamdhere","author_inst":"Georgia Institute of Technology and Emory University"},{"author_name":"Guadalupe Astorga","author_inst":"Rutgers New Jersey Medical School,"},{"author_name":"Moses  Lutaakome Joloba","author_inst":"MakCHS: Makerere University College of Health Sciences"},{"author_name":"Jerrold Ellner","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Anant Madabhushi","author_inst":"Emory University"},{"author_name":"Yingda Linda Xie","author_inst":"Rutgers New Jersey Medical School"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Deep learning of point-of-care lung ultrasound and clinical data for pulmonary tuberculosis triage in Uganda","rel_doi":"10.64898\/2026.11.14.26368125","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368125","rel_abs":"Rationale: Point of care lung ultrasound is portable and radiation free and could extend tuberculosis screening to settings without chest radiography, but no standardized criteria exist for interpreting it for tuberculosis. Objectives: To develop and internally evaluate deep learning models that classify pulmonary tuberculosis from lung ultrasound images, alone and combined with routine clinical variables, and to derive an abbreviated scanning protocol. Methods: In a prospective study in Kampala, Uganda (2023 to 2025), we enrolled people aged 13 years or older with microbiologically confirmed pulmonary tuberculosis, their household contacts, and symptomatic people with other respiratory conditions. One still frame from each of 12 lung ultrasound zones was analyzed with an attention-based multiple-instance learning network. We compared clinical-only (random forest), ultrasound only, and combined models and derived a 6 zone protocol from training set attention weights. Participants were allocated to training (n = 223), validation (n = 20), and held-out test (n = 73) sets. Results: Of 318 enrolled participants, 316 were analyzed (118 with and 198 without tuberculosis). In the test set, areas under the receiver operating characteristic curve were 0.88 (95% confidence interval, 0.80 to 0.95) for the clinical-only model; 0.93 (0.86 to 0.97) and 0.95 (0.89 to 0.99) for the 12 zone ultrasound-only and combined models; and 0.91 (0.83 to 0.97) and 0.93 (0.86 to 0.99) for the corresponding 6-zone models. At 90% sensitivity, specificity was 82.2% (34.9 to 97.8) for the 12-zone combined model and 91.1% (25.0 to 98.0) for the 6-zone combined model. Point estimates for all 12-zone models and the 6-zone combined model met the 2025 World Health Organization minimum accuracy targets for a high-sensitivity screening test ([&ge;]90% sensitivity, [&ge;]60% specificity). Conclusion: Lung ultrasound analyzed with attention-based deep learning and combined with clinical variables showed high internal discrimination for pulmonary tuberculosis, and a simplified 6-zone protocol retained most of this performance. External validation in intended-use screening populations is needed","rel_num_authors":13,"rel_authors":[{"author_name":"Akanksha Sharma","author_inst":"Emory University"},{"author_name":"Lydia Nakiyingi","author_inst":"Makerere University Infectious Diseases Institute"},{"author_name":"Elena Jovanovska Janeva","author_inst":"Rutgers university"},{"author_name":"Keith Guevarra","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Wycliff Nate","author_inst":"Makerere University, Infectious Diseases Institute, Kampala, Uganda"},{"author_name":"Eva Nabawanuka","author_inst":"Mulago National Referral Hospital, Department of Radiology, Kampala, Uganda"},{"author_name":"Raphael Shankman","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Rohan Dhamdhere","author_inst":"Georgia Institute of Technology and Emory University"},{"author_name":"Guadalupe Astorga","author_inst":"Rutgers New Jersey Medical School,"},{"author_name":"Moses  Lutaakome Joloba","author_inst":"MakCHS: Makerere University College of Health Sciences"},{"author_name":"Jerrold Ellner","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Anant Madabhushi","author_inst":"Emory University"},{"author_name":"Yingda Linda Xie","author_inst":"Rutgers New Jersey Medical School"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Deep learning of point-of-care lung ultrasound and clinical data for pulmonary tuberculosis triage in Uganda","rel_doi":"10.64898\/2026.11.14.26368125","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368125","rel_abs":"Rationale: Point of care lung ultrasound is portable and radiation free and could extend tuberculosis screening to settings without chest radiography, but no standardized criteria exist for interpreting it for tuberculosis. Objectives: To develop and internally evaluate deep learning models that classify pulmonary tuberculosis from lung ultrasound images, alone and combined with routine clinical variables, and to derive an abbreviated scanning protocol. Methods: In a prospective study in Kampala, Uganda (2023 to 2025), we enrolled people aged 13 years or older with microbiologically confirmed pulmonary tuberculosis, their household contacts, and symptomatic people with other respiratory conditions. One still frame from each of 12 lung ultrasound zones was analyzed with an attention-based multiple-instance learning network. We compared clinical-only (random forest), ultrasound only, and combined models and derived a 6 zone protocol from training set attention weights. Participants were allocated to training (n = 223), validation (n = 20), and held-out test (n = 73) sets. Results: Of 318 enrolled participants, 316 were analyzed (118 with and 198 without tuberculosis). In the test set, areas under the receiver operating characteristic curve were 0.88 (95% confidence interval, 0.80 to 0.95) for the clinical-only model; 0.93 (0.86 to 0.97) and 0.95 (0.89 to 0.99) for the 12 zone ultrasound-only and combined models; and 0.91 (0.83 to 0.97) and 0.93 (0.86 to 0.99) for the corresponding 6-zone models. At 90% sensitivity, specificity was 82.2% (34.9 to 97.8) for the 12-zone combined model and 91.1% (25.0 to 98.0) for the 6-zone combined model. Point estimates for all 12-zone models and the 6-zone combined model met the 2025 World Health Organization minimum accuracy targets for a high-sensitivity screening test ([&ge;]90% sensitivity, [&ge;]60% specificity). Conclusion: Lung ultrasound analyzed with attention-based deep learning and combined with clinical variables showed high internal discrimination for pulmonary tuberculosis, and a simplified 6-zone protocol retained most of this performance. External validation in intended-use screening populations is needed","rel_num_authors":13,"rel_authors":[{"author_name":"Akanksha Sharma","author_inst":"Emory University"},{"author_name":"Lydia Nakiyingi","author_inst":"Makerere University Infectious Diseases Institute"},{"author_name":"Elena Jovanovska Janeva","author_inst":"Rutgers university"},{"author_name":"Keith Guevarra","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Wycliff Nate","author_inst":"Makerere University, Infectious Diseases Institute, Kampala, Uganda"},{"author_name":"Eva Nabawanuka","author_inst":"Mulago National Referral Hospital, Department of Radiology, Kampala, Uganda"},{"author_name":"Raphael Shankman","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Rohan Dhamdhere","author_inst":"Georgia Institute of Technology and Emory University"},{"author_name":"Guadalupe Astorga","author_inst":"Rutgers New Jersey Medical School,"},{"author_name":"Moses  Lutaakome Joloba","author_inst":"MakCHS: Makerere University College of Health Sciences"},{"author_name":"Jerrold Ellner","author_inst":"Rutgers New Jersey Medical School"},{"author_name":"Anant Madabhushi","author_inst":"Emory University"},{"author_name":"Yingda Linda Xie","author_inst":"Rutgers New Jersey Medical School"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Practical evaluation of AI models to forecast a respiratory seasonal epidemic in Canada","rel_doi":"10.64898\/2026.11.14.26368122","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368122","rel_abs":"Public health organizations can benefit greatly from infectious disease epidemic forecasting to guide and support interventions and policies that reduce morbidity. However, accurate and reliable epidemic forecasting remains notoriously challenging and is an evolving field in which new scientific advances continue to support forecasting efforts. Computational models that underpin artificial intelligence (AI) models are promising developments that may improve seasonal epidemic forecasting. This study aims to compare the performance of a selection of AI models previously identified as well adapted to epidemic forecasting, including machine learning (XGBoost), deep learning models (Long Short-Term Memory (LSTM), Gated Recurrent Unit (GRU), Transformer), time-series foundation model (Chronos), and a hybrid model: physics-informed neural networks (PINNs), against statistical models (Autoregressive Integrated Moving Average (ARIMA), Prophet) and a compartmental epidemiological model (CEM) in seasonal epidemic forecasting across Canada. The study uses weekly positivity-rate incidence of seasonal influenza A across eight Canadian provinces during the 2025\/2026 season as a test case. Each model generated short-term (up to 5 weeks ahead) forecasts independently for each province from October 11, 2025, to March 28, 2026. We evaluated performance using mean absolute error (MAE) for each province. Our results show that AI models, specifically GRU, Transformer, and Chronos models, achieve lower MAE than CEM in four of eight provinces (Alberta, British Columbia, Prince Edward Island, and Saskatchewan). Meanwhile, CEM and ARIMA outperform all AI models in three provinces (Ontario, Quebec, Manitoba) and one province (Nova Scotia), respectively. Furthermore, data pooling strategies that leverage multi-province data for the target virus or multi-virus data within individual provinces greatly improve deep learning models, and Chronos performs well under zero-shot forecasting in British Columbia. In contrast, Prophet always has the highest MAE, and PINN is worse than CEMs. Overall, AI models performed comparably to, or slightly better than, CEMs. However, these modest gains may not offset their lack of interpretability, high computational costs, and reliance on the specialized expertise required for implementation. We therefore conclude that AI models are best as a complement, rather than a replacement, to CEMs, which remain crucial for interpretability and informing decision-making.","rel_num_authors":4,"rel_authors":[{"author_name":"Benjamin Longaou Benteke","author_inst":"University of Guelph"},{"author_name":"Warsame Yusuf","author_inst":"Public Health Agency of Canada"},{"author_name":"Monica Gabriela Cojocaru","author_inst":"University of Guelph"},{"author_name":"David Champredon","author_inst":"Public Health Agency of Canada"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Changes in Resting-State Functional Network Specialization in Progressive Supranuclear Palsy","rel_doi":"10.64898\/2026.11.14.26367857","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26367857","rel_abs":"Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy characterized by heterogeneous clinical presentations and disruption of distributed neural networks. Resting-state functional MRI (rs-fMRI) provides a systems-level approach to examine intrinsic brain connectivity and may offer insights into disease-related network dysfunction. In this study, we compared rs-fMRI connectivity measures between individuals with PSP and healthy controls and explored differences across PSP clinical variants. 23 participants with probable or possible PSP and 23 age- and sex-matched healthy controls underwent structural and functional MRI. Graph theory metrics and functional connectivity measures across seven canonical resting-state networks were analyzed. Clinical severity was assessed using the PSP Rating Scale (PSPRS) and cognitive measures including the Montreal Cognitive Assessment (MoCA) and frontal assessment battery (FAB). Compared with controls, participants with PSP demonstrated significantly reduced global network modularity and segregation, indicating decreased functional network specialization. Functional connectivity was significantly reduced in multiple large-scale networks, including frontoparietal control, default mode, dorsal attention, somatomotor, and visual networks. No significant differences in graph theory metrics or network connectivity were observed between PSP clinical variants. These findings suggest that PSP is associated with widespread disruption of intrinsic functional networks, reflected by reduced modular organization and network segregation across several canonical resting-state systems while preserving local nodal clustering and global efficiency. Network-level alterations appear broadly similar across clinical variants, supporting the concept that PSP represents a distributed network disorder.","rel_num_authors":5,"rel_authors":[{"author_name":"Juan Vazquez","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Anja Soldan","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Marilyn Albert","author_inst":"Johns Hopkins University"},{"author_name":"Hanzhang Lu","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Alexander Pantelyat","author_inst":"Johns Hopkins University School of Medicine"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"White Matter Pathway-Specific Effects of Subthalamic Deep Brain Stimulation on Vergence Motor Strategy and Binocular Stability","rel_doi":"10.64898\/2026.11.14.26368127","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368127","rel_abs":"Objective: Clear vision across viewing distances requires the eyes to achieve binocular alignment and hold it steady. Alignment can be established through smooth dysconjugate eye movement, vergence, alone or in conjunction with rapid saccades. The circuits governing movement strategy and subsequent gaze holding remain less understood. Methods: We used subthalamic nucleus (STN) deep brain stimulation (DBS) to probe these components in 23 participants with Parkinson disease (PD), comparing binocular eye movements with stimulation on and off and relating behavioral changes to modeled stimulation anatomy. Results: Combined saccade vergence responses predominated in both stimulation states, but individual strategy changes were associated with stimulation location. Greater field of Forel coverage was associated with reduced saccade assisted divergence, and stimulation anatomy helped predict individual changes in this movement strategy. Greater right associative STN coverage correlated with shorter convergence latency. The clearest group effect emerged after movement ended; DBS reduced gaze-holding variance by 37.0% after convergence and 29.4% after divergence, an overall reduction of 33.3% (95% confidence interval, 13.7 to 49.3%; p=0.008). Participants with improved gaze holding had numerically greater modeled exposure to Forel and cerebellothalamic pathways. Conclusions: These findings suggest distinct contributions of associative STN to initiation, consistent with go\/no-go control, and Forel pathways to movement strategy. Improved gaze holding raises the novel possibility that stimulation engaging Forel and cerebellar outflow pathways enhances vergence neural integration. Significance: Binocular eye movements reveal how basal ganglia and cerebellar pathways establish movement strategy and sustain alignment, guiding targeted stimulation studies in PD.","rel_num_authors":5,"rel_authors":[{"author_name":"Ibrahim Quagraine","author_inst":"Case Western Reserve Univerity"},{"author_name":"Aratrik Guha","author_inst":"Case Western Reserve University University"},{"author_name":"Camilla Kilbane","author_inst":"Case Western Reserve University"},{"author_name":"Fatema F Ghasia","author_inst":"Cleveland Clinic"},{"author_name":"Aasef G Shaikh","author_inst":"Case Western Reserve University"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Sex and Gender Reporting and Female Participation Relative to Disease Burden in ClinicalTrials.gov","rel_doi":"10.64898\/2026.11.14.26368113","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368113","rel_abs":"Importance: Assessing representation by sex assigned at birth and gender identity requires reporting of both in trials. If disclosure of full gender and sex participation from clinicaltrials.gov is limited, it poses challenges in characterization and understanding of those participant experiences. Objective: To determine how often ClinicalTrials.gov trials published trials report sex and gender, which characteristics are associated with reporting, and how participants' female share compares with that of the general public. Design, Setting, and Participants: Cross-sectional study of interventional trials registered to ClinicalTrials.gov, with or without US sites, with primary completion on or after September 27, 2008, and results first posted from January 1, 2009, through April 30, 2026. Exposures: Funder type, phase, US sites, enrollment, primary completion year, number of countries, and therapeutic area. Main Outcomes and Measures: Reporting of sex and gender, and the female participation-to-prevalence ratio (PPR; trial female share divided by the number of people with the condition). Results: Among 58,007 trials (median enrollment, 72 [IQR, 31 to 206]; 42,644 [74%] with US sites), 553 (0.95%) reported gender and 57,683 (99.44%) reported sex. Gender reporting was more common with National Institutes of Health (NIH) funding (odds ratio [OR], 9.05; 95% CI, 6.65 to 12.6), US sites (OR, 4.21; 95% CI, 2.96 to 6.22), and larger enrollment. Across 10 conditions (15,552 mixed-sex trials), median PPR ranged from 0.68 (95% CI, 0.64 to 0.71) for chronic obstructive pulmonary disease to 1.05 (95% CI, 1.01 to 1.09) for obesity and had a relatively lower female share in 8. Among the 10 conditions most prevalent in our cohort, 6,917 of 16,097 trial condition combinations (43.0%) reached a PPR of at least 0.90; odds of reaching it were higher for NIH-funded (OR, 1.22; 95% CI, 1.11 to 1.34) and lower for government-funded trials (OR, 0.26; 95% CI, 0.20 to 0.33) as compared to industry-funded trials. Conclusions and Relevance: In ClinicalTrials.gov, sex reporting is nearly universal, whereas gender reporting is concentrated among NIH-funded, US-based, and larger trials. Female trial enrollment fell below the female share of people with the condition for most conditions, emphasizing the benefit of condition-specific benchmarks in clinical trials.","rel_num_authors":9,"rel_authors":[{"author_name":"Michael D. Green","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Maryam Aziz","author_inst":"Duke University School of Medicine"},{"author_name":"Rebecca D. Sullenger","author_inst":"Duke University School of Medicine"},{"author_name":"Brandon J. Yoo","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Emily C. O'Brien","author_inst":"Duke University School of Medicine"},{"author_name":"Ann Marie Navar","author_inst":"University of Texas Southwestern"},{"author_name":"Brenice Duroseau","author_inst":"Duke University School of Nursing"},{"author_name":"Roland J. Thorpe Jr.","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Carly L. Brantner","author_inst":"Duke University School of Medicine"}],"rel_date":"2026-11-17","rel_site":"medrxiv"},{"rel_title":"Reprogramming a thiosulfate bacterial two-component system into a perchlorate biosensor","rel_doi":"10.64898\/2026.11.13.766565","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.13.766565","rel_abs":"Engineering bacterial two-component systems (TCSs) to sense new molecules would enable programmable whole-cell biosensors, but retargeting membrane-bound sensor histidine kinases is challenging because ligand recognition and signal transduction are tightly coupled. Here, we reprogram the thiosulfate-responsive TCS from Shewanella halifaxensis (ThsSR) to detect perchlorate, for which no naturally occurring TCS sensor has been reported. Using a dual growth selection, we simultaneously selected for perchlorate-dependent signaling and against native thiosulfate responsiveness. This strategy first converted wild-type ThsS into a perchlorate-responsive generalist and then produced specialized variants with improved sensitivity, greatly reduced thiosulfate response, and discrimination against related oxyanions. We next applied the physicsinformed reinforcement learning design method protCAD to functional intermediates identified by directed evolution. protCAD-selected substitutions further enhanced sensitivity or signaling output in specialized sensors, even in backgrounds that were refractory to additional random mutagenesis and gene shuffling. As a final demonstration, we used the engineered TCS sensor in a whole cell biosensor to detect perchlorate in unsterile environmental samples. Together, these results define a productive division of labor between experiment and computation: directed evolution discovers signaling-competent, specificity-altered sequence space, while computation explores that evolved space more completely to refine performance. This evolution-computational strategy provides a framework for reprogramming TCS biosensors toward non-native analytes.","rel_num_authors":7,"rel_authors":[{"author_name":"Samuel Lim","author_inst":"Yonsei University"},{"author_name":"James J McCann","author_inst":"The City College of New York"},{"author_name":"Piyush Kumar","author_inst":"Columbia University"},{"author_name":"Zhujin Xia","author_inst":"Columbia University"},{"author_name":"William R Henson","author_inst":"Battelle Memorial Institute"},{"author_name":"Ronald L Koder","author_inst":"The City College of New York"},{"author_name":"Scott Banta","author_inst":"Columbia University"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Semi-stability and unfolding of a KH domain modulate RNA binding and functions of MEX3A","rel_doi":"10.64898\/2026.11.15.766395","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766395","rel_abs":"MEX3A is essential for binding to Ago2\/miR-126-5p and inhibition of apoptosis in endothelial cells implicated in cardiovascular health. Here, we discovered that the KH1 domain within the RNA binding region of MEX3A exists in equilibrium with an unfolded conformation. Using NMR spectroscopy and biophysical analysis, we dissect the KH1 folding kinetics and show that increased KH1 stability correlates with higher RNA affinity. The unfolded state of KH1 enables phosphorylation of T162, locking the domain in the unfolded conformation and enables recognition by 14-3-3 {zeta}. Residues in MEX3A KH1 that reduce its stability are located outside the RNA-binding interface and are evolutionary selected compared to human MEX3 paralogs. Semi-stability of KH domains in MEX3A and other multi-KH proteins may provide a general mechanism to tune RNA binding, enable phosphorylation and regulate biological function.","rel_num_authors":7,"rel_authors":[{"author_name":"Philipp H O Mayer","author_inst":"Bavarian NMR Center, Technical University of Munich, 85747 Garching, Germany"},{"author_name":"Charlotte Crauwels","author_inst":"Interuniversity Institute of Bioinformatics in Brussels, VUB\/ULB, Brussels, Belgium"},{"author_name":"Peijian Zou","author_inst":"Bavarian NMR Center, Technical University of Munich, 85747 Garching, Germany"},{"author_name":"Clara Hipp","author_inst":"Bavarian NMR Center, Technical University of Munich, 85747 Garching, Germany"},{"author_name":"Sam Asami","author_inst":"Bavarian NMR Center, Technical University of Munich, 85747 Garching, Germany"},{"author_name":"Wim F Vranken","author_inst":"Interuniversity Institute of Bioinformatics in Brussels, VUB\/ULB, Brussels, Belgium"},{"author_name":"Michael Sattler","author_inst":"Bavarian NMR Center, Technical University of Munich, 85747 Garching, Germany"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"High-throughput identification of changes in cellular localization for RNA-binding proteins during adenovirus infection reveals viral harnessing of nuclear speckles","rel_doi":"10.64898\/2026.11.16.765444","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.765444","rel_abs":"Adenovirus (AdV) is a human DNA virus reliant on host RNA processing machinery. While research into AdV has yielded landmark discoveries in RNA biology, studies investigating the scope of AdV dependency on specific host RNA-binding proteins (RBPs) are lacking. Here we performed optical pooled screening on a cell library where hundreds of RBPs are endogenously tagged. Pooled imaging followed by in situ barcode sequencing revealed a broad view of virus-induced host RBP relocalization patterns, including those recruited to viral replication compartments (VRCs). A targeted siRNA screen of relocalized RBPs demonstrated a requirement for the nuclear speckle (NS) core protein SON during virus infection. Depletion of SON resulted in reduced viral gene expression, impaired NS protein recruitment to early-stage VRCs, and impaired mobility of SRRM2 during infection. These findings suggest a crucial role of SON and NS functions in regulating viral gene expression and demonstrate the power of pooled tagging coupled to optical screening in investigating virus-host interactions.","rel_num_authors":11,"rel_authors":[{"author_name":"Amber R. N. Abbott","author_inst":"The Children's Hospital of Philadelphia; University of Pennsylvania Perelman School of Medicine; The Wistar Institute"},{"author_name":"Tomer Lapidot","author_inst":"The Children's Hospital of Philadelphia; University of Pennsylvania Perelman School of Medicine"},{"author_name":"Tanner M Tessier","author_inst":"The Children's Hospital of Philadelphia"},{"author_name":"Songtao Ye","author_inst":"Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University School of Medicine"},{"author_name":"Holly Chan","author_inst":"The Children's Hospital of Philadelphia"},{"author_name":"Edwin Halko","author_inst":"The Children's Hospital of Philadelphia"},{"author_name":"Giorgia Piserchia","author_inst":"The Children's Hospital of Philadelphia"},{"author_name":"Danfeng Cai","author_inst":"Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University School of Medicine; Johns Hopkins School of Medicine"},{"author_name":"Ophir Shalem","author_inst":"The Children's Hospital of Philadelphia; University of Pennsylvania Perelman School of Medicine"},{"author_name":"Alexander M Price","author_inst":"The Wistar Institute"},{"author_name":"Matthew D Weitzman","author_inst":"The Children's Hospital of Philadelphia; University of Pennsylvania Perelman School of Medicine"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Maternal obesity disrupts glucose oxidation and mitochondrial fission in the myometrium at term gestation","rel_doi":"10.64898\/2026.11.16.766658","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766658","rel_abs":"Women with obesity experience delayed spontaneous labor onset, slow labor progression, and elevated risk of labor dystocia, but the underlying mechanisms are poorly understood. We previously established a mouse model of diet-induced obesity that exhibits decreased uterine contractility, labor dystocia, and elevated fatty acids in the myometrium. Here, we used this model to determine how maternal obesity affects energy production and mitochondrial homeostasis in the myometrium at term. Myometrium tissue and myometrial smooth muscle cells from diet-induced obese mice at term showed decreased pyruvate utilization, inhibition of glucose oxidation, and disruption of mitochondrial fission and mitophagy. Treatment with medium-chain fatty acids in both murine and human primary myometrial cells resulted in significant decreases in abundance of mitochondrial fission proteins. Finally, mitochondrial spare capacity in human myometrial cells decreased with body mass index of the patient providing the cells. Taken together, these findings indicate that fatty acid accumulation dysregulates energy metabolism and mitochondrial homeostasis in the myometrium and may contribute to dysfunctional labor in women with obesity.","rel_num_authors":7,"rel_authors":[{"author_name":"Kevin K Prifti","author_inst":"Washington University School of Medicine"},{"author_name":"Jordan L Rich","author_inst":"Washington University School of Medicine"},{"author_name":"Amelia M Giecek","author_inst":"Washington University School of Medicine"},{"author_name":"Ruth M Gill","author_inst":"Washington University School of Medicine"},{"author_name":"Terri A Pietka","author_inst":"Washington University School of Medicine"},{"author_name":"Wandy L Beatty","author_inst":"Washington University School of Medicine"},{"author_name":"Antonina I Frolova","author_inst":"Washington University School of Medicine"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Quiescent Cells Exhibit a Senescence-Like Secretory Phenotype","rel_doi":"10.64898\/2026.11.15.766855","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766855","rel_abs":"Cellular quiescence is traditionally considered a reversible state of cell cycle arrest, distinct from senescence, which is associated with a characteristic senescence-associated secretory phenotype (SASP). However, whether quiescent cells exhibit a comparable secretory program remains poorly understood. Here, we identify and characterize a Quiescence-Associated Secretory Phenotype (QASP) by integrating single-cell and bulk RNA sequencing datasets from human fibroblasts and preadipocytes. We find that quiescent cells exhibit increased expression of genes encoding inflammatory mediators and extracellular matrix-associated proteins, with substantial overlap between the QASP and SASP. This transcriptional program is highly heterogeneous, varying across cell types, quiescence induction methods, and environmental oxygen levels. In particular, contact inhibition induces a stronger inflammatory signature than serum withdrawal in several cellular contexts. Multiplexed cytokine profiling demonstrated active secretion of inflammatory mediators, including IL-1{beta}, IL-6, IL-15, and CCL2, in quiescent fibroblasts, with secretion levels varying by induction method and generally higher following contact inhibition than serum withdrawal. Analysis of single-cell transcriptomic data from human lung tissue further reveals increased QASP-associated gene expression in idiopathic pulmonary fibrosis (IPF), particularly in myofibroblasts, linking this phenotype to inflammatory signaling and extracellular matrix remodeling. Together, these findings identify the QASP as a context-dependent secretory program that shares features with the SASP and may contribute to inflammatory signaling and extracellular matrix remodeling in both physiological and pathological conditions.","rel_num_authors":4,"rel_authors":[{"author_name":"Azucena Rocha","author_inst":"Brown University"},{"author_name":"Radha Kalekar","author_inst":"Brown University"},{"author_name":"John M Sedivy","author_inst":"Brown University"},{"author_name":"Nicola Neretti","author_inst":"Brown University"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Genetic, neural and early-environmental architecture of resilience","rel_doi":"10.64898\/2026.11.16.767004","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767004","rel_abs":"Resilience is shaped by factors ranging from the genome through early-life experience to the brain, yet its biological basis in humans remains unclear because studies have rarely integrated these levels and have been confined to small samples. Using the Brief Resilience Scale (BRS) and multimodal data from tens of thousands of UK Biobank (UKB) participants, with replication in Generation Scotland (GS), we found that resting-state functional connectivity, particularly within the flexibility and valuation networks, is a robust neural correlate of resilience. Resilience also showed a generalizable genetic basis: a polygenic score (PGS) derived from a UKB genome-wide association study predicted BRS in GS. Genes and childhood experiences converged on the flexibility network through distinct routes: the polygenic association with resilience was partly explained by central executive-salience integration, whereas childhood experiences were associated with default-mode-centered integration. By separating genetically anchored from experience-sensitive routes, these findings point to network targets that interventions could tailor to the sources of an individual's vulnerability.","rel_num_authors":6,"rel_authors":[{"author_name":"Tung-Yen Wu","author_inst":"Department of Economics, National Taiwan University, Taipei, Taiwan"},{"author_name":"Yun-Yen Yang","author_inst":"Department of Economics, National Taiwan University, Taipei, Taiwan"},{"author_name":"Yu-Jen Liang","author_inst":"Institute of Statistical Science, Academia Sinica, Taipei, Taiwan"},{"author_name":"Fa-Hsuan Lin","author_inst":"Physical Sciences Platform, Sunnybrook Research Institute, Toronto, Canada"},{"author_name":"Hsin-Chou Yang","author_inst":"Institute of Statistical Science, Academia Sinica, Taipei, Taiwan"},{"author_name":"Chen-Ying Huang","author_inst":"Department of Economics, National Taiwan University, Taipei, Taiwan"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Genetic, neural and early-environmental architecture of resilience","rel_doi":"10.64898\/2026.11.16.767004","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767004","rel_abs":"Resilience is shaped by factors ranging from the genome through early-life experience to the brain, yet its biological basis in humans remains unclear because studies have rarely integrated these levels and have been confined to small samples. Using the Brief Resilience Scale (BRS) and multimodal data from tens of thousands of UK Biobank (UKB) participants, with replication in Generation Scotland (GS), we found that resting-state functional connectivity, particularly within the flexibility and valuation networks, is a robust neural correlate of resilience. Resilience also showed a generalizable genetic basis: a polygenic score (PGS) derived from a UKB genome-wide association study predicted BRS in GS. Genes and childhood experiences converged on the flexibility network through distinct routes: the polygenic association with resilience was partly explained by central executive-salience integration, whereas childhood experiences were associated with default-mode-centered integration. By separating genetically anchored from experience-sensitive routes, these findings point to network targets that interventions could tailor to the sources of an individual's vulnerability.","rel_num_authors":6,"rel_authors":[{"author_name":"Tung-Yen Wu","author_inst":"Department of Economics, National Taiwan University, Taipei, Taiwan"},{"author_name":"Yun-Yen Yang","author_inst":"Department of Economics, National Taiwan University, Taipei, Taiwan"},{"author_name":"Yu-Jen Liang","author_inst":"Institute of Statistical Science, Academia Sinica, Taipei, Taiwan"},{"author_name":"Fa-Hsuan Lin","author_inst":"Physical Sciences Platform, Sunnybrook Research Institute, Toronto, Canada"},{"author_name":"Hsin-Chou Yang","author_inst":"Institute of Statistical Science, Academia Sinica, Taipei, Taiwan"},{"author_name":"Chen-Ying Huang","author_inst":"Department of Economics, National Taiwan University, Taipei, Taiwan"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Calsarcin-1 modulates the muscle LIM protein\/Z-disc complex mechanosensing in familial hypertrophic cardiomyopathy","rel_doi":"10.64898\/2026.11.15.766848","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766848","rel_abs":"BACKGROUND: Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disease mainly caused by sarcomeric mutations. The Z-disc is a critical mechanosensory interface linking sarcomeric stress to biochemical signaling, yet the role of calsarcin-1 in maintaining Z-disc integrity remains unclear. Patient-specific iPSC-CM-based engineered heart tissues (EHTs) are being developed for disease modeling and drug screening; however, the loading conditions to recapitulate pathological mechanical stress remain underdeveloped. METHODS: HCM patient heart, three patient-specific iPSC lines (MLP-W4R;MYH7-R723C, MYH7-R663H, and MYBPC3-V321M), derived cardiomyocytes (iPSC-CMs), and engineered heart tissues (EHTs) were employed. Calsarcin-1 expression was assessed, and its role in MLP\/Z-disc mechanosensing was investigated through gain- and loss-of-function approaches. An EHT bioreactor was developed to recapitulate HCM-associated elevated afterload, electrical pacing, and cyclic mechanical loading; isogenic wild type and MLP-W4R iPSC lines were generated by genome editing. Calsarcin-1 treatment to rescue the hypertrophic phenotype of isogenic (Iso) MLP-W4R iPSC-CM-EHTs was evaluated. RESULTS: Calsarcin-1 was markedly downregulated in myocardium from an HCM proband carrying heterozygous MLP-W4R and MYH7-R723C variants, as well as in patient-specific iPSC-CMs and EHTs, accompanied by marked upregulation of the hypertrophic markers atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP). Ectopic expression of calsarcin-1 via viral infection in MLP-W4R;MYH7-R723C iPSC-CMs stabilized the MLP\/Z-disc machinery and reversed hypertrophy in all three patient-specific iPSC-CMs (MLP-W4R;MYH7-R723C, MYH7-R663H, and MYBPC3-V321M). Knockdown of calsarcin-1 attenuated the rescue effect of MLP overexpression in MLP-W4R;MYH7-R723C iPSC-CMs. Isogenic wild type and MLP-W4R iPSCs were generated by correcting mutations in MLP-W4R;MYH7-R723C iPSCs. Moreover, we developed a 3D-EHT bioreactor system that integrates controlled mechanical loading and electrical pacing to recapitulate the elevated afterload and cyclic mechanical stress characteristic of HCM. The additional mechanical resistance imposed by high afterload prolongs TTP and RT50 and increases the normalized force-time integral (nFTI), suggesting that excessively high afterload drives pathological remodeling in IsoMLP-W4R-iPSC-CM-EHTs. More importantly, calsarcin-1 significantly rescued both systolic and diastolic dysfunction of IsoMLP-W4R-iPSC-CM-EHTs exposed to pathological high afterload. CONCLUSIONS: Calsarcin-1 is a nodal regulator of pathological cardiac remodeling that restores MLP\/Z-disc mechanosensing. A patient-derived EHT bioreactor model recapitulating pathological HCM loading identifies calsarcin-1 as a potential therapeutic target.","rel_num_authors":16,"rel_authors":[{"author_name":"Xin Li","author_inst":"Yale University"},{"author_name":"Yinsheng Lu","author_inst":"Yale University"},{"author_name":"Xianmu Li","author_inst":"Yale University"},{"author_name":"Muhammad Riaz","author_inst":"Yale University"},{"author_name":"Thomas Blum","author_inst":"Yale University"},{"author_name":"Hangqi Luo","author_inst":"Yale University"},{"author_name":"Marie Hoareau","author_inst":"Yale University"},{"author_name":"Yufeng Liu","author_inst":"Yale University"},{"author_name":"Saba Fooladi","author_inst":"Yale University"},{"author_name":"Qinzhe Xing","author_inst":"Yale University"},{"author_name":"Ilhan Gokhan","author_inst":"Yale University"},{"author_name":"Xia Li","author_inst":"Yale University"},{"author_name":"Jinkyu Park","author_inst":"Yale University"},{"author_name":"Lixia Yue","author_inst":"University of Connecticut School of Medicine"},{"author_name":"Stuart G. Campbell","author_inst":"Yale University"},{"author_name":"Yibing Qyang","author_inst":"Yale University"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"The intestinal microbiome shapes responses to the GD2\/GD3 cancer vaccine in children with high-risk neuroblastoma","rel_doi":"10.64898\/2026.11.16.766479","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766479","rel_abs":"The intestinal microbiome influences vaccine responses, but its role in therapeutic cancer vaccination remains largely unexplored. We investigated the gut microbiome, vaccine immunogenicity and clinical outcomes in 137 children with high-risk neuroblastoma receiving GD2\/GD3 vaccination with oral b-glucan. Microbiome-perturbing antibiotic exposure was associated with inferior progression-free survival (PFS). Among patients vaccinated in first remission, higher a-diversity and enrichment of Lachnospiraceae, including Blautia, were associated with higher anti-GD2 IgG1 responses, while higher Clostridia abundance was associated with superior PFS. Patients had microbiome profiles resembling those of chronologically younger healthy children, consistent with delayed microbiome maturation. A greater discrepancy between patients' chronological age and the age of microbiome-matched healthy children was associated with inferior PFS among patients in first remission. In a complementary mouse model, antibiotic treatment impaired vaccine-induced anti-GD2 IgG responses and accelerated tumor growth. Together, these findings support a role for the intestinal microbiome in therapeutic cancer vaccine responses and identify microbiome maturation as a clinically relevant feature in pediatrics.","rel_num_authors":32,"rel_authors":[{"author_name":"Lanying Ma","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Kimon Argyropoulos","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Kanaka Dhuri","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Nicholas Waters","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Teng Fei","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Irene Y. Cheung","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Xiaohong Wu","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Yunlin Zhang","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Leena Babiker","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Katlyn Lederer","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Leana Harford","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Nadia Brijmohan","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Chi Nguyen","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Kristen Victor","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Jianmin Yang","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Anqi Dai","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Jonathan Peled","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Alan Hanash","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Stephen R. Roberts","author_inst":"Doernbecher Children's Hospital"},{"author_name":"Jaap J. Boelens","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Stefan Nierkens","author_inst":"Princess Maxima Center"},{"author_name":"Gretchen Diehl","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Kate A. Markey","author_inst":"Fred Hutchinson Cancer Center"},{"author_name":"Ying Taur","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Marina da Silva","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Brian Kushner","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Ivan Maillard","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Ragupathi Govind","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Nai-Kong Cheung","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Marcel van den Brink","author_inst":"City of Hope"},{"author_name":"Shakeel Modak","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Oriana Miltiadous","author_inst":"Memorial Sloan Kettering Cancer Center"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"The intestinal microbiome shapes responses to the GD2\/GD3 cancer vaccine in children with high-risk neuroblastoma","rel_doi":"10.64898\/2026.11.16.766479","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766479","rel_abs":"The intestinal microbiome influences vaccine responses, but its role in therapeutic cancer vaccination remains largely unexplored. We investigated the gut microbiome, vaccine immunogenicity and clinical outcomes in 137 children with high-risk neuroblastoma receiving GD2\/GD3 vaccination with oral b-glucan. Microbiome-perturbing antibiotic exposure was associated with inferior progression-free survival (PFS). Among patients vaccinated in first remission, higher a-diversity and enrichment of Lachnospiraceae, including Blautia, were associated with higher anti-GD2 IgG1 responses, while higher Clostridia abundance was associated with superior PFS. Patients had microbiome profiles resembling those of chronologically younger healthy children, consistent with delayed microbiome maturation. A greater discrepancy between patients' chronological age and the age of microbiome-matched healthy children was associated with inferior PFS among patients in first remission. In a complementary mouse model, antibiotic treatment impaired vaccine-induced anti-GD2 IgG responses and accelerated tumor growth. Together, these findings support a role for the intestinal microbiome in therapeutic cancer vaccine responses and identify microbiome maturation as a clinically relevant feature in pediatrics.","rel_num_authors":32,"rel_authors":[{"author_name":"Lanying Ma","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Kimon Argyropoulos","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Kanaka Dhuri","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Nicholas Waters","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Teng Fei","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Irene Y. Cheung","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Xiaohong Wu","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Yunlin Zhang","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Leena Babiker","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Katlyn Lederer","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Leana Harford","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Nadia Brijmohan","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Chi Nguyen","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Kristen Victor","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Jianmin Yang","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Anqi Dai","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Jonathan Peled","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Alan Hanash","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Stephen R. Roberts","author_inst":"Doernbecher Children's Hospital"},{"author_name":"Jaap J. Boelens","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Stefan Nierkens","author_inst":"Princess Maxima Center"},{"author_name":"Gretchen Diehl","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Kate A. Markey","author_inst":"Fred Hutchinson Cancer Center"},{"author_name":"Ying Taur","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Marina da Silva","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Brian Kushner","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Ivan Maillard","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Ragupathi Govind","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Nai-Kong Cheung","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Marcel van den Brink","author_inst":"City of Hope"},{"author_name":"Shakeel Modak","author_inst":"Memorial Sloan Kettering Cancer Center"},{"author_name":"Oriana Miltiadous","author_inst":"Memorial Sloan Kettering Cancer Center"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"FluoMALDI Imaging: An Integrated Multimodality Platform for Biologically Informed Spatial-Omics","rel_doi":"10.64898\/2026.11.15.766883","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766883","rel_abs":"FluoMALDI imaging integrates fluorescence microscopy and matrix-assisted laser desorption\/ionization mass spectrometry imaging (MALDI-MSI) of tissues and cells, leveraging matrix-enhanced fluorescence signals to enable spatially guided functional molecular discovery. Here we report three broadly applicable FluoMALDI paradigms that link how genes, proteins, and organelles shape spatial molecular composition. These advances are achieved by integrating immuno-, HaloTag-, and dye-based labels into a unified FluoMALDI imaging framework. These approaches enabled us to interrogate cell-specific lipidomic compositions in human hippocampal vasculature, neural crest cells in chick embryo tissue, and human induced pluripotent stem cell-derived astrocytes. We also determined that fluorophore-MALDI matrix co-crystals resulted in FluoMALDI-induced fluorescence enhancements. Single-crystal X-ray crystallography showed that their co-crystallization produced localized, finite {pi}-{pi} interactions between two fluorophore molecules, or a fluorophore and a matrix molecule, throughout the crystal lattice. Together, these findings provide structural insight into the basis of fluorescence enhancement and support FluoMALDI as a broadly applicable multimodality imaging platform for biologically informed, cell-specific spatial-omics.","rel_num_authors":12,"rel_authors":[{"author_name":"Tae-Hun Hahm","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Michael L. Piacentino","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Waqar Ahmed","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Maxime A. Siegler","author_inst":"Johns Hopkins University"},{"author_name":"Dalton R. Brown","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Caitlin M. Tressler","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Juan C. Troncoso","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Arvind P. Pathak","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Swati Tanwar","author_inst":"Johns Hopkins University Whiting School of Engineering"},{"author_name":"Ishan Barman","author_inst":"Johns Hopkins University Whiting School of Engineering"},{"author_name":"Vasiliki Mahairaki","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Kristine Glunde","author_inst":"Johns Hopkins University School of Medicine"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Genetic regulation of ALK inhibitor response in diverse human cell types","rel_doi":"10.64898\/2026.11.16.766986","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766986","rel_abs":"Anaplastic lymphoma kinase (ALK) inhibitors are effective treatments for ALK-positive non-small cell lung cancer but cause diverse adverse events affecting multiple tissues. Genetic variation may contribute to inter-individual differences in susceptibility, but the small number of treated patients limits the power of genetic association studies. Moreover, the diversity of affected tissues and cell types makes functional investigation challenging. We used induced pluripotent stem cells from 49 individuals to generate heterogeneous differentiating cultures (HDCs) containing multiple cell types, treated them with five ALK inhibitors (crizotinib, alectinib, ceritinib, brigatinib, and lorlatinib) for 24 hours, and characterized transcriptional responses using single-cell RNA sequencing. These responses showed cell-type-specific and shared transcriptional effects. Integrating gene expression with individual genotypes, we identified 4,371 expression quantitative trait loci (eQTLs) across 21 cell types, including 2,137 response eQTLs whose regulatory effects differ between untreated and drug-treated cells. These results nominate candidates for future studies of ALK inhibitor toxicity.","rel_num_authors":7,"rel_authors":[{"author_name":"Elizabeth Geena Woo","author_inst":"Committee on Genetics, Genomics, and Systems Biology, University of Chicago, Chicago, IL, USA"},{"author_name":"Katherine L. Rhodes","author_inst":"Department of Medicine, University of Chicago, Chicago, IL, USA"},{"author_name":"Natalia M. Gonzales","author_inst":"Department of Medicine, University of Chicago, Chicago, IL, USA"},{"author_name":"Kenneth A. Barr","author_inst":"Department of Medicine, University of Chicago, Chicago, IL, USA"},{"author_name":"Emaan Mohsin","author_inst":"Feinberg School of Medicine, Northwestern University, Chicago, IL, USA"},{"author_name":"Everett E. Vokes","author_inst":"University of Chicago Comprehensive Cancer Center, Chicago, IL, USA"},{"author_name":"Yoav Gilad","author_inst":"Department of Medicine, University of Chicago, Chicago, IL, USA"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"p53 supports healthy aging","rel_doi":"10.64898\/2026.11.16.766897","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766897","rel_abs":"p53 is a master regulator of cellular stress responses that is also implicated in the aging process. Its role in aging is often considered an example of antagonistic pleiotropy (AP), where it acts beneficially as a tumor suppressor early in life, but detrimentally in late life, for example by driving accumulation of stress-associated, pro-inflammatory senescent cells. However, the causal role of p53 in aging is not well-defined, and the AP model has not been definitively tested through loss- of-function studies. Here we show, contrary to the prediction of AP, that p53 promotes healthy aging in mouse liver by suppressing excessive inflammation and maintaining metabolic function. Multimodal RNA, protein, epigenetic and spatial profiling at the single-cell level in aged mouse liver confirmed age-dependent increase in p53 pathway activation. Hepatocyte-specific knockout of p53 in livers of aged mice, but not of young mice, increased inflammation and immune infiltration. Mechanistically, p53 suppressed DNA replication stress and DNA damage, known precursors to inflammatory signaling. In aged hepatocytes, p53 also directly targeted and maintained expression of metabolic genes, and knockout of p53 sensitized aged mice to metabolic stress-induced liver damage. Complementing these loss-of-function data, pharmacological activation of p53 with the small-molecule MDM2 inhibitor HDM201 in aged mice reversed age-associated suppression of metabolic genes, decreased age-associated inflammation and delayed onset of frailty. These results identify p53 activity in aged tissue as protective rather than degenerative. Importantly, this protective function is pharmacologically targetable, potentially for the benefit of healthy aging in humans.","rel_num_authors":43,"rel_authors":[{"author_name":"Marcos G. Teneche","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Karl N. Miller","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Kelly Yichen Li","author_inst":"Center for Data Science and Artificial Intelligence; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Kat Lande","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Sainath Mamde","author_inst":"Center for Epigenomics; Department of Cellular and Molecular Medicine; University of California San Diego; La Jolla, CA, USA"},{"author_name":"Christina Huan Shi","author_inst":"Center for Data Science and Artificial Intelligence; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Adarsh Rajesh","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Aaron P. Havas","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Jessica Proulx","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Rouven Arnold","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Michael Alcaraz","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Andrew Davis","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Armin Gandhi","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Laurence Haddadin","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Xue Lei","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Irene Huang","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Gabriele Guarnaccia","author_inst":"Center for Cardiovascular and Muscular Diseases; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Jake Castillo","author_inst":"Center for Epigenomics; Department of Cellular and Molecular Medicine; University of California San Diego; La Jolla, CA, USA"},{"author_name":"Monica Sevilla","author_inst":"Shared Resources; NCI-designated Cancer Center; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Hiroshi Tanaka","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Cray Minor","author_inst":"Cancer Metabolism and Microenvironment Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Caroline Kumsta","author_inst":"Cancer Metabolism and Microenvironment Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Tatiana Moreno","author_inst":"Cancer Metabolism and Microenvironment Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Erik Hultenius","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Carolina Cano Macip","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Garrett Evensen","author_inst":"Bioinformatics Core; Salk Institute; La Jolla, CA, USA"},{"author_name":"Shreeya Patel","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Colin Kern","author_inst":"Center for Epigenomics; Department of Cellular and Molecular Medicine; University of California San Diego; La Jolla, CA, USA"},{"author_name":"Elizabeth Smoot","author_inst":"Center for Epigenomics; Department of Cellular and Molecular Medicine; University of California San Diego; La Jolla, CA, USA"},{"author_name":"Jacqueline Olness","author_inst":"Center for Epigenomics; Department of Cellular and Molecular Medicine; University of California San Diego; La Jolla, CA, USA"},{"author_name":"Andrea Rodriguez-Agustin","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Guillermina Garcia","author_inst":"Shared Resources; NCI-designated Cancer Center; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Yu Xin Wang","author_inst":"Cancer Metabolism and Microenvironment Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Kevin M. Tharp","author_inst":"Cancer Metabolism and Microenvironment Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Alessandra Sacco","author_inst":"Center for Cardiovascular and Muscular Diseases; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Rebecca A. Porritt","author_inst":"Shared Resources; NCI-designated Cancer Center; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Quan Zhu","author_inst":"Center for Epigenomics; Department of Cellular and Molecular Medicine; University of California San Diego; La Jolla, CA, USA"},{"author_name":"Allen Wang","author_inst":"Center for Epigenomics; Department of Cellular and Molecular Medicine; University of California San Diego; La Jolla, CA, USA"},{"author_name":"Bing Ren","author_inst":"New York Genome Center; New York, NY, USA"},{"author_name":"April Williams","author_inst":"Bioinformatics Core; Salk Institute; La Jolla, CA, USA"},{"author_name":"Nathan Zemke","author_inst":"Center for Epigenomics; Department of Cellular and Molecular Medicine; University of California San Diego; La Jolla, CA, USA"},{"author_name":"Kevin Y. Yip","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Peter D. Adams","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"p53 supports healthy aging","rel_doi":"10.64898\/2026.11.16.766897","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766897","rel_abs":"p53 is a master regulator of cellular stress responses that is also implicated in the aging process. Its role in aging is often considered an example of antagonistic pleiotropy (AP), where it acts beneficially as a tumor suppressor early in life, but detrimentally in late life, for example by driving accumulation of stress-associated, pro-inflammatory senescent cells. However, the causal role of p53 in aging is not well-defined, and the AP model has not been definitively tested through loss- of-function studies. Here we show, contrary to the prediction of AP, that p53 promotes healthy aging in mouse liver by suppressing excessive inflammation and maintaining metabolic function. Multimodal RNA, protein, epigenetic and spatial profiling at the single-cell level in aged mouse liver confirmed age-dependent increase in p53 pathway activation. Hepatocyte-specific knockout of p53 in livers of aged mice, but not of young mice, increased inflammation and immune infiltration. Mechanistically, p53 suppressed DNA replication stress and DNA damage, known precursors to inflammatory signaling. In aged hepatocytes, p53 also directly targeted and maintained expression of metabolic genes, and knockout of p53 sensitized aged mice to metabolic stress-induced liver damage. Complementing these loss-of-function data, pharmacological activation of p53 with the small-molecule MDM2 inhibitor HDM201 in aged mice reversed age-associated suppression of metabolic genes, decreased age-associated inflammation and delayed onset of frailty. These results identify p53 activity in aged tissue as protective rather than degenerative. Importantly, this protective function is pharmacologically targetable, potentially for the benefit of healthy aging in humans.","rel_num_authors":43,"rel_authors":[{"author_name":"Marcos G. Teneche","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Karl N. Miller","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Kelly Yichen Li","author_inst":"Center for Data Science and Artificial Intelligence; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Kat Lande","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Sainath Mamde","author_inst":"Center for Epigenomics; Department of Cellular and Molecular Medicine; University of California San Diego; La Jolla, CA, USA"},{"author_name":"Christina Huan Shi","author_inst":"Center for Data Science and Artificial Intelligence; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Adarsh Rajesh","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Aaron P. Havas","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Jessica Proulx","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Rouven Arnold","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Michael Alcaraz","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Andrew Davis","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Armin Gandhi","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Laurence Haddadin","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Xue Lei","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Irene Huang","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Gabriele Guarnaccia","author_inst":"Center for Cardiovascular and Muscular Diseases; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Jake Castillo","author_inst":"Center for Epigenomics; Department of Cellular and Molecular Medicine; University of California San Diego; La Jolla, CA, USA"},{"author_name":"Monica Sevilla","author_inst":"Shared Resources; NCI-designated Cancer Center; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Hiroshi Tanaka","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Cray Minor","author_inst":"Cancer Metabolism and Microenvironment Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Caroline Kumsta","author_inst":"Cancer Metabolism and Microenvironment Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Tatiana Moreno","author_inst":"Cancer Metabolism and Microenvironment Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Erik Hultenius","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Carolina Cano Macip","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Garrett Evensen","author_inst":"Bioinformatics Core; Salk Institute; La Jolla, CA, USA"},{"author_name":"Shreeya Patel","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Colin Kern","author_inst":"Center for Epigenomics; Department of Cellular and Molecular Medicine; University of California San Diego; La Jolla, CA, USA"},{"author_name":"Elizabeth Smoot","author_inst":"Center for Epigenomics; Department of Cellular and Molecular Medicine; University of California San Diego; La Jolla, CA, USA"},{"author_name":"Jacqueline Olness","author_inst":"Center for Epigenomics; Department of Cellular and Molecular Medicine; University of California San Diego; La Jolla, CA, USA"},{"author_name":"Andrea Rodriguez-Agustin","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Guillermina Garcia","author_inst":"Shared Resources; NCI-designated Cancer Center; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Yu Xin Wang","author_inst":"Cancer Metabolism and Microenvironment Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Kevin M. Tharp","author_inst":"Cancer Metabolism and Microenvironment Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Alessandra Sacco","author_inst":"Center for Cardiovascular and Muscular Diseases; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Rebecca A. Porritt","author_inst":"Shared Resources; NCI-designated Cancer Center; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Quan Zhu","author_inst":"Center for Epigenomics; Department of Cellular and Molecular Medicine; University of California San Diego; La Jolla, CA, USA"},{"author_name":"Allen Wang","author_inst":"Center for Epigenomics; Department of Cellular and Molecular Medicine; University of California San Diego; La Jolla, CA, USA"},{"author_name":"Bing Ren","author_inst":"New York Genome Center; New York, NY, USA"},{"author_name":"April Williams","author_inst":"Bioinformatics Core; Salk Institute; La Jolla, CA, USA"},{"author_name":"Nathan Zemke","author_inst":"Center for Epigenomics; Department of Cellular and Molecular Medicine; University of California San Diego; La Jolla, CA, USA"},{"author_name":"Kevin Y. Yip","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"},{"author_name":"Peter D. Adams","author_inst":"Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Comparative chemogenetic profiling of Hedgehog pathway inhibitors reveals class-specific genetic modifiers","rel_doi":"10.64898\/2026.11.15.766797","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766797","rel_abs":"Chemogenetic profiling is a powerful method to dissect compound-gene interactions and to reveal a compound's mechanism of action and possible resistance mechanisms. Here, we extended the use of chemogenetic profiling beyond cytotoxic compounds to classify non-toxic inhibitors of the Hedgehog signaling pathway. We performed Hedgehog pathway-focused genetic screens in NIH\/3T3 mouse fibroblasts using two chemically distinct inhibitors each of Smoothened (SMO) and BET bromodomain proteins. The resulting chemogenetic profiles revealed class-specific modifiers, with loss of Mosmo conferring resistance to SMO inhibitors, and loss of Paxip1 conferring resistance to BET bromodomain inhibitors. Beyond these compound-specific effects, we show how loss of Nf2, Paxip1, or Mosmo differentially impacts Hedgehog pathway transduction upstream, at the level of the cilium, and\/or downstream, at the level of transcription. Together, the Mosmo- and Paxip1-knockout lines provide new tools for epistasis mapping, and the profiling strategy a route to mechanism-of-action studies for inhibitors of ciliary signaling.","rel_num_authors":5,"rel_authors":[{"author_name":"Quentin T.L. Pasquer","author_inst":"University of Geneva"},{"author_name":"Charlotte Rossion","author_inst":"University of Geneva"},{"author_name":"Hao Li","author_inst":"University of Geneva"},{"author_name":"Rocaya C. Gross","author_inst":"University of Geneva"},{"author_name":"Sascha Hoogendoorn","author_inst":"University of Geneva"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Depolymerases unmask a conserved receptor to enable phage control of capsulated Acinetobacter baumannii","rel_doi":"10.64898\/2026.11.16.766953","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766953","rel_abs":"We characterized bacteriophage Abs1 that infects clinical Acinetobacter baumannii isolates via the highly prevalent and conserved outer-membrane protein receptor, OprC. However, phage Abs1 is unable to infect capsulated A. baumannii strains as the capsule prevents phage access to its underlying receptor. To circumvent this, we combined phage Abs1 with recombinant depolymerases targeting the major A. baumannii capsule types. In a murine bacteremia model, this combination significantly reduced bacterial burden caused by diverse, capsulated A. baumannii strains.","rel_num_authors":14,"rel_authors":[{"author_name":"Leo Kan","author_inst":"Monash University"},{"author_name":"Laura Avellaneda-Franco","author_inst":"Monash University"},{"author_name":"Dinesh Subedi","author_inst":"Monash University"},{"author_name":"Denis Korneev","author_inst":"Monash University"},{"author_name":"Ella Gillis","author_inst":"Monash University"},{"author_name":"Isabelle Magnin-Bougma","author_inst":"Monash University"},{"author_name":"Mark Carascal","author_inst":"Monash University"},{"author_name":"Shankar Devkota","author_inst":"Adelaide University"},{"author_name":"Surendra Kunwar","author_inst":"Monash University"},{"author_name":"Ram Bhusal","author_inst":"Monash University"},{"author_name":"Ruth M. Hall","author_inst":"The University of Sydney"},{"author_name":"Johanna J Kenyon","author_inst":"Griffith University"},{"author_name":"Anton Y Peleg","author_inst":"Monash University"},{"author_name":"Jeremy J Barr","author_inst":"Monash University"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Intra-thalamic coordination maintains arousability in slow-wave sleep","rel_doi":"10.64898\/2026.11.15.766872","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766872","rel_abs":"Slow-wave sleep preserves the capacity for spontaneous or stimulus-evoked awakening despite reduced responsiveness, yet how thalamic nuclei coordinate to preserve arousability remains unclear. We analysed six fMRI and EEG datasets spanning sleep, propofol anesthesia and unresponsive wakefulness syndrome (UWS). During N2 and N3, centromedian (CM) and ventral posterolateral (VPL) nuclei showed convergent edge-community profiles and increased closed-loop intra-thalamic motifs, changes not observed during anesthesia or UWS. During N3, directed effective connectivity along CM[-&gt;]VPL[-&gt;]pulvinar (PUL) increased versus wakefulness and N2. Stronger CM[-&gt;]VPL and VPL[-&gt;]PUL connectivity covaried with greater N3 delta power, which was higher before awakening than before transitions to N2 and positively associated with three-month improvement in behavioural responsiveness in UWS. These findings identify a CM-VPL-PUL-centred pattern of intra-thalamic organization linked to preserved arousability during slow-wave sleep, extending accounts focused on individual nuclei and thalamocortical interactions.","rel_num_authors":9,"rel_authors":[{"author_name":"Junrong Han","author_inst":"Key Laboratory of Brain, Cognition and Education Sciences, Ministry of Education, Institute for Brain Research and Rehabilitation, Guangdong Key Laboratory of M"},{"author_name":"Qiuyou Xie","author_inst":"Department of Rehabilitation Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong, China; Joint Research Centre for Disorders o"},{"author_name":"Ying Huang","author_inst":"Key Laboratory of Brain, Cognition and Education Sciences, Ministry of Education, Center for Studies of Psychological Application, School of Psychology, South C"},{"author_name":"Man Li","author_inst":"School of Automation Science and Engineering, South China University of Technology, Guangzhou 510641, China; Research Center for Brain-Computer Interface, Pazho"},{"author_name":"Xiaoqing Hu","author_inst":"Department of Psychology, The University of Hong Kong, Hong Kong SAR, China; HKU-Shenzhen Institute of Research and Innovation, Shenzhen, China"},{"author_name":"Georg Northoff","author_inst":"Mind, Brain Imaging and Neuroethics Research Unit, The Royal's Institute of Mental Health Research, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canad"},{"author_name":"Yuanqing Li","author_inst":"School of Automation Science and Engineering, South China University of Technology, Guangzhou 510641, China; Research Center for Brain-Computer Interface, Pazho"},{"author_name":"Jun Zhang","author_inst":"Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"author_name":"Pengmin Qin","author_inst":"Key Laboratory of Brain, Cognition and Education Sciences, Ministry of Education, Institute for Brain Research and Rehabilitation, Guangdong Key Laboratory of M"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Intra-thalamic coordination maintains arousability in slow-wave sleep","rel_doi":"10.64898\/2026.11.15.766872","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766872","rel_abs":"Slow-wave sleep preserves the capacity for spontaneous or stimulus-evoked awakening despite reduced responsiveness, yet how thalamic nuclei coordinate to preserve arousability remains unclear. We analysed six fMRI and EEG datasets spanning sleep, propofol anesthesia and unresponsive wakefulness syndrome (UWS). During N2 and N3, centromedian (CM) and ventral posterolateral (VPL) nuclei showed convergent edge-community profiles and increased closed-loop intra-thalamic motifs, changes not observed during anesthesia or UWS. During N3, directed effective connectivity along CM[-&gt;]VPL[-&gt;]pulvinar (PUL) increased versus wakefulness and N2. Stronger CM[-&gt;]VPL and VPL[-&gt;]PUL connectivity covaried with greater N3 delta power, which was higher before awakening than before transitions to N2 and positively associated with three-month improvement in behavioural responsiveness in UWS. These findings identify a CM-VPL-PUL-centred pattern of intra-thalamic organization linked to preserved arousability during slow-wave sleep, extending accounts focused on individual nuclei and thalamocortical interactions.","rel_num_authors":9,"rel_authors":[{"author_name":"Junrong Han","author_inst":"Key Laboratory of Brain, Cognition and Education Sciences, Ministry of Education, Institute for Brain Research and Rehabilitation, Guangdong Key Laboratory of M"},{"author_name":"Qiuyou Xie","author_inst":"Department of Rehabilitation Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong, China; Joint Research Centre for Disorders o"},{"author_name":"Ying Huang","author_inst":"Key Laboratory of Brain, Cognition and Education Sciences, Ministry of Education, Center for Studies of Psychological Application, School of Psychology, South C"},{"author_name":"Man Li","author_inst":"School of Automation Science and Engineering, South China University of Technology, Guangzhou 510641, China; Research Center for Brain-Computer Interface, Pazho"},{"author_name":"Xiaoqing Hu","author_inst":"Department of Psychology, The University of Hong Kong, Hong Kong SAR, China; HKU-Shenzhen Institute of Research and Innovation, Shenzhen, China"},{"author_name":"Georg Northoff","author_inst":"Mind, Brain Imaging and Neuroethics Research Unit, The Royal's Institute of Mental Health Research, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canad"},{"author_name":"Yuanqing Li","author_inst":"School of Automation Science and Engineering, South China University of Technology, Guangzhou 510641, China; Research Center for Brain-Computer Interface, Pazho"},{"author_name":"Jun Zhang","author_inst":"Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"author_name":"Pengmin Qin","author_inst":"Key Laboratory of Brain, Cognition and Education Sciences, Ministry of Education, Institute for Brain Research and Rehabilitation, Guangdong Key Laboratory of M"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Intra-thalamic coordination maintains arousability in slow-wave sleep","rel_doi":"10.64898\/2026.11.15.766872","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766872","rel_abs":"Slow-wave sleep preserves the capacity for spontaneous or stimulus-evoked awakening despite reduced responsiveness, yet how thalamic nuclei coordinate to preserve arousability remains unclear. We analysed six fMRI and EEG datasets spanning sleep, propofol anesthesia and unresponsive wakefulness syndrome (UWS). During N2 and N3, centromedian (CM) and ventral posterolateral (VPL) nuclei showed convergent edge-community profiles and increased closed-loop intra-thalamic motifs, changes not observed during anesthesia or UWS. During N3, directed effective connectivity along CM[-&gt;]VPL[-&gt;]pulvinar (PUL) increased versus wakefulness and N2. Stronger CM[-&gt;]VPL and VPL[-&gt;]PUL connectivity covaried with greater N3 delta power, which was higher before awakening than before transitions to N2 and positively associated with three-month improvement in behavioural responsiveness in UWS. These findings identify a CM-VPL-PUL-centred pattern of intra-thalamic organization linked to preserved arousability during slow-wave sleep, extending accounts focused on individual nuclei and thalamocortical interactions.","rel_num_authors":9,"rel_authors":[{"author_name":"Junrong Han","author_inst":"Key Laboratory of Brain, Cognition and Education Sciences, Ministry of Education, Institute for Brain Research and Rehabilitation, Guangdong Key Laboratory of M"},{"author_name":"Qiuyou Xie","author_inst":"Department of Rehabilitation Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong, China; Joint Research Centre for Disorders o"},{"author_name":"Ying Huang","author_inst":"Key Laboratory of Brain, Cognition and Education Sciences, Ministry of Education, Center for Studies of Psychological Application, School of Psychology, South C"},{"author_name":"Man Li","author_inst":"School of Automation Science and Engineering, South China University of Technology, Guangzhou 510641, China; Research Center for Brain-Computer Interface, Pazho"},{"author_name":"Xiaoqing Hu","author_inst":"Department of Psychology, The University of Hong Kong, Hong Kong SAR, China; HKU-Shenzhen Institute of Research and Innovation, Shenzhen, China"},{"author_name":"Georg Northoff","author_inst":"Mind, Brain Imaging and Neuroethics Research Unit, The Royal's Institute of Mental Health Research, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canad"},{"author_name":"Yuanqing Li","author_inst":"School of Automation Science and Engineering, South China University of Technology, Guangzhou 510641, China; Research Center for Brain-Computer Interface, Pazho"},{"author_name":"Jun Zhang","author_inst":"Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"author_name":"Pengmin Qin","author_inst":"Key Laboratory of Brain, Cognition and Education Sciences, Ministry of Education, Institute for Brain Research and Rehabilitation, Guangdong Key Laboratory of M"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Backstroke rowing as an adaptation for low-Reynolds-number flight in tiny whiteflies (Bemisia tabaci)","rel_doi":"10.64898\/2026.11.15.766885","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766885","rel_abs":"The force resisting gravity during flight is typically aerodynamic-lift generated by the wings. However, in the smallest insects the low Reynolds number associated with a wing size [&le;]1mm reduces the efficiency of using lift for flight. We examined how miniature whiteflies (Bemisia tabaci) modulate their flapping kinematics to control flight in the vertical plane. Free-flying whiteflies were recorded using high-speed video cameras, and their 3D wing flapping kinematics were analyzed as a function of flight speed and climb angle. Whiteflies displayed the crescent-shaped wingtip trajectory typical to the drag-utilizing propulsion previously described in other miniature insects. To fly faster, they increased the wing sweep amplitude during the upstroke, resulting in increased wingtip speed relative to the body. To fly at steeper climbing angles the insects oriented their body to direct the upstroke wing motion downwards at a high angle-of-attack. Robotic force measurements confirmed that this downwards rowing in air provides vertical aerodynamic force exceeding body weight at least twofold. To direct the upstroke wing motion into a downwards rowing stroke, the insects used a combination of body pitch and roll that often resulted in the insects flying upside-down. This atypical flight posture emphasizes the adjustments required from tiny insects to convert a flight apparatus that was originally intended for utilizing lift into a drag-utilizing propulsion system, enabling flight at low Reynolds numbers.","rel_num_authors":4,"rel_authors":[{"author_name":"Amir Sarig","author_inst":"Tel Aviv University"},{"author_name":"Lior Gurka","author_inst":"Tel Aviv University"},{"author_name":"Maor Shemesh","author_inst":"Tel Aviv University"},{"author_name":"Gal Ribak","author_inst":"Tel Aviv University"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"LDEN: Alternating projections for whole genome linkage disequilibrium estimation from next-generation sequencing data","rel_doi":"10.64898\/2026.11.16.766929","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766929","rel_abs":"Viral populations often exist as quasispecies of closely-related variants with different mutations. Variants that possess combinations of mutations conferring an overall fitness advantage replicate preferentially. Understanding the true fitness effects of mutations involves disentangling the effects of individual mutations from their genetic background. This problem becomes particularly challenging due to linkage disequilibrium, the non-random association between mutations, which can cause neutral mutations to appear fit and vice versa. Viral populations are typically studied via next-generation sequencing, in which the read length is much shorter than the genome length, rendering long-range linkage disequilibrium unobservable. Estimation of linkage disequilibrium can be performed via population reconstruction, which reconstructs complete sequences before calculating linkage disequilibrium. However, this approach is computationally slow, memory-intensive, and prone to errors, particularly in regions of low coverage. In this work, we present a novel, population reconstruction-independent method for linkage disequilibrium estimation directly from next-generation sequencing data. Our approach uses the observed intra-read linkage disequilibrium values to estimate the unobservable inter-read ones by enforcing mathematical constraints on the linkage disequilibrium matrix. Specifically, because linkage disequilibrium quantifies the covariance between mutant allele frequencies, the linkage disequilibrium matrix must be positive semidefinite. We have formulated linkage disequilibrium estimation as a matrix completion problem and solve it via alternating projections on the constraints of positive semidefiniteness and observed linkage disequilibrium values. This allows the propagation of information from observed intra-read associations to the unobservable inter-read ones without reconstructing the individual variants. We demonstrate that our method yields higher accuracy while being two orders of magnitude faster compared to population reconstruction-based estimation. We demonstrate the performance of the method on both simulated as well as real data showing that it can estimate linkage disequilibrium from a variety of populations.","rel_num_authors":2,"rel_authors":[{"author_name":"Syed Muhammad Umer Abdullah","author_inst":"City University of Hong Kong"},{"author_name":"Yanni Sun","author_inst":"City University of Hong Kong"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"How a Disease-Associated Mutation Destabilizes the Sliding Clamp PCNA","rel_doi":"10.64898\/2026.11.15.766507","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766507","rel_abs":"The eukaryotic sliding clamp, Proliferating Cell Nuclear Antigen (PCNA), is a homo-trimeric ring-shaped protein complex that encircles DNA and serves as a scaffold for enzymes during DNA replication and the DNA damage response. Patients harboring the homozygous point mutation C148S in PCNA have the genetic disease PCNA Associated DNA Repair Disorder (PARD). Our lab showed that this PCNA variant has a drastic 10 {degrees}C thermostability defect. However, the crystal structure of the C148S variant displays a nearly identical conformation as WT PCNA, so it remained unclear how this point mutation destabilizes PCNA. Here, we use extensive all-atom classical molecular dynamics and well-tempered metadynamics simulations to predict how this mutation destabilizes PCNA. We first show that the C148S substitution changes an internal hydrogen-bond network and permits water molecules to transiently bind within the protein core, distorting the -helix containing C148S. This distortion in turn weakens the subunit interface, providing a molecular explanation for the lowered stability of the PCNA ring. Thus, our study addresses the molecular mechanism by which this disease-associated variant destabilizes PCNA and highlights the importance of understanding protein dynamics to interpret the effects of mutations in disease.","rel_num_authors":4,"rel_authors":[{"author_name":"Joshua Pajak","author_inst":"University of Massachusetts Chan Medical School"},{"author_name":"Kendra E. Baker","author_inst":"University of Massachusetts Chan Medical School"},{"author_name":"Joseph Magrino","author_inst":"University of Massachusetts Chan Medical School"},{"author_name":"Brian A Kelch","author_inst":"University of Massachusetts Medical School"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Altered visual responses in Drosophila BBSome mutants support a nonciliary role in the retina","rel_doi":"10.64898\/2026.11.16.766922","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766922","rel_abs":"The BBSome regulates ciliary membrane protein trafficking and mutations in its individual subunits lead in humans, to Bardet-Biedl syndrome, characterized by ciliopathic features including retinal degeneration. Here, we investigated BBSome function in Drosophila melanogaster, whose retinal photoreceptors lack cilia. We used CRISPR\/Cas9 mutagenesis to generate null alleles of six of the conserved BBSome subunits and the associated regulatory molecule BBS3\/ARL6. Each single mutant was viable and fertile and only the BBS1-BBS9 double mutant combination showed reduced male fertility. The BBSome mutants retained robust climbing ability and normal ciliary features in their sensory organs. However, all mutant genotypes showed reduced positive phototaxis. Locomotor recordings also demonstrated reduced light responsiveness in the mutants, with a transient suppression of activity during a light pulse in constant darkness. Fluorescently tagged wild-type BBSome subunits formed puncta in differentiating photoreceptors suggesting their association within the developing eye. In the adult mutants, a Rhodopsin 1-GFP reporter showed increased rhabdomeric fluorescence and additional puncta in the photoreceptor cell-body region which were not present in the wild-type. These findings support a non-ciliary contribution of BBSome proteins to orchestrating rhodopsin distribution and determining visual function. The altered localization of rhodopsin 1-GFP is consistent with disrupted rhodopsin trafficking or turnover, through a transport step independent of ciliary axonemes.","rel_num_authors":6,"rel_authors":[{"author_name":"Sarolta Szentes","author_inst":"Faculty of Medical and Health Sciences, Babes-Bolyai University, Cluj-Napoca, Romania"},{"author_name":"Milena Damulewicz","author_inst":"Department of Cell Biology and Imaging, Jagiellonian University, Krakow, Poland"},{"author_name":"Kinga Kapusi","author_inst":"Faculty of Medical and Health Sciences, Babes-Bolyai University, Cluj-Napoca, Romania"},{"author_name":"Katalin Farkas","author_inst":"Faculty of Medical and Health Sciences, Babes-Bolyai University, Cluj-Napoca, Romania"},{"author_name":"David M Glover","author_inst":"Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, USA."},{"author_name":"Levente Kovacs","author_inst":"Babe\u0219-Bolyai University"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Sequence-based models predict TF binding with negligible contributions from motif cooperativity","rel_doi":"10.64898\/2026.11.16.766980","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766980","rel_abs":"How transcription factors (TFs) selectively recognize their genomic targets among numerous sites containing similar DNA motifs remains an open question. Cooperative binding at neighboring motif sites is widely considered a key mechanism of TF specificity, yet its genome-wide contribution remains unclear. Machine learning models can now predict TF binding directly from DNA sequence, providing opportunities to investigate its underlying determinants. Here, we leveraged BPNet models trained on ~2,000 ENCODE TF binding profiles to systematically assess motif cooperativity. Although detected at individual loci, cooperativity made a negligible contribution to genome-wide binding predictions. Nevertheless, the models captured differences in binding preferences between TFs with similar motif preferences, even within the same cellular environment. These findings highlight the need to critically assess prevailing assumptions and explore alternative mechanisms underlying selective TF binding.","rel_num_authors":2,"rel_authors":[{"author_name":"Vladimir Mindel","author_inst":"Weizmann Institute of Science"},{"author_name":"Naama Barkai","author_inst":"Weizmann Institute of Science"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Brain disorder mechanisms and therapeutic targets identified from developmental, cell-specific gene regulation","rel_doi":"10.64898\/2026.11.15.766341","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766341","rel_abs":"Genetic variation influences brain physiology and disease across cell types and development. We integrated whole-genome sequencing, bulk RNA sequencing, and single-nucleus multiome profiling from 231 human dorsolateral prefrontal cortex donors spanning six postconceptional weeks to 92 years. Across 24 brain-related traits, neurodevelopmental and psychiatric genetic risk was enriched in neuronal transcriptomic and chromatin profiles, whereas neurodegenerative risk was enriched in microglia. Thousands of expression, chromatin accessibility, and splicing quantitative trait loci revealed developmental and cell-type-specific regulatory effects. Colocalization linked multiple sclerosis risk to AHI1 expression in prenatal neurons and problematic alcohol use to GPX1 expression in postnatal glia. Leveraging dynamic cis-regulatory elements, we identified therapeutic candidates for haploinsufficient neurodevelopmental disorders, including a SOX5 enhancer whose CRISPR activation increased transcript and protein abundance. Together, these findings establish a publicly accessible genomic resource for resolving the developmental and cellular contexts of genetic risk and identifying therapeutic targets in the human brain.","rel_num_authors":47,"rel_authors":[{"author_name":"Narjes Rohani","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Rothem Kovner","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Yuting Liu","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Antonio Garcia Guerra","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Theodora Markati","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Soo-Whee Kim","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Yujin Kim","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Qi Xu","author_inst":"School of Statistics, University of Minnesota, Minneapolis, MN 55455, USA"},{"author_name":"Emilie M Wigdor","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Jakob Weiss","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Joseph L Lalli","author_inst":"Laboratory of Genetics, University of Wisconsin Madison, Madison, WI 53706, USA"},{"author_name":"Shan Dong","author_inst":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA 94158, USA"},{"author_name":"Anandita Nadkarni","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Xuran Wang","author_inst":"Department   of Psychiatry; Department of Genetics and Genomic Sciences; Seaver Autism Center for Research and   Treatment, Icahn School of Medicine at Mount Si"},{"author_name":"Lambertus Klei","author_inst":"Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA"},{"author_name":"Sirisha Pochareddy","author_inst":"Genome Sciences Core, Penn State University College of Medicine, Hershey, PA 17033, USA"},{"author_name":"Daniel Speckhard-Pasque","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Chimmi Dema","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Sandra Canosa","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Hyesun Cho","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Ashley Deveau-French","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Gracie Gordon","author_inst":"Department of Cellular and Tissue Genomics, Genentech Research and Early Development, Genentech, South San Francisco, CA 94080, USA"},{"author_name":"Michael Griffiths","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Karan Jaisingh","author_inst":"Program in Medical and Population Genetics and Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for"},{"author_name":"Joy Kachko","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Pooja Kathail","author_inst":"Department of Electrical Engineering and Computer Sciences, Center for Computational Biology, University of California, Berkeley, Berkeley, CA 94720, USA"},{"author_name":"Mingli Li","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Dan Liang","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Alicia Ljungdahl","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK; Department of Psychiatry and Behavio"},{"author_name":"Shaojie Ma","author_inst":"Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, University of Chinese Academy of Sciences, Chinese Academy of"},{"author_name":"Ruhani Makkar","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX37TY; Oxford Children's Hospital, John Radcliff"},{"author_name":"Nicholas F Page","author_inst":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA 94158, USA"},{"author_name":"Alexa-Nicole Sliby","author_inst":"Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, USA"},{"author_name":"Menglei Zhang","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Xuefang Zhao","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research; Department of Neurology, Broad Institute of"},{"author_name":"Homa Adle-Biassette","author_inst":"Universite Paris Cite, Inserm, NeuroDiderot, Paris 75019, France; Department of Pathology, Biobank BB-0033-00064, AP-HP, Lariboisiere Hospital, Paris 75010, Fra"},{"author_name":"Chun Jimmie Ye","author_inst":"Division of Rheumatology, University of California San Francisco; Institute for Human Genetics, UCSF, San Francisco, CA 94143, USA"},{"author_name":"Harrison Brand","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research; Department of Neurology, Broad Institute of"},{"author_name":"Michael E Talkowski","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research;  Department of Neurology, Broad Institute o"},{"author_name":"Philip L De Jager","author_inst":"Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA"},{"author_name":"Donna M Werling","author_inst":"Laboratory of Genetics, University of Wisconsin Madison, Madison, WI 53706, USA"},{"author_name":"Matthew J Girgenti","author_inst":"Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, USA; Division of Rheumatology, University of California San Francisco, San Francisco, CA"},{"author_name":"Carlo Rinaldi","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Kathryn Roeder","author_inst":"Department of Statistics and Data Science; Department of Computational Biology, Carnegie Mellon University, Pittsburgh, PA 15213, USA"},{"author_name":"Bernie Devlin","author_inst":"Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA"},{"author_name":"Nenad Sestan","author_inst":"Department of Psychiatry; Department of Genetics; Department of Neuroscience; Kavli Institute for Neuroscience, Yale School of Medicine, New Haven, CT 06510, US"},{"author_name":"Stephan J Sanders","author_inst":"Institute of Developmental and Regenerative Medicine, University of Oxford, OX3 7TY ; Department of Psychiatry and Behavioral Sciences, UCSF; Weill Institute fo"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Brain disorder mechanisms and therapeutic targets identified from developmental, cell-specific gene regulation","rel_doi":"10.64898\/2026.11.15.766341","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766341","rel_abs":"Genetic variation influences brain physiology and disease across cell types and development. We integrated whole-genome sequencing, bulk RNA sequencing, and single-nucleus multiome profiling from 231 human dorsolateral prefrontal cortex donors spanning six postconceptional weeks to 92 years. Across 24 brain-related traits, neurodevelopmental and psychiatric genetic risk was enriched in neuronal transcriptomic and chromatin profiles, whereas neurodegenerative risk was enriched in microglia. Thousands of expression, chromatin accessibility, and splicing quantitative trait loci revealed developmental and cell-type-specific regulatory effects. Colocalization linked multiple sclerosis risk to AHI1 expression in prenatal neurons and problematic alcohol use to GPX1 expression in postnatal glia. Leveraging dynamic cis-regulatory elements, we identified therapeutic candidates for haploinsufficient neurodevelopmental disorders, including a SOX5 enhancer whose CRISPR activation increased transcript and protein abundance. Together, these findings establish a publicly accessible genomic resource for resolving the developmental and cellular contexts of genetic risk and identifying therapeutic targets in the human brain.","rel_num_authors":47,"rel_authors":[{"author_name":"Narjes Rohani","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Rothem Kovner","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Yuting Liu","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Antonio Garcia Guerra","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Theodora Markati","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Soo-Whee Kim","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Yujin Kim","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Qi Xu","author_inst":"School of Statistics, University of Minnesota, Minneapolis, MN 55455, USA"},{"author_name":"Emilie M Wigdor","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Jakob Weiss","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Joseph L Lalli","author_inst":"Laboratory of Genetics, University of Wisconsin Madison, Madison, WI 53706, USA"},{"author_name":"Shan Dong","author_inst":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA 94158, USA"},{"author_name":"Anandita Nadkarni","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Xuran Wang","author_inst":"Department   of Psychiatry; Department of Genetics and Genomic Sciences; Seaver Autism Center for Research and   Treatment, Icahn School of Medicine at Mount Si"},{"author_name":"Lambertus Klei","author_inst":"Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA"},{"author_name":"Sirisha Pochareddy","author_inst":"Genome Sciences Core, Penn State University College of Medicine, Hershey, PA 17033, USA"},{"author_name":"Daniel Speckhard-Pasque","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Chimmi Dema","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Sandra Canosa","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Hyesun Cho","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Ashley Deveau-French","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Gracie Gordon","author_inst":"Department of Cellular and Tissue Genomics, Genentech Research and Early Development, Genentech, South San Francisco, CA 94080, USA"},{"author_name":"Michael Griffiths","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Karan Jaisingh","author_inst":"Program in Medical and Population Genetics and Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for"},{"author_name":"Joy Kachko","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Pooja Kathail","author_inst":"Department of Electrical Engineering and Computer Sciences, Center for Computational Biology, University of California, Berkeley, Berkeley, CA 94720, USA"},{"author_name":"Mingli Li","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Dan Liang","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Alicia Ljungdahl","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK; Department of Psychiatry and Behavio"},{"author_name":"Shaojie Ma","author_inst":"Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, University of Chinese Academy of Sciences, Chinese Academy of"},{"author_name":"Ruhani Makkar","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX37TY; Oxford Children's Hospital, John Radcliff"},{"author_name":"Nicholas F Page","author_inst":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA 94158, USA"},{"author_name":"Alexa-Nicole Sliby","author_inst":"Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, USA"},{"author_name":"Menglei Zhang","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Xuefang Zhao","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research; Department of Neurology, Broad Institute of"},{"author_name":"Homa Adle-Biassette","author_inst":"Universite Paris Cite, Inserm, NeuroDiderot, Paris 75019, France; Department of Pathology, Biobank BB-0033-00064, AP-HP, Lariboisiere Hospital, Paris 75010, Fra"},{"author_name":"Chun Jimmie Ye","author_inst":"Division of Rheumatology, University of California San Francisco; Institute for Human Genetics, UCSF, San Francisco, CA 94143, USA"},{"author_name":"Harrison Brand","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research; Department of Neurology, Broad Institute of"},{"author_name":"Michael E Talkowski","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research;  Department of Neurology, Broad Institute o"},{"author_name":"Philip L De Jager","author_inst":"Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA"},{"author_name":"Donna M Werling","author_inst":"Laboratory of Genetics, University of Wisconsin Madison, Madison, WI 53706, USA"},{"author_name":"Matthew J Girgenti","author_inst":"Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, USA; Division of Rheumatology, University of California San Francisco, San Francisco, CA"},{"author_name":"Carlo Rinaldi","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Kathryn Roeder","author_inst":"Department of Statistics and Data Science; Department of Computational Biology, Carnegie Mellon University, Pittsburgh, PA 15213, USA"},{"author_name":"Bernie Devlin","author_inst":"Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA"},{"author_name":"Nenad Sestan","author_inst":"Department of Psychiatry; Department of Genetics; Department of Neuroscience; Kavli Institute for Neuroscience, Yale School of Medicine, New Haven, CT 06510, US"},{"author_name":"Stephan J Sanders","author_inst":"Institute of Developmental and Regenerative Medicine, University of Oxford, OX3 7TY ; Department of Psychiatry and Behavioral Sciences, UCSF; Weill Institute fo"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Brain disorder mechanisms and therapeutic targets identified from developmental, cell-specific gene regulation","rel_doi":"10.64898\/2026.11.15.766341","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766341","rel_abs":"Genetic variation influences brain physiology and disease across cell types and development. We integrated whole-genome sequencing, bulk RNA sequencing, and single-nucleus multiome profiling from 231 human dorsolateral prefrontal cortex donors spanning six postconceptional weeks to 92 years. Across 24 brain-related traits, neurodevelopmental and psychiatric genetic risk was enriched in neuronal transcriptomic and chromatin profiles, whereas neurodegenerative risk was enriched in microglia. Thousands of expression, chromatin accessibility, and splicing quantitative trait loci revealed developmental and cell-type-specific regulatory effects. Colocalization linked multiple sclerosis risk to AHI1 expression in prenatal neurons and problematic alcohol use to GPX1 expression in postnatal glia. Leveraging dynamic cis-regulatory elements, we identified therapeutic candidates for haploinsufficient neurodevelopmental disorders, including a SOX5 enhancer whose CRISPR activation increased transcript and protein abundance. Together, these findings establish a publicly accessible genomic resource for resolving the developmental and cellular contexts of genetic risk and identifying therapeutic targets in the human brain.","rel_num_authors":47,"rel_authors":[{"author_name":"Narjes Rohani","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Rothem Kovner","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Yuting Liu","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Antonio Garcia Guerra","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Theodora Markati","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Soo-Whee Kim","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Yujin Kim","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Qi Xu","author_inst":"School of Statistics, University of Minnesota, Minneapolis, MN 55455, USA"},{"author_name":"Emilie M Wigdor","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Jakob Weiss","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Joseph L Lalli","author_inst":"Laboratory of Genetics, University of Wisconsin Madison, Madison, WI 53706, USA"},{"author_name":"Shan Dong","author_inst":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA 94158, USA"},{"author_name":"Anandita Nadkarni","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Xuran Wang","author_inst":"Department   of Psychiatry; Department of Genetics and Genomic Sciences; Seaver Autism Center for Research and   Treatment, Icahn School of Medicine at Mount Si"},{"author_name":"Lambertus Klei","author_inst":"Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA"},{"author_name":"Sirisha Pochareddy","author_inst":"Genome Sciences Core, Penn State University College of Medicine, Hershey, PA 17033, USA"},{"author_name":"Daniel Speckhard-Pasque","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Chimmi Dema","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Sandra Canosa","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Hyesun Cho","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Ashley Deveau-French","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Gracie Gordon","author_inst":"Department of Cellular and Tissue Genomics, Genentech Research and Early Development, Genentech, South San Francisco, CA 94080, USA"},{"author_name":"Michael Griffiths","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Karan Jaisingh","author_inst":"Program in Medical and Population Genetics and Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for"},{"author_name":"Joy Kachko","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Pooja Kathail","author_inst":"Department of Electrical Engineering and Computer Sciences, Center for Computational Biology, University of California, Berkeley, Berkeley, CA 94720, USA"},{"author_name":"Mingli Li","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Dan Liang","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Alicia Ljungdahl","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK; Department of Psychiatry and Behavio"},{"author_name":"Shaojie Ma","author_inst":"Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, University of Chinese Academy of Sciences, Chinese Academy of"},{"author_name":"Ruhani Makkar","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX37TY; Oxford Children's Hospital, John Radcliff"},{"author_name":"Nicholas F Page","author_inst":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA 94158, USA"},{"author_name":"Alexa-Nicole Sliby","author_inst":"Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, USA"},{"author_name":"Menglei Zhang","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Xuefang Zhao","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research; Department of Neurology, Broad Institute of"},{"author_name":"Homa Adle-Biassette","author_inst":"Universite Paris Cite, Inserm, NeuroDiderot, Paris 75019, France; Department of Pathology, Biobank BB-0033-00064, AP-HP, Lariboisiere Hospital, Paris 75010, Fra"},{"author_name":"Chun Jimmie Ye","author_inst":"Division of Rheumatology, University of California San Francisco; Institute for Human Genetics, UCSF, San Francisco, CA 94143, USA"},{"author_name":"Harrison Brand","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research; Department of Neurology, Broad Institute of"},{"author_name":"Michael E Talkowski","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research;  Department of Neurology, Broad Institute o"},{"author_name":"Philip L De Jager","author_inst":"Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA"},{"author_name":"Donna M Werling","author_inst":"Laboratory of Genetics, University of Wisconsin Madison, Madison, WI 53706, USA"},{"author_name":"Matthew J Girgenti","author_inst":"Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, USA; Division of Rheumatology, University of California San Francisco, San Francisco, CA"},{"author_name":"Carlo Rinaldi","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Kathryn Roeder","author_inst":"Department of Statistics and Data Science; Department of Computational Biology, Carnegie Mellon University, Pittsburgh, PA 15213, USA"},{"author_name":"Bernie Devlin","author_inst":"Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA"},{"author_name":"Nenad Sestan","author_inst":"Department of Psychiatry; Department of Genetics; Department of Neuroscience; Kavli Institute for Neuroscience, Yale School of Medicine, New Haven, CT 06510, US"},{"author_name":"Stephan J Sanders","author_inst":"Institute of Developmental and Regenerative Medicine, University of Oxford, OX3 7TY ; Department of Psychiatry and Behavioral Sciences, UCSF; Weill Institute fo"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Brain disorder mechanisms and therapeutic targets identified from developmental, cell-specific gene regulation","rel_doi":"10.64898\/2026.11.15.766341","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766341","rel_abs":"Genetic variation influences brain physiology and disease across cell types and development. We integrated whole-genome sequencing, bulk RNA sequencing, and single-nucleus multiome profiling from 231 human dorsolateral prefrontal cortex donors spanning six postconceptional weeks to 92 years. Across 24 brain-related traits, neurodevelopmental and psychiatric genetic risk was enriched in neuronal transcriptomic and chromatin profiles, whereas neurodegenerative risk was enriched in microglia. Thousands of expression, chromatin accessibility, and splicing quantitative trait loci revealed developmental and cell-type-specific regulatory effects. Colocalization linked multiple sclerosis risk to AHI1 expression in prenatal neurons and problematic alcohol use to GPX1 expression in postnatal glia. Leveraging dynamic cis-regulatory elements, we identified therapeutic candidates for haploinsufficient neurodevelopmental disorders, including a SOX5 enhancer whose CRISPR activation increased transcript and protein abundance. Together, these findings establish a publicly accessible genomic resource for resolving the developmental and cellular contexts of genetic risk and identifying therapeutic targets in the human brain.","rel_num_authors":47,"rel_authors":[{"author_name":"Narjes Rohani","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Rothem Kovner","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Yuting Liu","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Antonio Garcia Guerra","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Theodora Markati","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Soo-Whee Kim","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Yujin Kim","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Qi Xu","author_inst":"School of Statistics, University of Minnesota, Minneapolis, MN 55455, USA"},{"author_name":"Emilie M Wigdor","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Jakob Weiss","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Joseph L Lalli","author_inst":"Laboratory of Genetics, University of Wisconsin Madison, Madison, WI 53706, USA"},{"author_name":"Shan Dong","author_inst":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA 94158, USA"},{"author_name":"Anandita Nadkarni","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Xuran Wang","author_inst":"Department   of Psychiatry; Department of Genetics and Genomic Sciences; Seaver Autism Center for Research and   Treatment, Icahn School of Medicine at Mount Si"},{"author_name":"Lambertus Klei","author_inst":"Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA"},{"author_name":"Sirisha Pochareddy","author_inst":"Genome Sciences Core, Penn State University College of Medicine, Hershey, PA 17033, USA"},{"author_name":"Daniel Speckhard-Pasque","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Chimmi Dema","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Sandra Canosa","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Hyesun Cho","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Ashley Deveau-French","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Gracie Gordon","author_inst":"Department of Cellular and Tissue Genomics, Genentech Research and Early Development, Genentech, South San Francisco, CA 94080, USA"},{"author_name":"Michael Griffiths","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Karan Jaisingh","author_inst":"Program in Medical and Population Genetics and Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for"},{"author_name":"Joy Kachko","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Pooja Kathail","author_inst":"Department of Electrical Engineering and Computer Sciences, Center for Computational Biology, University of California, Berkeley, Berkeley, CA 94720, USA"},{"author_name":"Mingli Li","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Dan Liang","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Alicia Ljungdahl","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK; Department of Psychiatry and Behavio"},{"author_name":"Shaojie Ma","author_inst":"Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, University of Chinese Academy of Sciences, Chinese Academy of"},{"author_name":"Ruhani Makkar","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX37TY; Oxford Children's Hospital, John Radcliff"},{"author_name":"Nicholas F Page","author_inst":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA 94158, USA"},{"author_name":"Alexa-Nicole Sliby","author_inst":"Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, USA"},{"author_name":"Menglei Zhang","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Xuefang Zhao","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research; Department of Neurology, Broad Institute of"},{"author_name":"Homa Adle-Biassette","author_inst":"Universite Paris Cite, Inserm, NeuroDiderot, Paris 75019, France; Department of Pathology, Biobank BB-0033-00064, AP-HP, Lariboisiere Hospital, Paris 75010, Fra"},{"author_name":"Chun Jimmie Ye","author_inst":"Division of Rheumatology, University of California San Francisco; Institute for Human Genetics, UCSF, San Francisco, CA 94143, USA"},{"author_name":"Harrison Brand","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research; Department of Neurology, Broad Institute of"},{"author_name":"Michael E Talkowski","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research;  Department of Neurology, Broad Institute o"},{"author_name":"Philip L De Jager","author_inst":"Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA"},{"author_name":"Donna M Werling","author_inst":"Laboratory of Genetics, University of Wisconsin Madison, Madison, WI 53706, USA"},{"author_name":"Matthew J Girgenti","author_inst":"Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, USA; Division of Rheumatology, University of California San Francisco, San Francisco, CA"},{"author_name":"Carlo Rinaldi","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Kathryn Roeder","author_inst":"Department of Statistics and Data Science; Department of Computational Biology, Carnegie Mellon University, Pittsburgh, PA 15213, USA"},{"author_name":"Bernie Devlin","author_inst":"Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA"},{"author_name":"Nenad Sestan","author_inst":"Department of Psychiatry; Department of Genetics; Department of Neuroscience; Kavli Institute for Neuroscience, Yale School of Medicine, New Haven, CT 06510, US"},{"author_name":"Stephan J Sanders","author_inst":"Institute of Developmental and Regenerative Medicine, University of Oxford, OX3 7TY ; Department of Psychiatry and Behavioral Sciences, UCSF; Weill Institute fo"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Brain disorder mechanisms and therapeutic targets identified from developmental, cell-specific gene regulation","rel_doi":"10.64898\/2026.11.15.766341","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766341","rel_abs":"Genetic variation influences brain physiology and disease across cell types and development. We integrated whole-genome sequencing, bulk RNA sequencing, and single-nucleus multiome profiling from 231 human dorsolateral prefrontal cortex donors spanning six postconceptional weeks to 92 years. Across 24 brain-related traits, neurodevelopmental and psychiatric genetic risk was enriched in neuronal transcriptomic and chromatin profiles, whereas neurodegenerative risk was enriched in microglia. Thousands of expression, chromatin accessibility, and splicing quantitative trait loci revealed developmental and cell-type-specific regulatory effects. Colocalization linked multiple sclerosis risk to AHI1 expression in prenatal neurons and problematic alcohol use to GPX1 expression in postnatal glia. Leveraging dynamic cis-regulatory elements, we identified therapeutic candidates for haploinsufficient neurodevelopmental disorders, including a SOX5 enhancer whose CRISPR activation increased transcript and protein abundance. Together, these findings establish a publicly accessible genomic resource for resolving the developmental and cellular contexts of genetic risk and identifying therapeutic targets in the human brain.","rel_num_authors":47,"rel_authors":[{"author_name":"Narjes Rohani","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Rothem Kovner","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Yuting Liu","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Antonio Garcia Guerra","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Theodora Markati","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Soo-Whee Kim","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Yujin Kim","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Qi Xu","author_inst":"School of Statistics, University of Minnesota, Minneapolis, MN 55455, USA"},{"author_name":"Emilie M Wigdor","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Jakob Weiss","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Joseph L Lalli","author_inst":"Laboratory of Genetics, University of Wisconsin Madison, Madison, WI 53706, USA"},{"author_name":"Shan Dong","author_inst":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA 94158, USA"},{"author_name":"Anandita Nadkarni","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Xuran Wang","author_inst":"Department   of Psychiatry; Department of Genetics and Genomic Sciences; Seaver Autism Center for Research and   Treatment, Icahn School of Medicine at Mount Si"},{"author_name":"Lambertus Klei","author_inst":"Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA"},{"author_name":"Sirisha Pochareddy","author_inst":"Genome Sciences Core, Penn State University College of Medicine, Hershey, PA 17033, USA"},{"author_name":"Daniel Speckhard-Pasque","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Chimmi Dema","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Sandra Canosa","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Hyesun Cho","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Ashley Deveau-French","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Gracie Gordon","author_inst":"Department of Cellular and Tissue Genomics, Genentech Research and Early Development, Genentech, South San Francisco, CA 94080, USA"},{"author_name":"Michael Griffiths","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Karan Jaisingh","author_inst":"Program in Medical and Population Genetics and Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for"},{"author_name":"Joy Kachko","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Pooja Kathail","author_inst":"Department of Electrical Engineering and Computer Sciences, Center for Computational Biology, University of California, Berkeley, Berkeley, CA 94720, USA"},{"author_name":"Mingli Li","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Dan Liang","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Alicia Ljungdahl","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK; Department of Psychiatry and Behavio"},{"author_name":"Shaojie Ma","author_inst":"Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, University of Chinese Academy of Sciences, Chinese Academy of"},{"author_name":"Ruhani Makkar","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX37TY; Oxford Children's Hospital, John Radcliff"},{"author_name":"Nicholas F Page","author_inst":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA 94158, USA"},{"author_name":"Alexa-Nicole Sliby","author_inst":"Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, USA"},{"author_name":"Menglei Zhang","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Xuefang Zhao","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research; Department of Neurology, Broad Institute of"},{"author_name":"Homa Adle-Biassette","author_inst":"Universite Paris Cite, Inserm, NeuroDiderot, Paris 75019, France; Department of Pathology, Biobank BB-0033-00064, AP-HP, Lariboisiere Hospital, Paris 75010, Fra"},{"author_name":"Chun Jimmie Ye","author_inst":"Division of Rheumatology, University of California San Francisco; Institute for Human Genetics, UCSF, San Francisco, CA 94143, USA"},{"author_name":"Harrison Brand","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research; Department of Neurology, Broad Institute of"},{"author_name":"Michael E Talkowski","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research;  Department of Neurology, Broad Institute o"},{"author_name":"Philip L De Jager","author_inst":"Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA"},{"author_name":"Donna M Werling","author_inst":"Laboratory of Genetics, University of Wisconsin Madison, Madison, WI 53706, USA"},{"author_name":"Matthew J Girgenti","author_inst":"Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, USA; Division of Rheumatology, University of California San Francisco, San Francisco, CA"},{"author_name":"Carlo Rinaldi","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Kathryn Roeder","author_inst":"Department of Statistics and Data Science; Department of Computational Biology, Carnegie Mellon University, Pittsburgh, PA 15213, USA"},{"author_name":"Bernie Devlin","author_inst":"Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA"},{"author_name":"Nenad Sestan","author_inst":"Department of Psychiatry; Department of Genetics; Department of Neuroscience; Kavli Institute for Neuroscience, Yale School of Medicine, New Haven, CT 06510, US"},{"author_name":"Stephan J Sanders","author_inst":"Institute of Developmental and Regenerative Medicine, University of Oxford, OX3 7TY ; Department of Psychiatry and Behavioral Sciences, UCSF; Weill Institute fo"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Brain disorder mechanisms and therapeutic targets identified from developmental, cell-specific gene regulation","rel_doi":"10.64898\/2026.11.15.766341","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766341","rel_abs":"Genetic variation influences brain physiology and disease across cell types and development. We integrated whole-genome sequencing, bulk RNA sequencing, and single-nucleus multiome profiling from 231 human dorsolateral prefrontal cortex donors spanning six postconceptional weeks to 92 years. Across 24 brain-related traits, neurodevelopmental and psychiatric genetic risk was enriched in neuronal transcriptomic and chromatin profiles, whereas neurodegenerative risk was enriched in microglia. Thousands of expression, chromatin accessibility, and splicing quantitative trait loci revealed developmental and cell-type-specific regulatory effects. Colocalization linked multiple sclerosis risk to AHI1 expression in prenatal neurons and problematic alcohol use to GPX1 expression in postnatal glia. Leveraging dynamic cis-regulatory elements, we identified therapeutic candidates for haploinsufficient neurodevelopmental disorders, including a SOX5 enhancer whose CRISPR activation increased transcript and protein abundance. Together, these findings establish a publicly accessible genomic resource for resolving the developmental and cellular contexts of genetic risk and identifying therapeutic targets in the human brain.","rel_num_authors":47,"rel_authors":[{"author_name":"Narjes Rohani","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Rothem Kovner","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Yuting Liu","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Antonio Garcia Guerra","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Theodora Markati","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Soo-Whee Kim","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Yujin Kim","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Qi Xu","author_inst":"School of Statistics, University of Minnesota, Minneapolis, MN 55455, USA"},{"author_name":"Emilie M Wigdor","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Jakob Weiss","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Joseph L Lalli","author_inst":"Laboratory of Genetics, University of Wisconsin Madison, Madison, WI 53706, USA"},{"author_name":"Shan Dong","author_inst":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA 94158, USA"},{"author_name":"Anandita Nadkarni","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Xuran Wang","author_inst":"Department   of Psychiatry; Department of Genetics and Genomic Sciences; Seaver Autism Center for Research and   Treatment, Icahn School of Medicine at Mount Si"},{"author_name":"Lambertus Klei","author_inst":"Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA"},{"author_name":"Sirisha Pochareddy","author_inst":"Genome Sciences Core, Penn State University College of Medicine, Hershey, PA 17033, USA"},{"author_name":"Daniel Speckhard-Pasque","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Chimmi Dema","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Sandra Canosa","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Hyesun Cho","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Ashley Deveau-French","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Gracie Gordon","author_inst":"Department of Cellular and Tissue Genomics, Genentech Research and Early Development, Genentech, South San Francisco, CA 94080, USA"},{"author_name":"Michael Griffiths","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Karan Jaisingh","author_inst":"Program in Medical and Population Genetics and Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for"},{"author_name":"Joy Kachko","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Pooja Kathail","author_inst":"Department of Electrical Engineering and Computer Sciences, Center for Computational Biology, University of California, Berkeley, Berkeley, CA 94720, USA"},{"author_name":"Mingli Li","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Dan Liang","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Alicia Ljungdahl","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK; Department of Psychiatry and Behavio"},{"author_name":"Shaojie Ma","author_inst":"Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, University of Chinese Academy of Sciences, Chinese Academy of"},{"author_name":"Ruhani Makkar","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX37TY; Oxford Children's Hospital, John Radcliff"},{"author_name":"Nicholas F Page","author_inst":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA 94158, USA"},{"author_name":"Alexa-Nicole Sliby","author_inst":"Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, USA"},{"author_name":"Menglei Zhang","author_inst":"Department of Neuroscience, Yale School of Medicine, New Haven, CT 06510, USA"},{"author_name":"Xuefang Zhao","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research; Department of Neurology, Broad Institute of"},{"author_name":"Homa Adle-Biassette","author_inst":"Universite Paris Cite, Inserm, NeuroDiderot, Paris 75019, France; Department of Pathology, Biobank BB-0033-00064, AP-HP, Lariboisiere Hospital, Paris 75010, Fra"},{"author_name":"Chun Jimmie Ye","author_inst":"Division of Rheumatology, University of California San Francisco; Institute for Human Genetics, UCSF, San Francisco, CA 94143, USA"},{"author_name":"Harrison Brand","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research; Department of Neurology, Broad Institute of"},{"author_name":"Michael E Talkowski","author_inst":"Center for Genomic Medicine; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research;  Department of Neurology, Broad Institute o"},{"author_name":"Philip L De Jager","author_inst":"Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA"},{"author_name":"Donna M Werling","author_inst":"Laboratory of Genetics, University of Wisconsin Madison, Madison, WI 53706, USA"},{"author_name":"Matthew J Girgenti","author_inst":"Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, USA; Division of Rheumatology, University of California San Francisco, San Francisco, CA"},{"author_name":"Carlo Rinaldi","author_inst":"Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK"},{"author_name":"Kathryn Roeder","author_inst":"Department of Statistics and Data Science; Department of Computational Biology, Carnegie Mellon University, Pittsburgh, PA 15213, USA"},{"author_name":"Bernie Devlin","author_inst":"Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA"},{"author_name":"Nenad Sestan","author_inst":"Department of Psychiatry; Department of Genetics; Department of Neuroscience; Kavli Institute for Neuroscience, Yale School of Medicine, New Haven, CT 06510, US"},{"author_name":"Stephan J Sanders","author_inst":"Institute of Developmental and Regenerative Medicine, University of Oxford, OX3 7TY ; Department of Psychiatry and Behavioral Sciences, UCSF; Weill Institute fo"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"A conserved MoxR-vWA chaperone complex drives starvation-induced protein degradation in bacteria","rel_doi":"10.64898\/2026.11.14.766676","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.14.766676","rel_abs":"Bacteria must quickly adapt to changes in their environment, notably including the sudden loss of nutrients. We previously showed that in glucose-starved E. coli, widespread starvation-induced protein degradation (SPD) fuels post-starvation proteome remodeling, degrading a wide swath of the proteome to supply the cell with energy and amino acids for synthesis of stress proteins. Here we demonstrate that SPD is mediated by a highly conserved complex of three proteins: the MoxR-type AAA+ ATPase SpdA, the von Willebrand factor A (vWA) domain protein SpdB, and the zinc metallopeptidase SpdC. Structural modeling and in vitro reconstitutions show that these proteins form a complex with 6:1:1 stoichiometry that resembles the widespread, but still poorly understood, family of MoxR-vWA chaperone complexes in bacteria and eukaryotes. Measurements of protein degradation in glucose-starved E. coli cells show that SpdA, SpdB, and SpdC work together to mediate the degradation of SPD substrates. Instead of directly degrading these substrates, our data suggest that limited structural perturbation and proteolysis \"softens\" SPD substrates and promotes their degradation by the cellular proteases ClpAP\/ClpXP and Lon. Thus, SPD enables extensive proteome remodeling during starvation by expanding the pool of proteins accessible to cellular proteases, rather than by increasing protease abundance. Phylogenetic analysis shows that SpdA, SpdB, and SpdC are highly conserved across bacteria, with notable homologs including the well-characterized Bacillus subtilis sporulation factors PrkA (SpdA), YhbH (SpdB), and SpoVR (SpdC).","rel_num_authors":16,"rel_authors":[{"author_name":"Hiroyuki Okano","author_inst":"UC San Diego"},{"author_name":"Qiaozhen Ye","author_inst":"UC San Diego"},{"author_name":"Matteo Mori","author_inst":"UC San Diego"},{"author_name":"Gabriel Manzanarez","author_inst":"UC San Diego"},{"author_name":"Zhongge Zhang","author_inst":"UC San Diego"},{"author_name":"Franziska Hackbarth","author_inst":"Technical University of Munich, Germany"},{"author_name":"Lydia R Chambers","author_inst":"UC San Diego"},{"author_name":"Rohan Balakrishnan","author_inst":"UC San Diego"},{"author_name":"Harish Kannan","author_inst":"UC San Diego"},{"author_name":"Elina Tian","author_inst":"UC San Diego"},{"author_name":"Francisco Mendez-Diaz","author_inst":"UC San Diego"},{"author_name":"Jialu Huo","author_inst":"UC San Diego"},{"author_name":"Eray Enustun","author_inst":"UC San Diego"},{"author_name":"Christina Ludwig","author_inst":"Technical University of Munich, Germany"},{"author_name":"Terence Hwa","author_inst":"UC San Diego"},{"author_name":"Kevin D Corbett","author_inst":"University of California, San Diego"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Embedding kernels for sequence-function relationships","rel_doi":"10.64898\/2026.11.15.766687","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766687","rel_abs":"A central challenge in biology is understanding how variation in biological sequences (DNA, RNA, and protein) impacts function. Recent advances in high-throughput techniques have enabled the measurement of such sequence-function relationships on an unprecedented scale. However, analyzing these complex datasets requires models that are both flexible and mathematically tractable. We consider Gaussian process regression, a Bayesian method that specifies a Gaussian prior distribution over sequence-function relationships. The prior is defined by a kernel function that encodes the expected covariance between pairs of sequences. We study a family of embedding kernels in which the covariance depends on the distance between sequences in a learned embedding space, making these kernels both expressive and interpretable. We show that linear embedding kernels generalize previously studied classes of kernels and can more flexibly express variability in the expected similarity between mutational effects across genetic backgrounds, allowing the resulting priors to encode more complex biological mechanisms such as RNA base-pairing. We implement these methods using a GPU-accelerated Gaussian process framework, allowing us to learn linear embeddings and make predictions with datasets containing hundreds of thousands of measurements. We find that our embedding kernels match or improve the predictive performance of other kernels across various high-throughput sequence-function datasets, including protein datasets ranging from short motifs to full-length proteins. Furthermore, the learned embedding spaces provide insight into biological mechanisms underlying sequence-function relationships.","rel_num_authors":4,"rel_authors":[{"author_name":"Waverly Carabba","author_inst":"Tufts University"},{"author_name":"Carlos Mart\u00ed-G\u00f3mez","author_inst":"Cold Spring Harbor Laboratory"},{"author_name":"David Martin McCandlish","author_inst":"Cold Spring Harbor Laboratory"},{"author_name":"Samantha Petti","author_inst":"Tufts University"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Global Epistasis Constrains the Dynamics of Fitness in Multiple Environments","rel_doi":"10.64898\/2026.11.14.766606","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.14.766606","rel_abs":"Adaptive mutations in one (home) environment often have diverse effects in other (non-home) environments. This so-called pleiotropy has important implications for the ability of populations to survive environmental fluctuations, which are common in nature. But how the fitness effects vary across mutations, genetic backgrounds and environments is poorly characterized empirically, and a unifying theory describing this variation is lacking. To address this gap, we develop the so-called global epistasis family of models and find that it explains a substantial proportion of variation in the distributions of mutational effects across genetic backgrounds and environments in a published yeast dataset. We then examine evolutionary dynamics that emerge in this model and we find that, as a population adapts at home, its non-home fitness can either converge to an intermediate finite value, or increase or decline indefinitely, with the empirical parameters being consistent with the first two outcomes. This work provides a quantitative unification of pleiotropy and epistasis, generates testable predictions for the pleiotropic consequences of adaptation and enables a better understanding of evolution in fluctuating environments.","rel_num_authors":3,"rel_authors":[{"author_name":"Jhelam N. Deshpande","author_inst":"University of California San Diego"},{"author_name":"Sarah M. Ardell","author_inst":"Verdant Associates, Berkeley, CA 94707"},{"author_name":"Sergey Kryazhimskiy","author_inst":"University of California, San Diego"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Label-Free Lymphocyte Subtype and State Classification by Stimulated Raman Scattering Microscopy","rel_doi":"10.64898\/2026.11.16.766877","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766877","rel_abs":"Accurate immune cell subtype and functional state profiling are essential for studying immune regulation, disease progression, and therapeutic response. Established single-cell analysis techniques rely heavily on either endpoint, destructive measurements or complex labeling that can potentially affect cell functions. Stimulated Raman scattering (SRS) microscopy offers quantitative, label-free imaging of cells and tissues by providing contrast based on subcellular concentrations of intrinsic biomolecules at high spatial and temporal resolution. Here, we demonstrate that Vision Transformer based hyperspectral SRS imaging classification can accurately and non-destructively classify various lymphocyte phenotypes, including lymphocyte lineage (T and B cells), T cell subset and differentiation state (CD4+ and CD8+ T cells, effector, memory, and naive for both), and functional states (naive T, activated T, exhausted T) using fluorescent markers for training. By leveraging attention-based spatial-spectral feature learning, the approach captures biomolecular patterns associated with immune cell identity and state while preserving cells for downstream or longitudinal analysis. This provides a potential platform for label-free immune profiling, live-cell analysis, and longitudinal studies of immune cell type and state transitions.","rel_num_authors":6,"rel_authors":[{"author_name":"King Wai Chiu","author_inst":"University of Washington"},{"author_name":"Paul J. Leanza","author_inst":"University of Washington"},{"author_name":"Ziang Li","author_inst":"University of Washington"},{"author_name":"Bryce Manifold","author_inst":"University of Washington"},{"author_name":"Ho Yuan Kueh","author_inst":"University of Washington"},{"author_name":"Dan Fu","author_inst":"University of Washington"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Automated, high-throughput kinematic analysis of skilled reaching in rodent models of neurological injury","rel_doi":"10.64898\/2026.11.13.766238","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.13.766238","rel_abs":"Neurological dysfunction can diminish quality of life by disrupting the movement capacity required to accomplish tasks. Kinematic studies guide treatment development by revealing subtle relationships between patterns of movement and neurological dysfunction. However, these studies produce a large quantity of opaque, multifaceted, and often highly correlated data. Here we present a novel and efficient approach to collecting, analyzing, and interpreting kinematic data with high throughput. We automated a single pellet reaching task in mice and created a video analysis pipeline that scores task success and extracts kinematic features from reaches. To analyze the resulting data, principal component analysis was first applied to group covarying measurements into a few overarching dimensions of behavior. Regularized regression was then applied separately to select reach qualities that best predicted task success. Applied to four nervous system injury models, this approach revealed differences in the effects of injury type and rehabilitative intervention on movement patterns that were not apparent from task success alone.","rel_num_authors":14,"rel_authors":[{"author_name":"Logan S. Friedrich","author_inst":"Marquette University"},{"author_name":"Esmeralda Mendoza","author_inst":"University of California, San Francisco"},{"author_name":"J. Russell Huie","author_inst":"UCSF"},{"author_name":"Jose Rosas","author_inst":"Marquette University"},{"author_name":"Zimei Wang","author_inst":"Marquette University"},{"author_name":"Sunil Mathew","author_inst":"Marquette University"},{"author_name":"Colin Schultz","author_inst":"Marquette University"},{"author_name":"Neil Chhikara","author_inst":"Marquette University"},{"author_name":"Nick Samburg","author_inst":"Marquette University"},{"author_name":"Riley Specht","author_inst":"Marquette University"},{"author_name":"Isabel Antolak","author_inst":"Marquette University"},{"author_name":"Pantelis Tsoulfas","author_inst":"University of Miami"},{"author_name":"Adam Ferguson","author_inst":"University of California, San Francisco"},{"author_name":"Murray G Blackmore","author_inst":"Marquette University"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Structural basis of cage assembly by a bacterial flotillin","rel_doi":"10.64898\/2026.11.15.766717","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766717","rel_abs":"Flotillins organize membrane microdomains implicated in signaling, cell-wall synthesis, and antibiotic resistance, yet how bacterial flotillins assemble remains unknown. Here, we report a 3.1 [A] cryo-EM structure of the Escherichia coli flotillin YqiK, purified through its NfeD-family partner YqiJ - the first high-resolution structure of a bacterial flotillin assembly. YqiK forms a membrane assembly of 54 identical subunits. Unlike human flotillin cages, which contain two alternating paralogues, YqiK assembles from a single transmembrane protein. The cage is ~38 nm wide and encloses ~900 nm2 of membrane within its ring of 54 transmembrane helices. Its wall helices run continuously for ~287 &Aring, the longest in any SPFH assembly, making this the largest membrane-anchored SPFH cage reported to date. In YqiK, helix length and tilt set cage dimensions, while intersubunit salt bridges and hydrophobic interactions stabilize the assembly. Focused classification revealed local discontinuities in the cage wall, suggesting possible conformational flexibility. Mass spectrometry identified stress-associated membrane proteins and respiratory complexes that co-purify with YqiK-YqiJ. Together, these findings reveal how a bacterial flotillin builds a large membrane-associated scaffold and provide a structural basis for investigating how such compartments organize membrane proteins within the microdomain they define.","rel_num_authors":2,"rel_authors":[{"author_name":"Naseer Iqbal","author_inst":"Washington University in St. Louis"},{"author_name":"Alireza Ghanbarpour","author_inst":"Washington University School of Medicine"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Pluripotent and differentiated cells display distinct genomic and nuclear landscapes of genome folding variability","rel_doi":"10.64898\/2026.11.16.766639","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.766639","rel_abs":"Chromosome folding varies between cells. It is not known whether cell types differ in the extent of folding variability, whether distinct chromosomal regions in the same cell type display different levels of variability, and how folding variability relates to sub-nuclear location and gene expression. We combined two single-cell Hi-C approaches with 3D genome modeling of pseudo-single cells (IGM), DNA FISH, chromosome painting, and single-cell RNA-seq across a five-stage differentiation trajectory from human embryonic stem cells to hepatocyte-like cells. In all cell types folding variability correlates with compartment status, is highest towards the nuclear interior, decreases as a function of radial position in the nucleus, and is the lowest at the periphery. Loci associated with nuclear landmarks such as speckles, and especially the nuclear periphery display more consistent subnuclear positioning in all cell stages. Moreover, pluripotent and differentiated cells display different overall levels of chromosome folding variability: in H1 pluripotent cells the entire genome displays higher folding and positional variability. In contrast, in differentiated cells folding variability is generally lower along the genome and the number of loci that become consistently positioned at the nuclear periphery increases sharply. The two distinct patterns of folding variability were correlated with cell-to-cell gene expression variation: In pluripotent cells gene expression variation is large, pervasive and seen throughout the genome and the nucleus. In differentiated cells cell-to-cell variation in gene expression is much lower and restricted mostly to genes located near the center of the nucleus, consistent with the restricted pattern of chromosome folding variation. These findings reveal two distinct genomic states: pluripotent cells maintain a variably folded, spatially permissive genome and transcriptional plasticity, whereas differentiated cells mature into a spatially deterministic, more consistently folded organization that correlates with more restricted transcriptional programs.","rel_num_authors":9,"rel_authors":[{"author_name":"Xiangru Huo","author_inst":"University of Massachusetts Chan Medical School"},{"author_name":"Ye Wang","author_inst":"UCLA"},{"author_name":"Liyan Yang","author_inst":"University of Massachusetts Chan Medical School"},{"author_name":"Jiang Min","author_inst":"University of Massachusetts Chan Medical School, Jacksons lab."},{"author_name":"Jack Huey","author_inst":"University of Massachusetts Chan Medical School"},{"author_name":"Rene Maehr","author_inst":"UMass Med School"},{"author_name":"Johan H. Gibcus","author_inst":"University of Massachusetts Chan Medical School"},{"author_name":"Frank Alber","author_inst":"University of California Los Angeles"},{"author_name":"Job Dekker","author_inst":"University of Massachusetts Chan Medical School"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Magnetic separation screens identify G alpha 15 as a central regulator of degranulation downstream of neutrophil chemoattractant receptors","rel_doi":"10.64898\/2026.11.14.766678","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.14.766678","rel_abs":"Neutrophil recruitment and effector functions protect the body from infection. However, their excessive activity is central to inflammatory diseases, in which neutrophil granule proteins damage tissues and amplify inflammation. These proteins are released through degranulation, a regulated secretion process that can be triggered by the same chemoattractant molecules that drive neutrophil recruitment. Neutrophils detect attractants using G protein-coupled receptors (GPCRs) that signal through Gi G-proteins. How the activity of these receptors is channeled to promote degranulation versus chemotaxis in the proper contexts remains unclear. Here, we identify positive and negative regulators of degranulation in HL-60 neutrophils using genome-wide CRISPR\/Cas9 screens that exploit the transient surface exposure of granule membrane proteins. We identify G15 as a critical degranulation-specific effector of the attractant GPCRs FPR1 and LTB4R, and branched actin assembly as the dominant process limiting degranulation. Our results suggest that use of a second G subunit allows a switch to the degranulation output.","rel_num_authors":7,"rel_authors":[{"author_name":"Stefan M Lundgren","author_inst":"University of California, Davis"},{"author_name":"Alexandra L Calderon","author_inst":"University of California, Davis"},{"author_name":"Emel Akdo\u011fan","author_inst":"University of California, Davis"},{"author_name":"Kimberly M Bonger","author_inst":"Leiden University"},{"author_name":"Roarke A Kamber","author_inst":"University of California, San Francisco"},{"author_name":"Michael C Bassik","author_inst":"Stanford Univeristy"},{"author_name":"Sean R Collins","author_inst":"University of California, Davis"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"A histone hitchhiking mechanism for chromatin maintenance during mammalian transcription elongation","rel_doi":"10.64898\/2026.11.16.751813","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.751813","rel_abs":"Eukaryotic transcription machinery faces the dual challenge of having to dismantle the nucleosome barrier for efficient elongation and faithfully restore the chromatin landscape in its wake to prevent aberrant transcription. The sequence of molecular events from nucleosome unwrapping to reassembly has yet to be delineated. Here, we use a single-molecule platform to visualize the dynamics of chromatin transcription by mammalian elongation complex (EC) in real time. When supplemented with a set of elongation factors and histone chaperones, the EC can efficiently traverse the nucleosome it encounters and, surprisingly, carry the dislodged histones while continuing translocation on DNA, a phenomenon we termed histone 'hitchhiking'. The formation of this hitchhiking complex is facilitated by the elongation factor SPT6 and IWS1 through distinct mechanisms. On the other hand, the histone chaperones FACT and NAP1L1 promote the transition from histone hitchhiking to nucleosome reassembly. We further showed that the next nucleosome presents a strong barrier against the hitchhiking complex, thus limiting long-range chromatin disruption. Overall, our results revealed that histone hitchhiking by EC is a prevalent intermediate during chromatin transcription, and the timing and location of its resolution are tuned by multiple factors. This mechanism may provide the robustness and flexibility needed to maintain the local organization of transcriptionally active chromatin.","rel_num_authors":8,"rel_authors":[{"author_name":"Yukun Wang","author_inst":"The Rockefeller University"},{"author_name":"Xizi Chen","author_inst":"Fudan University Shanghai Cancer Center"},{"author_name":"Yiqing Luo","author_inst":"Chinese Academy of Sciences Center for Excellence in Molecular Cell Science"},{"author_name":"John Wilson Watters","author_inst":"The Rockefeller University"},{"author_name":"Aixia Song","author_inst":"Chinese Academy of Sciences Center for Excellence in Molecular Cell Science"},{"author_name":"Fei Xavier Chen","author_inst":"Chinese Academy of Sciences Center for Excellence in Molecular Cell Science"},{"author_name":"Yanhui Xu","author_inst":"Fudan University Shanghai Cancer Center"},{"author_name":"Shixin Liu","author_inst":"The Rockefeller University"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Scaling up naturalistic narrative research: A reproducible large language model-based tool for evaluating contextual information gain","rel_doi":"10.64898\/2026.11.14.766702","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.14.766702","rel_abs":"Narratives are a universal part of natural human experience. As experimental stimuli, narratives allow scientists to study complex mental processes with direct relevance to everyday experience. These analyses typically require manual labeling of key event features. Such characterization of narrative stimuli are extremely labor-intensive and prone to subjectivity. Automated tools could reduce these difficulties and enable scaling to longer, varied stimuli by exposing the exact quantities computed. We address this by introducing a metric that uses open-weight LLMs to compute contextual information gain. Our metric correlates with human ratings of event importance and causal centrality, critically distinguishing the latter from semantic centrality, thus overcoming limitations of existing automated tools. The metric similarly captures shared coactivation in the default mode network, a network implicated in narrative comprehension. Taken together, these results validate an automated, empirically-grounded tool that researchers can use to identify behaviorally- and neurally-relevant computational quantities in naturalistic stimuli.","rel_num_authors":6,"rel_authors":[{"author_name":"Rohin A Palsule","author_inst":"University of California, Irvine"},{"author_name":"Aidan Goeschel","author_inst":"Princeton University"},{"author_name":"Jungsun Yoo","author_inst":"Princeton University"},{"author_name":"Janice Chen","author_inst":"Johns Hopkins University"},{"author_name":"Aaron M Bornstein","author_inst":"University of California, Irvine"},{"author_name":"Ari Khoudary","author_inst":"University of California, Irvine"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"A spatial correlation function approach reveals zonation loss in liver disease","rel_doi":"10.64898\/2026.11.16.767021","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.16.767021","rel_abs":"Spatial transcriptomics measures the expression of hundreds to thousands of genes in each cell together with the cell's position in the tissue. Here we use spatial correlation functions, which describe how the correlation of gene expression between cells decays with distance, to quantify how the spatial organization of gene expression changes in disease. From the correlation function of each gene, or of each pair of genes, we extract two numbers: a susceptibility, which measures how strongly gene expression is correlated between nearby cells, and a correlation length, the distance over which this correlation extends. Both are in physical units and can be compared directly between samples and conditions. We apply the approach to healthy and fibrotic mouse liver using newly generated data, and to healthy and fibrotic human liver using published data. Correlations between gene pairs identify genes of the same hepatocyte zone, and assign a zone to 1,266 genes that are not known zonation markers. The two fibrotic conditions differ: CCl4 injection in mice produces a moderate reorganization in which some genes lose spatial correlation and others gain it, while in human fibrosis almost every measured gene loses it. Changes in spatial correlation are only weakly related to changes in expression level. For instance Cyp2c29 and Pon1 partially lose their spatial correlation in treated mice, although their average expression does not consistently fall. Spatial correlation functions therefore detect changes in tissue organization that measurements of expression level alone miss.","rel_num_authors":11,"rel_authors":[{"author_name":"Krishna Chaitanya Ginne","author_inst":"Michigan State University"},{"author_name":"Derek Bowman","author_inst":"Michigan State University"},{"author_name":"Jordi Pi\u00f1ero","author_inst":"Universitat Politecnica de Catalunya"},{"author_name":"Jorge Cobos-Figueroa","author_inst":"Universidad de Malaga"},{"author_name":"Jorge Ca\u00f1as-Mart\u00edn","author_inst":"Universidade de Santiago de Compostela"},{"author_name":"Alba Capelo-Diz","author_inst":"Universidade de Santiago de Compostela"},{"author_name":"Marta Varela-Rey","author_inst":"Universidade de Santiago de Compostela"},{"author_name":"Christoph Kuppe","author_inst":"Rheinisch-Westfalische Technische Hochschule Aachen"},{"author_name":"Adrian Ruiz-Villalba","author_inst":"Universidad de Malaga"},{"author_name":"Sudin Bhattacharya","author_inst":"Michigan State University"},{"author_name":"Carlo Piermarocchi","author_inst":"Michigan State University"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Adaptive signal evolution and gene flow drive variable speciation outcomes in bark anoles","rel_doi":"10.64898\/2026.11.15.760982","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.760982","rel_abs":"New species evolve in a complex and non-linear fashion, resulting in situations where genomic and phenotypic variation between diverging lineages become decoupled. For example, natural selection acting on traits commonly used to diagnose species can instead drive trait variation to disagree with genomic evidence for species boundaries, challenging systematists aiming to delimit species. In this study, we combine phylogenetic, population genomic, and coalescent-based gene flow analyses to test whether convergence of a signaling trait has a shared genomic basis and to evaluate the evidence for unrecognized species level diversity in the Anolis distichus species group, a polytypic clade of lizards spanning the island of Hispaniola and the Bahamas in which diversity of a sex-linked signaling trait conflicts with genetic evidence for species boundaries. Comparing evolutionary histories of autosomes, sex chromosomes, and mitochondrial DNA, we find that the entire spectrum of signaling trait variation is present in four major geographic clades of the A. distichus species group and recover support for the independent evolution of this convergent signal. By quantifying isolation-by-distance and inferring migration across all contact zones on Hispaniola, we find evidence for lineages spanning the entire speciation continuum---from interbreeding populations to lineages exhibiting signatures of strong reproductive isolation. Together, our study highlights how phenotypic and genomic divergence may decouple during speciation, and provides a robust framework for gene flow-informed taxonomic revisions of the A. distichus species group.","rel_num_authors":6,"rel_authors":[{"author_name":"Tanner C Myers","author_inst":"University of Puerto Rico"},{"author_name":"Pietro Longo Hollanda de Mello","author_inst":"College de France"},{"author_name":"Javier Torres","author_inst":"University of Nebraska-Lincoln"},{"author_name":"Paul M Hime","author_inst":"Washington University School of Medicine"},{"author_name":"Anthony J Geneva","author_inst":"Rutgers University Camden"},{"author_name":"Richard E Glor","author_inst":"University of Kansas"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Adaptive signal evolution and gene flow drive variable speciation outcomes in bark anoles","rel_doi":"10.64898\/2026.11.15.760982","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.760982","rel_abs":"New species evolve in a complex and non-linear fashion, resulting in situations where genomic and phenotypic variation between diverging lineages become decoupled. For example, natural selection acting on traits commonly used to diagnose species can instead drive trait variation to disagree with genomic evidence for species boundaries, challenging systematists aiming to delimit species. In this study, we combine phylogenetic, population genomic, and coalescent-based gene flow analyses to test whether convergence of a signaling trait has a shared genomic basis and to evaluate the evidence for unrecognized species level diversity in the Anolis distichus species group, a polytypic clade of lizards spanning the island of Hispaniola and the Bahamas in which diversity of a sex-linked signaling trait conflicts with genetic evidence for species boundaries. Comparing evolutionary histories of autosomes, sex chromosomes, and mitochondrial DNA, we find that the entire spectrum of signaling trait variation is present in four major geographic clades of the A. distichus species group and recover support for the independent evolution of this convergent signal. By quantifying isolation-by-distance and inferring migration across all contact zones on Hispaniola, we find evidence for lineages spanning the entire speciation continuum---from interbreeding populations to lineages exhibiting signatures of strong reproductive isolation. Together, our study highlights how phenotypic and genomic divergence may decouple during speciation, and provides a robust framework for gene flow-informed taxonomic revisions of the A. distichus species group.","rel_num_authors":6,"rel_authors":[{"author_name":"Tanner C Myers","author_inst":"University of Puerto Rico"},{"author_name":"Pietro Longo Hollanda de Mello","author_inst":"College de France"},{"author_name":"Javier Torres","author_inst":"University of Nebraska-Lincoln"},{"author_name":"Paul M Hime","author_inst":"Washington University School of Medicine"},{"author_name":"Anthony J Geneva","author_inst":"Rutgers University Camden"},{"author_name":"Richard E Glor","author_inst":"University of Kansas"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Adaptive signal evolution and gene flow drive variable speciation outcomes in bark anoles","rel_doi":"10.64898\/2026.11.15.760982","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.760982","rel_abs":"New species evolve in a complex and non-linear fashion, resulting in situations where genomic and phenotypic variation between diverging lineages become decoupled. For example, natural selection acting on traits commonly used to diagnose species can instead drive trait variation to disagree with genomic evidence for species boundaries, challenging systematists aiming to delimit species. In this study, we combine phylogenetic, population genomic, and coalescent-based gene flow analyses to test whether convergence of a signaling trait has a shared genomic basis and to evaluate the evidence for unrecognized species level diversity in the Anolis distichus species group, a polytypic clade of lizards spanning the island of Hispaniola and the Bahamas in which diversity of a sex-linked signaling trait conflicts with genetic evidence for species boundaries. Comparing evolutionary histories of autosomes, sex chromosomes, and mitochondrial DNA, we find that the entire spectrum of signaling trait variation is present in four major geographic clades of the A. distichus species group and recover support for the independent evolution of this convergent signal. By quantifying isolation-by-distance and inferring migration across all contact zones on Hispaniola, we find evidence for lineages spanning the entire speciation continuum---from interbreeding populations to lineages exhibiting signatures of strong reproductive isolation. Together, our study highlights how phenotypic and genomic divergence may decouple during speciation, and provides a robust framework for gene flow-informed taxonomic revisions of the A. distichus species group.","rel_num_authors":6,"rel_authors":[{"author_name":"Tanner C Myers","author_inst":"University of Puerto Rico"},{"author_name":"Pietro Longo Hollanda de Mello","author_inst":"College de France"},{"author_name":"Javier Torres","author_inst":"University of Nebraska-Lincoln"},{"author_name":"Paul M Hime","author_inst":"Washington University School of Medicine"},{"author_name":"Anthony J Geneva","author_inst":"Rutgers University Camden"},{"author_name":"Richard E Glor","author_inst":"University of Kansas"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Capsular surveillance-guided phage cocktails against carbapenem-resistant Klebsiella pneumoniae","rel_doi":"10.64898\/2026.11.13.766362","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.13.766362","rel_abs":"Carbapenem-resistant Klebsiella pneumoniae (CRKP) is among the most urgent antimicrobial-resistance threats, yet its extraordinary capsular diversity has kept phage therapy locked in per-isolate matching-a process too slow and labor-intensive for routine use. Here we convert this specificity problem into a look-up problem. Interrogating 26,138 CRKP genomes from 96 countries, we show that capsular diversity collapses onto a tractable target list: 14 capsular locus (KL) types dominate contemporary circulation and jointly account for 67-77% of the CRKP burden in every WHO region, stably from 2010 to 2024 and after removal of sampling bias. We assembled a repository of 48 strictly lytic phages spanning all 14 types and organized it into capsule-defined modules: for eight KL types a single capsule-targeting phage sufficed to prevent resistant regrowth over 24 h, and for the remaining six a two-phage module pairs a capsule-targeting phage with a capsule-independent phage that recognizes the second receptor layer exposed upon capsule loss. We treated 28 clinical isolates, covering two distinct STs for each of the 14 KL types. Modules were assigned from the KL call alone, without isolate-level matching data. Growth was suppressed in every strain, and ST background had no significant effect in 12 of 14 types. These results establish capsule type, not lineage, as the operative unit of CRKP phage preparedness: a single rapid KL-typing step converts a diagnostic result into a therapeutic decision, providing a practical, lineage-agnostic route from surveillance to treatment.","rel_num_authors":14,"rel_authors":[{"author_name":"CHAO WANG","author_inst":"Institute of Microbiology, Chinese Academy of Sciences"},{"author_name":"Jingyi Nie","author_inst":"Institute of Microbiology, Chinese Academy of Sciences"},{"author_name":"Min Wei","author_inst":"Institute of Microbiology, Chinese Academy of Sciences"},{"author_name":"Xueru Tian","author_inst":"Institute of Microbiology, Chinese Academy of Sciences"},{"author_name":"Yurou Sun","author_inst":"Institute of Microbiology, Chinese Academy of Sciences"},{"author_name":"Yuan Zeng","author_inst":"Institute of Microbiology, Chinese Academy of Sciences"},{"author_name":"Dawei Wei","author_inst":"Institute of Microbiology, Chinese Academy of Sciences"},{"author_name":"Yuqin Song","author_inst":"Institute of Microbiology, Chinese Academy of Sciences"},{"author_name":"Gang Zhang","author_inst":"Institute of Microbiology, Chinese Academy of Sciences"},{"author_name":"Xiaobing Chu","author_inst":"Peking Union Medical College Hospital"},{"author_name":"Qiwen Yang","author_inst":"Peking Union Medical College Hospital"},{"author_name":"Zhemin Zhou","author_inst":"Soochow University"},{"author_name":"Linhuan Wu","author_inst":"Institute of Microbiology, Chinese Academy of Sciences"},{"author_name":"Jie Feng","author_inst":"Institute of Microbiology, Chinese Academy of Sciences"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Treponema pallidum eight-stranded beta-barrels: an evolving, versatile family of outer membrane proteins in the service of stealth pathogenicity.","rel_doi":"10.64898\/2026.11.15.766778","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766778","rel_abs":"Syphilis is a multistage sexually transmitted infection caused by the highly invasive and immunoevasive spirochete Treponema pallidum (TPA). TPA depends on the import of many host-derived nutrients to sustain its auxotrophic lifestyle. Moreover, its invasive nature requires interactions with diverse host molecules to successfully disseminate and persist. The outer membrane proteins (OMPs) mediating these processes remain largely uncharacterized. In other bacteria, 8-stranded {beta}-barrels (8S{beta}Bs) perform such functions, including nutrient uptake and host interactions. Here, we investigated the composition, structural diversity and evolutionary dynamics of the 8S{beta}B family in TPA. Reexamination of the TPA OMPeome revealed four previously unrecognized members in addition to the four known 8SBs, expanding the family to eight members. Based on RNAseq, all eight were transcribed in treponemes harvested from rabbit testes. Predicted structures revealed substantial differences in channel properties and extracellular loop (ECL) architecture, consistent with functional diversification. AlphaFold 3 modeling predicted interactions with diverse host molecules implicated in nutrient uptake, adherence, and immune regulation, providing testable hypotheses for the functional specialization of individual 8SBBBs. Despite containing predicted B-cell epitopes, most TPA 8S{beta}B ECLs exhibited limited antigenicity during rabbit infection. Analysis of global clinical strains revealed distinct patterns of sequence variation across the 8S{beta}B family, although most were highly conserved and appeared to be under purifying selection. Variation within hypermutable intragenic polyguanosine tracts emerged as an additional potential mechanism for modulating 8S{beta}B repertoire composition. Our findings highlight the 8S{beta}B family as an important component of the molecular architecture underlying TPA stealth pathogenicity and reveal an ongoing mechanism through which the spirochete diversifies its OMP repertoire within circulating populations.","rel_num_authors":8,"rel_authors":[{"author_name":"Everton B. Bettin","author_inst":"UConn Health"},{"author_name":"Farhang Aghakhanian","author_inst":"University of North Carolina at Chapel Hill"},{"author_name":"Byron Dillon Vannest","author_inst":"UConn Health"},{"author_name":"Andre A. Grassmann","author_inst":"UConn Health Center: UConn Health"},{"author_name":"Jonathan B Parr","author_inst":"University of North Carolina at Chapel Hill"},{"author_name":"Kelly L. Hawley","author_inst":"University of Connecticut Health Center"},{"author_name":"Justin D Radolf","author_inst":"UConn Health"},{"author_name":"Melissa J Caimano","author_inst":"University of Connecticut Health Center"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"A neuronal atlas of neurexin isoform expression in Caenorhabditis elegans","rel_doi":"10.64898\/2026.11.14.766646","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.14.766646","rel_abs":"The Caenorhabditis elegans neurexin gene nrx-1 encodes both long () and short ({gamma}) isoforms, but how their expression varies across individual neurons remains unclear. Using NeuroPAL and endogenous transcriptional reporters, we generated a nervous system-wide atlas of nrx-1 expression in L4 hermaphrodites. We assessed reporters for one  and two {gamma} transcript groups in 267 identified neurons. The two {gamma} reporters collectively marked a broader set of neurons than the  reporter, and most neurons expressing the  reporter also expressed at least one {gamma} reporter. Among the ventral nerve cord motor neurons examined,  reporter expression was restricted to cholinergic neurons, while one {gamma} reporter was detected exclusively in GABAergic neurons. The other {gamma} reporter was consistently detected in most cholinergic motor neurons and detected in only a subset of GABAergic motor neurons, often variably across animals. In two-fold embryos, this same {gamma} reporter was detected in more neurons than the  reporter. Two upstream regulatory elements contributed to its expression in different neuronal populations. At dorsal nerve cord synapses, disruption of either isoform class reduced NRX-1 fluorescence, with a larger reduction after disruption of the short isoforms. By identifying neurons that express different combinations of long and short neurexins, this atlas provides a starting point for testing where the two isoform classes have distinct synaptic roles and where they may act together.","rel_num_authors":5,"rel_authors":[{"author_name":"Elisa B Frankel","author_inst":"University of Puget Sound"},{"author_name":"Parise S Henry","author_inst":"Albert Einstein College of Medicine"},{"author_name":"Nikos Karmirantzos","author_inst":"University of Puget Sound"},{"author_name":"Maggi Leider","author_inst":"University of Puget Sound"},{"author_name":"Peri T Kurshan","author_inst":"Albert Einstein College of Medicine"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"A multiscale map of the descending sympathetic innervation of the spleen","rel_doi":"10.64898\/2026.11.15.766191","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766191","rel_abs":"Brain regulation of visceral organ function depends on descending neural circuits. The spleen is the largest secondary lymphoid organ, and studies indicate that descending neural activity can alter splenic immune responses. Here, we combined retrograde tracing, single-nucleus RNA sequencing, spinal cord and brain reconstruction, and glycoprotein-complemented rabies tracing to map the sympathetic circuits associated with these organs in mice. Catecholaminergic fibers densely innervated the spleen and pancreas, and retrograde labeling identified largely distinct populations of postganglionic neurons within the celiac-superior mesenteric ganglion complex (CMG). Spleen-projecting neurons were enriched in suprarenal regions, whereas pancreas-projecting neurons were distributed more broadly. Single nucleus transcriptomics resolved three CMG neuron types and a Cre line marking the Rxfp1+ neurons labeled spleen-projecting neurons. CMG-projecting sympathetic preganglionic neurons occupied the intermediolateral cell column, intercalated nucleus, and spinal nucleus of the thoracic spinal cord. A tracing strategy designed to identify neurons upstream of these preganglionic populations labeled neurons in the medulla, pons, midbrain, hypothalamus, and several areas of the cortex including motor cortex. Motor-cortex axons formed vGlut1-positive boutons in close apposition to retrogradely labeled CMG-projecting neurons, providing anatomical support for a descending cortical route to sympathetic spinal circuits. These data provide an integrated anatomical and transcriptomic description of the descending circuits innervating the spleen and pancreas, and suggest that motor cortex is an effector cortex that controls more than movement through its projections to the spinal cord.","rel_num_authors":24,"rel_authors":[{"author_name":"Leonor Rem\u00e8dio","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States; Zuckerman Mind Brain Behavior Institute, Columbia Univers"},{"author_name":"Zachary R. Lewis","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Emma D. Thomas","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Ines Rodrigues-Vaz","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States; Zuckerman Mind Brain Behavior Institute, Columbia Univers"},{"author_name":"Christine R. Schmidt","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Lin T. Tun","author_inst":"Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY United States"},{"author_name":"Tiffany X. Chen","author_inst":"Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY United States"},{"author_name":"Katherine A. Fancher","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Joshua S. Greene","author_inst":"Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY United States"},{"author_name":"Darren Bertagnolli","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Jeff Goldy","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Christine Rimorin","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Michael Tieu","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Trangthanh Cardenas","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Amy Torkelson","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Junitta Guzman","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Rebecca Ferrer","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Anish Chakka","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Ana M. Vicente","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Shenqin Yao","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Kimberly A. Smith","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Bosiljka Tasic","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Darcy S. Peterka","author_inst":"Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY United States"},{"author_name":"Rui M. Costa","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States; Zuckerman Mind Brain Behavior Institute, Columbia Univers"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"A multiscale map of the descending sympathetic innervation of the spleen","rel_doi":"10.64898\/2026.11.15.766191","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.15.766191","rel_abs":"Brain regulation of visceral organ function depends on descending neural circuits. The spleen is the largest secondary lymphoid organ, and studies indicate that descending neural activity can alter splenic immune responses. Here, we combined retrograde tracing, single-nucleus RNA sequencing, spinal cord and brain reconstruction, and glycoprotein-complemented rabies tracing to map the sympathetic circuits associated with these organs in mice. Catecholaminergic fibers densely innervated the spleen and pancreas, and retrograde labeling identified largely distinct populations of postganglionic neurons within the celiac-superior mesenteric ganglion complex (CMG). Spleen-projecting neurons were enriched in suprarenal regions, whereas pancreas-projecting neurons were distributed more broadly. Single nucleus transcriptomics resolved three CMG neuron types and a Cre line marking the Rxfp1+ neurons labeled spleen-projecting neurons. CMG-projecting sympathetic preganglionic neurons occupied the intermediolateral cell column, intercalated nucleus, and spinal nucleus of the thoracic spinal cord. A tracing strategy designed to identify neurons upstream of these preganglionic populations labeled neurons in the medulla, pons, midbrain, hypothalamus, and several areas of the cortex including motor cortex. Motor-cortex axons formed vGlut1-positive boutons in close apposition to retrogradely labeled CMG-projecting neurons, providing anatomical support for a descending cortical route to sympathetic spinal circuits. These data provide an integrated anatomical and transcriptomic description of the descending circuits innervating the spleen and pancreas, and suggest that motor cortex is an effector cortex that controls more than movement through its projections to the spinal cord.","rel_num_authors":24,"rel_authors":[{"author_name":"Leonor Rem\u00e8dio","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States; Zuckerman Mind Brain Behavior Institute, Columbia Univers"},{"author_name":"Zachary R. Lewis","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Emma D. Thomas","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Ines Rodrigues-Vaz","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States; Zuckerman Mind Brain Behavior Institute, Columbia Univers"},{"author_name":"Christine R. Schmidt","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Lin T. Tun","author_inst":"Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY United States"},{"author_name":"Tiffany X. Chen","author_inst":"Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY United States"},{"author_name":"Katherine A. Fancher","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Joshua S. Greene","author_inst":"Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY United States"},{"author_name":"Darren Bertagnolli","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Jeff Goldy","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Christine Rimorin","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Michael Tieu","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Trangthanh Cardenas","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Amy Torkelson","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Junitta Guzman","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Rebecca Ferrer","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Anish Chakka","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Ana M. Vicente","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Shenqin Yao","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Kimberly A. Smith","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Bosiljka Tasic","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States"},{"author_name":"Darcy S. Peterka","author_inst":"Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY United States"},{"author_name":"Rui M. Costa","author_inst":"Allen Institute, Brain Science, Neurobiology of Action and Neural Dynamics, Seattle, WA United States; Zuckerman Mind Brain Behavior Institute, Columbia Univers"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Distinct calcium, sodium, and water programs characterize mouse and human connecting tubule","rel_doi":"10.64898\/2026.11.13.766571","rel_link":"http:\/\/biorxiv.org\/content\/10.64898\/2026.11.13.766571","rel_abs":"The kidney connecting tubule lies between the distal convoluted tubule and collecting duct. Even though short, it plays a key role in regulating calcium, sodium, and potassium excretion and water balance in health and disease. In rodents and humans, transitions between distal segments are gradual, making the assignment of functional properties to cell types difficult. To address this, we enriched mouse kidney distal tubule cells prior to performing single nucleus RNA-sequencing. Connecting tubule cells separated into three clusters, one expressed genes that are relevant to calcium transport, while another expressed genes that are relevant to water transport. The third was intermediate between the other two. While genes for electrogenic sodium transport were expressed throughout the connecting tubule, Hsd11b2, the gene responsible for aldosterone-responsiveness, was expressed primarily by the distal cluster. Immunocytochemistry confirmed the separation of calcium and water transport pathways and spatial transcriptomics confirmed the linear organization of this segment. Human transcriptomic data showed similar gene separation. The results show that rodent and human connecting tubules separate calcium and water transport, thereby limiting tubule fluid calcium accumulation. They also restrict aldosterone action to segments that are responsive to arginine vasopressin to maintain sodium homeostasis during antidiuresis.","rel_num_authors":10,"rel_authors":[{"author_name":"JESSICA P BAHENA-LOPEZ","author_inst":"Oregon Health and Science University"},{"author_name":"Jeremiah V Reyes","author_inst":"Oregon Health and Science University"},{"author_name":"Mingzhen Su","author_inst":"Charite-Universitatsmedizin"},{"author_name":"Xiao-Tong Su","author_inst":"Oregon Health and Science University"},{"author_name":"Joshua N Curry","author_inst":"Oregon Health and Science University"},{"author_name":"Pat Thaitongsuk","author_inst":"Oregon Health and Science University"},{"author_name":"Sebastian Bachmann","author_inst":"Charite-Universitatsmedizin Berlin"},{"author_name":"Chao-Ling Yang","author_inst":"Oregon Health and Science University"},{"author_name":"Jonathan W Nelson","author_inst":"University of Southern California"},{"author_name":"David H. Ellison","author_inst":"Oregon Health and Science University"}],"rel_date":"2026-11-17","rel_site":"biorxiv"},{"rel_title":"Molecular age of Barrett's esophagus indicates onset often occurs decades before diagnosis","rel_doi":"10.64898\/2026.11.13.26367463","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26367463","rel_abs":"Background Timely identification of Barrett's esophagus (BE) is crucial for early esophageal adenocarcinoma (EAC) detection. Screening is recommended from age 50 in individuals with additional risk factors, but biological BE onset age remains unknown. Objective Estimate biological BE onset age and duration before clinical diagnosis (dwell time). Design We applied a BE epigenetic clock to 61 samples from 41 patients in a population-representative Northern Ireland cohort and 164 samples from 140 patients in an independent UK cohort. BE dwell times were compared between patients with concurrent dysplasia\/EAC and age- and sex-matched non-dysplastic BE controls in these cross-sectional studies. In a longitudinal cohort, pre-progression biopsies from 31 future high-grade dysplasia (HGD)\/EAC progressors were compared with 35 non-progressors. Results Median estimated BE onset ages in the cross-sectional cohorts were 29.5 (IQR=22.5-45.8) and 29.3 (IQR=20.4-39.0) years, respectively. These estimates were further supported by independent epidemiologic modeling of age-specific BE prevalence data from more than 70,000 BE cases. Estimated dwell times were longer in patients with concurrent dysplasia (median difference 14.3 years; p=0.0042) or EAC (12.5 years; p=0.0002) than matched non-dysplastic BE controls. Dwell time exceeding 19.8 years was associated with higher odds of HGD\/EAC progression (OR=12.1, 95% CI 3.7-47.5; p=9.96 x 10-9;). Conclusion BE may arise decades before diagnosis. Although these findings do not justify lowering screening age, they suggest one-time screening from age 50 years may detect existing high-risk BE. Further modeling is warranted to evaluate implications for population-based screening, alongside prospective validation of epigenetic tissue age for progression risk stratification.","rel_num_authors":15,"rel_authors":[{"author_name":"Talita Oliveira","author_inst":"Queen's University Belfast"},{"author_name":"Samuel R. Reynolds","author_inst":"University of California, San Diego"},{"author_name":"Enya Scanlon","author_inst":"Queen's University Belfast"},{"author_name":"Victoria Child","author_inst":"Queen's University Belfast"},{"author_name":"Damian T. McManus","author_inst":"Queen's University Belfast"},{"author_name":"Brian Johnston","author_inst":"Belfast Health & Social Care Trust"},{"author_name":"Zhijian Hu","author_inst":"University of California, San Diego"},{"author_name":"Sarah Killcoyne","author_inst":"University of Cambridge"},{"author_name":"Barbara Nutzinger","author_inst":"University of Cambridge"},{"author_name":"Ginny Devonshire","author_inst":"University of Cambridge"},{"author_name":"Rebecca C. Fitzgerald","author_inst":"University of Cambridge"},{"author_name":"Richard C. Turkington","author_inst":"Queen's University Belfast"},{"author_name":"Amy Jayne McKnight","author_inst":"Queen's University Belfast"},{"author_name":"Helen G. Coleman","author_inst":"Queen's University Belfast"},{"author_name":"Kit Curtius","author_inst":"University of California, San Diego"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Efficacy of an early first dose of whole-cell pertussis vaccine in infants for the prevention of IgE-mediated food allergy: A randomised controlled trial","rel_doi":"10.64898\/2026.11.13.26367163","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26367163","rel_abs":"Background Evidence from mechanistic and observational studies suggests that replacing the first acellular pertussis (aP) vaccine dose in early infancy with a whole-cell pertussis (wP)-containing vaccine may reduce the risk of developing IgE-mediated food allergy during childhood. Objective We aimed to determine if a dose of wP at approximately 6 weeks old, in lieu of aP vaccine, could reduce the incidence of food allergy in infants. Methods In this multicentre, randomised, participant and outcome assessor-blinded, parallel, two-stage, Bayesian adaptive trial we assigned Australian infants to one of two pertussis vaccination schedules. These consisted of either a standard homologous priming with a hexavalent combination aP vaccine (diphtheria, tetanus, aP, hepatitis B, inactivated poliovirus types 1, 2, and 3, and Haemophilus influenzae type b; DTaP-HepB-IPV-Hib) at approximately 6 weeks, 4 months and 6 months old ( aP-only&rsquo schedule), or a first dose of a WHO-prequalified pentavalent wP combination vaccine (DTwP-HepB-Hib; Pentabio, PT Bio Farma Indonesia) at approximately 6 weeks old, followed by hexavalent aP combination vaccine at approximately 4 months and 6 months old ( mixed wP\/aP&rsquo schedule). The primary outcome was physician-confirmed food allergy by age 12 months requiring both evidence of sensitisation and compatible symptoms in response to either incidental or medically supervised oral food challenge. The initial target sample size was 3,000 enrolments to provide approximately 85% power to detect a policy-relevant 3 percentage point reduction in the risk of the primary outcome. Results A total of 972 infants were enrolled, 486 in each study arm. Of these, 26 of 486 (5.3%) assigned to the aP-only group and 31 of 486 (6.4%) assigned to the mixed wP\/aP schedule met the primary endpoint definition. The posterior median difference (95% credible interval) in food allergy among recipients of the mixed wP\/aP schedule compared to recipients of the aP-only schedule was 0.01 (-0.02, 0.04; probability [<0] 0.25). There were six serious adverse events (SAEs) among children receiving the aP-only group versus 12 among children receiving the mixed wP\/aP schedule; one SAE (hospitalisation for irritability; length of stay < 48 hours) was deemed related to wP vaccine. The trial was stopped early owing to operational reasons. Conclusions There is a low probability of a policy-relevant reduction in food allergy in infants receiving mixed wP\/aP versus aP-only pertussis vaccine schedules. Funded by the National Health and Medical Research Council of Australia; ANZCTR number, ACTRN12617000065392p. Clinical implications An early first dose of wP is unlikely to afford a policy-relevant reduction in the probability of developing food allergy, eczema or atopic sensitisation in infants. Capsule summary An early first dose of a 5-in-1 wP combination vaccine is reasonably tolerated but would not be expected to have a material impact on the prevalence of food allergy in infants. Key words Diphtheria-Tetanus-Pertussis Vaccine. Diphtheria-Tetanus-acellular Pertussis Vaccines. Food Hypersensitivity. Infant. Australia.","rel_num_authors":24,"rel_authors":[{"author_name":"Gladymar Perez Chacon","author_inst":"Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia"},{"author_name":"James Totterdell","author_inst":"Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia."},{"author_name":"Marie J. Estcourt","author_inst":"Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia."},{"author_name":"Kirsten P. Perrett","author_inst":"Department of Allergy and Immunology, Royal Children's Hospital, Parkville, Victoria, Australia."},{"author_name":"Dianne E. Campbell","author_inst":"Discipline of Child and Adolescent Health, The University of Sydney, Sydney, New South Wales, Australia."},{"author_name":"Julie A. Marsh","author_inst":"Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia."},{"author_name":"Nicholas Wood","author_inst":"Discipline of Child and Adolescent Health, The University of Sydney, Sydney, New South Wales, Australia."},{"author_name":"Adam W. Bartlett","author_inst":"Department of Infectious Diseases, Sydney Children's Hospital, Randwick, Sydney, New South Wales, Australia."},{"author_name":"Phoebe C.M. Williams","author_inst":"Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia."},{"author_name":"Michael D. O'Sullivan","author_inst":"Department of Immunology, Perth Children's Hospital , Nedlands, Western Australia, Australia."},{"author_name":"Claire S. Waddington","author_inst":"Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom."},{"author_name":"Nicole L. Messina","author_inst":"Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia."},{"author_name":"Brynn Wainstein","author_inst":"Department of Immunology, Sydney Children's Hospital, Randwick, Sydney, New South Wales, Australia."},{"author_name":"Peter Hsu","author_inst":"The Children's Hospital at Westmead, Westmead, Australia."},{"author_name":"Sonia McAlister","author_inst":"Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia."},{"author_name":"Mark A. Jones","author_inst":"Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia."},{"author_name":"Catherine Hughes","author_inst":"Immunisation Foundation of Australia, Australia."},{"author_name":"Ushma Wadia","author_inst":"Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia."},{"author_name":"Peter B. McIntyre","author_inst":"Dunedin School of Medicine, University of Otago, Dunedin, New Zealand."},{"author_name":"Nigel Curtis","author_inst":"Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia."},{"author_name":"Michael Gold","author_inst":"Discipline of Paediatrics, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia."},{"author_name":"Patrick G. Holt","author_inst":"Wal-yan Respiratory Research Centre, The Kids Research Institute Australia, Nedlands, Western Australia, Australia."},{"author_name":"Peter C. Richmond","author_inst":"Division of Paediatrics, School of Medicine, The University of Western Australia, Perth, Western Australia, Australia."},{"author_name":"Tom Snelling","author_inst":"Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia."}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Exome-wide rare-variant associations vary across disease trajectories","rel_doi":"10.64898\/2026.11.14.26368035","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368035","rel_abs":"Genetic studies of chronic disease typically collapse longitudinal clinical histories into binary case-control outcomes, obscuring disease timing and differences in genetic association patterns across disease transitions. Time-to-event analysis can preserve this information, but rare-variant analysis of post-diagnosis progression is challenged by sparse carrier-events and extensive censoring. We developed GATE-GENE, a scalable gene-based framework that maintains calibration under these conditions. Across 300 onset phenotypes in UK Biobank (UKB), GATE-GENE identified 107 exome-wide significant germline associations involving 89 genes and 67 diseases. Across 95 multi-state trajectories comprising baseline (T0), an upstream disease state (T1) and a downstream disease state (T2), disease onset (T0[-&gt;]T1) and subsequent progression (T1[-&gt;]T2) showed limited detectable sharing of rare-variant association signals. Progression showed greater concordance of gene-level association signals with downstream phenotypes (T0[-&gt;]T2) when the analyses shared T2 events occurring after T1. Removing overlapping downstream events reduced the median correlation between gene-level association signals from 0.063 to 0.001, after accounting for background correlation. Null simulations reproduced the relationship between event overlap and concordance without genetic effects, whereas additional simulations showed that near-zero concordance could persist despite extensive underlying causal-gene sharing. This attenuation was reproduced across three ancestry groups in All of Us. Cross-biobank meta-analysis identified 12 additional exome-wide significant progression associations beyond three UKB discoveries, although clinical sensitivity analyses suggested that the strongest PKD1 signals largely reflected underlying cystic kidney disease. Together, these findings establish GATE-GENE for investigating rare-variant associations with disease timing and progression, while demonstrating how overlapping clinical events and limited carrier-event information complicate inference about genetic sharing across disease transitions.","rel_num_authors":15,"rel_authors":[{"author_name":"Ying Wang","author_inst":"Massachusetts General Hospital; Broad Institute of MIT and Harvard; Ohio State University"},{"author_name":"Weijun Luo","author_inst":"College of Computing, Georgia Institute of Technology"},{"author_name":"Linfeng Hu","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"},{"author_name":"Tony Chen","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"},{"author_name":"Wenhan Lu","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"},{"author_name":"Connor Dowd","author_inst":"Broad Institute or MIT and Harvard"},{"author_name":"Cindy Wen","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"},{"author_name":"Wenjian Bi","author_inst":"University of Michigan School of Public Health"},{"author_name":"Satoshi Koyama","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"},{"author_name":"Ida Surakka","author_inst":"University of Michigan"},{"author_name":"Benjamin M Neale","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"},{"author_name":"Mark Daly","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"},{"author_name":"Pradeep Nataranjan","author_inst":"Amgen"},{"author_name":"Alicia Martin","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"},{"author_name":"Wei Zhou","author_inst":"Massachusetts General Hospital; Broad Institute or MIT and Harvard"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Circulating Apolipoprotein Profiles and Their Associations with Mild Cognitive and Behavioral Impairment in Older Adults: A Cross-Sectional Study","rel_doi":"10.64898\/2026.11.14.26368084","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368084","rel_abs":"Background Mild cognitive impairment (MCI) and mild behavioral impairment (MBI) are overlapping prodromal states associated with dementia risk. Circulating apolipoproteins (Apos) may be linked to cognitive and behavioral changes, but their relationships remain unclear. Objective Examine plasma concentrations of multiple Apos in prodromal dementia. Methods This cross-sectional study included 148 Thai participants aged 60-75 years: 56 cognitively normal controls, 47 with MCI without MBI, and 45 with MBI with or without MCI. We measured ApoA1, ApoA2, ApoB, ApoC1, ApoC3, ApoD, ApoE, ApoH, and ApoJ, five lipids, and APOE genotype, and computed an atherogenic Apo composite (ApoB-ApoC1-ApoC3). Primary analyses used multivariable linear regression of quantitative cognitive and behavioral outcomes. Group comparisons were secondary and served to contextualize the dimensional regression findings. Results Across Montreal Cognitive Assessment (MoCA) models, 20.7-28.2% of variance was explained by combinations of ApoH, ApoC3, APOE {varepsilon}4 carrier status, age, and male sex (inverse associations), and free cholesterol and education (positive associations). The atherogenic composite was inversely associated with MoCA total, memory index, and delayed recall scores, and with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) verbal fluency and word list recall. No significant predictors emerged for Neuropsychiatric Inventory (NPI) scores or NPI caregiver distress. All nine Apos differed significantly between groups, with levels highest in MCI, intermediate in MBI, and lowest in controls. Conclusions Circulating Apo profiles differed across controls, MCI, and MBI groups and were more consistently associated with cognitive than behavioral outcomes. ApoH and the atherogenic Apo composite warrant further investigation as candidate biomarkers of early cognitive dysfunction.","rel_num_authors":6,"rel_authors":[{"author_name":"Arisara Amrapala","author_inst":"Chulalongkorn University"},{"author_name":"Solaphat Hemrungrojn","author_inst":"Chulalongkorn University"},{"author_name":"Natawut Nupairoj","author_inst":"Chulalongkorn University"},{"author_name":"Marco Solmi","author_inst":"University of Ottawa"},{"author_name":"Chavit Tunvirachaisakul","author_inst":"Faculty of Medicine, Chulalongkorn University"},{"author_name":"Michael Maes","author_inst":"University of Electronic Science and Technology of China"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Circulating Apolipoprotein Profiles and Their Associations with Mild Cognitive and Behavioral Impairment in Older Adults: A Cross-Sectional Study","rel_doi":"10.64898\/2026.11.14.26368084","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.14.26368084","rel_abs":"Background Mild cognitive impairment (MCI) and mild behavioral impairment (MBI) are overlapping prodromal states associated with dementia risk. Circulating apolipoproteins (Apos) may be linked to cognitive and behavioral changes, but their relationships remain unclear. Objective Examine plasma concentrations of multiple Apos in prodromal dementia. Methods This cross-sectional study included 148 Thai participants aged 60-75 years: 56 cognitively normal controls, 47 with MCI without MBI, and 45 with MBI with or without MCI. We measured ApoA1, ApoA2, ApoB, ApoC1, ApoC3, ApoD, ApoE, ApoH, and ApoJ, five lipids, and APOE genotype, and computed an atherogenic Apo composite (ApoB-ApoC1-ApoC3). Primary analyses used multivariable linear regression of quantitative cognitive and behavioral outcomes. Group comparisons were secondary and served to contextualize the dimensional regression findings. Results Across Montreal Cognitive Assessment (MoCA) models, 20.7-28.2% of variance was explained by combinations of ApoH, ApoC3, APOE {varepsilon}4 carrier status, age, and male sex (inverse associations), and free cholesterol and education (positive associations). The atherogenic composite was inversely associated with MoCA total, memory index, and delayed recall scores, and with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) verbal fluency and word list recall. No significant predictors emerged for Neuropsychiatric Inventory (NPI) scores or NPI caregiver distress. All nine Apos differed significantly between groups, with levels highest in MCI, intermediate in MBI, and lowest in controls. Conclusions Circulating Apo profiles differed across controls, MCI, and MBI groups and were more consistently associated with cognitive than behavioral outcomes. ApoH and the atherogenic Apo composite warrant further investigation as candidate biomarkers of early cognitive dysfunction.","rel_num_authors":6,"rel_authors":[{"author_name":"Arisara Amrapala","author_inst":"Chulalongkorn University"},{"author_name":"Solaphat Hemrungrojn","author_inst":"Chulalongkorn University"},{"author_name":"Natawut Nupairoj","author_inst":"Chulalongkorn University"},{"author_name":"Marco Solmi","author_inst":"University of Ottawa"},{"author_name":"Chavit Tunvirachaisakul","author_inst":"Faculty of Medicine, Chulalongkorn University"},{"author_name":"Michael Maes","author_inst":"University of Electronic Science and Technology of China"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Barriers and facilitators to cervical precancer treatment adherence among women in Harare, Zimbabwe: A qualitative study","rel_doi":"10.64898\/2026.11.13.26368072","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368072","rel_abs":"Adherence to recommended treatment after a positive cervical screening result remains suboptimal in Zimbabwe. This study explored how women interpreted a cervical precancer diagnosis and how emotional, interpersonal, economic, and health-system factors shaped treatment decisions. We conducted semi-structured in-depth interviews with 25 purposively selected women aged 25-50 years who had screened positive by visual inspection with acetic acid and were recommended for ablative or excisional treatment at two high-volume clinics in Harare. The qualitative component drew on the Health Belief Model and a phenomenological orientation to lived experience. Data were examined using combined deductive and inductive thematic analysis. Three interrelated themes were identified. First, women initially interpreted precancer through fear, shock, and uncertainty; misconceptions that precancer meant invasive cancer, infertility, or imminent death could delay action, whereas clear counselling reframed the diagnosis as treatable. Second, multilevel conditions shaped adherence. Supportive health workers, partner or family encouragement, prior awareness, and connection to HIV services facilitated treatment, while indirect costs, transport, fragmented referral pathways, scheduled excisional services, inconsistent communication, partner opposition, and sexual coercion impeded care. Third, Health Belief Model constructs operated in both directions: perceived severity motivated action when paired with credible benefits and self-efficacy, but produced avoidance when amplified by misinformation and weak support. Improving treatment completion will require standardised counselling, reliable navigation and follow-up, more accessible excisional services, and interventions that address partner dynamics and indirect costs. Screening scale-up should be matched by timely treatment capacity so that women with positive results complete the prevention pathway.","rel_num_authors":5,"rel_authors":[{"author_name":"Belinda Mutibura","author_inst":"University Of Zimbabwe"},{"author_name":"Grant Murewanhema","author_inst":"University of Zimbabwe Faculty of Medicine"},{"author_name":"Zvavahera  Michael Chirenje","author_inst":"University of Zimbabwe Faculty of Medicine"},{"author_name":"Nathan Mhungu","author_inst":"University of Zimbabwe Faculty of Medicine"},{"author_name":"Bothwell  Takaingofa Guzha","author_inst":"University of Zimbabwe Faculty of Medicine"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Wastewater metagenomic sequencing quantitatively tracks transmission dynamics for human pathogenic viruses","rel_doi":"10.64898\/2026.11.13.26368067","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368067","rel_abs":"Wastewater metagenomic sequencing theoretically characterizes all nucleic acids in a sample, but whether sequencing reads reflect transmission dynamics of circulating viruses in the contributing community is unknown. We evaluated if wastewater metagenomic sequencing data can be used to reconstruct transmission dynamics of endemic, routinely circulating viruses. Using deep, untargeted wastewater metagenomic sequencing data from four locations in the United States, we generated quantitative estimates of transmission dynamics (time-varying growth rate and effective reproduction number) within a Bayesian framework for widely monitored viruses. Across locations and viruses, estimates were statistically concordant with those derived from clinical surveillance and polymerase chain reaction (PCR)-based wastewater monitoring data. Furthermore, we estimated growth rate from wastewater metagenomic sequencing data for numerous viruses not otherwise widely monitored, demonstrating the data expands the targets that can feasibly be monitored in parallel. Wastewater metagenomic sequencing can support both novel pathogen detection and routine surveillance of endemic pathogens.","rel_num_authors":7,"rel_authors":[{"author_name":"Elana M G Chan","author_inst":"Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA"},{"author_name":"Lennart Justen","author_inst":"Broad Institute of MIT and Harvard, Cambridge, MA, USA"},{"author_name":"Alessandro Zulli","author_inst":"SecureBio, Cambridge, MA, USA"},{"author_name":"Michael R McLaren","author_inst":"SecureBio, Cambridge, MA, USA"},{"author_name":"Rebecca Y Linfield","author_inst":"Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Leon S Moskatel","author_inst":"Department of Neurology, Stanford University, Palo Alto, CA, USA"},{"author_name":"Charles Whittaker","author_inst":"Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Multi-omics models for hypertension prediction using blood pressure PRS and omics scores","rel_doi":"10.64898\/2026.11.13.26368055","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368055","rel_abs":"Background: Hypertension is a major modifiable risk factor for cardiovascular disease, yet the relative contributions of proteomic (ProtS), metabolomic (MetS), and polygenic risk scores (PRS) to incident hypertension risk remain incompletely characterized. Methods: We developed ProtS and MetS for systolic (SBP) and diastolic blood pressure (DBP), and hypertension using Elastic Net regression in the Multi-Ethnic Study of Atherosclerosis (MESA). We incorporated these scores with previously developed BP PRSs into 5 incremental XGBoost models, with external validation in the Jackson Heart Study (JHS). We further applied transfer learning to adapt the MESA-derived models to JHS. Elastic Net selected proteins were prioritized using Mendelian randomization, colocalization, and functional analyses. Results: In MESA, model discrimination improved with the addition of omics scores, with the combined model achieving an area under the curve (AUC) of 0.72 compared with 0.63 for the clinical baseline model. In JHS, ProtS showed the highest AUC of 0.68 and the smallest cross-cohort performance decline, compared to MetS and PRS. Incorporating measured SBP and DBP substantially improved discrimination, with the PRS+BP model achieving an AUC of 0.80 in MESA and the baseline+BP model achieving an AUC of 0.74 in JHS. Among JHS participants with normal baseline BP, ProtS provided the strongest discrimination among models without measured BP (AUC = 0.62), while PRS+BP model achieved an AUC of 0.69. Leaf-weight refreshing consistently improved calibration in JHS while preserving discrimination. Mendelian randomization identified 77 proteins associated with BP traits or hypertension, involved in vascular, inflammatory, renal, and natriuretic pathways. Conclusions: ProtS demonstrated superior predictive performance and cross-cohort transferability among the omics modalities evaluated, while measured BP remained the strongest predictors of incident hypertension. Proteomic and genetic information may provide complementary biological signals for identifying individuals at elevated hypertension risk, particularly before clinically elevated BP is detectable.","rel_num_authors":13,"rel_authors":[{"author_name":"Ziqing Wang","author_inst":"BIDMC"},{"author_name":"Yana Hrytsenko","author_inst":"Beth Israel Deaconess Medical Center"},{"author_name":"Sivan Almogy","author_inst":"Yale University"},{"author_name":"Brian W Spitzer","author_inst":"Beth Israel Deaconess Medical Center"},{"author_name":"Yogesh Purushotham","author_inst":"Beth Israel Deaconess Medical Center"},{"author_name":"Kent Taylor","author_inst":"The Lundquist Institute"},{"author_name":"Henry J. J. Lin","author_inst":"The Lundquist Institute"},{"author_name":"Usman A. Tahir","author_inst":"Beth Israel Deaconess Medical Center"},{"author_name":"Laura M. Raffield","author_inst":"University of North Carolina"},{"author_name":"Steve Rich","author_inst":"Virginia"},{"author_name":"Jerome Rotter","author_inst":"The Lundquist Institute"},{"author_name":"Zsu Zsu Chen","author_inst":"BIDMC"},{"author_name":"Tamar Sofer","author_inst":"Beth Israel Deaconess Medical Center"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Bipolar Disorder and Education: Deciphering a Complex Relationship using Genetic and Sibling Differences in a Multi-cohort Study","rel_doi":"10.64898\/2026.11.13.26368023","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368023","rel_abs":"Background. While bipolar disorder has a positive genetic correlation (r~0.3) with educational attainment (EA), individuals with bipolar disorder diagnoses have lower EA in adulthood. To clarify this paradox, we hypothesise that bipolar disorder and educational outcomes share a positive genetic association, reflected in high academic performance earlier in life, but that emerging bipolar disorder symptoms disrupt academic trajectories, leading to the observed poor long-term educational outcomes. Methods. We employed a sibling comparison design across four population-based cohorts (Ntotal = 1,145,795 siblings). First, we tested the association between bipolar disorder polygenic scores (PGS) and educational outcomes (EA and academic performance) in the Norwegian Mother, Father and Child Cohort Study (MoBa) and UK Biobank (UKB). Second, we examined associations between academic performance at ages 10, 12, 13, and 14 and subsequent bipolar disorder diagnosis using registry data from Statistics Netherlands and Statistics Norway (with the Norwegian Control and Payment of Health Reimbursements Databases). Findings. Siblings with higher bipolar disorder PGS had significantly higher EA ({beta}W = 0.03, 95% CI [0.01, 0.05], N=16,746) as well as higher academic performance at age 10 (0.03 [0.01, 0.05], N=17,677) in MoBa. Secondly, individuals with bipolar disorder had better overall academic performance than their unaffected sibling at ages 10 (HRW = 1.12 [1.02, 1.22], N=343,898) and 12 (1.59 [1.16, 2.19], N=619,796). However, individuals with bipolar disorder experienced a decline in academic performance at ages 13 (0.84 [0.73, 0.96], N=320,342) and 14 (0.72 [0.61, 0.85], N=299,039). Interpretation. Bipolar disorder shares a positive genetic association with educational outcomes, reflected in early academic advantage. This is followed by an academic decline in mid-adolescence, highlighting the period of educational disruption associated with bipolar disorder. Funding. The Dutch Ministry of Education, Culture and Sciences, European Research Council, the Research Council of Norway, the Swedish Research Council","rel_num_authors":8,"rel_authors":[{"author_name":"Vaishnavi K Madhavan","author_inst":"Vrije Universiteit Amsterdam"},{"author_name":"Perline A Demange","author_inst":"University of Oslo"},{"author_name":"Ziada Ayorech","author_inst":"University of Oslo"},{"author_name":"Jouke Jan Hottenga","author_inst":"Hamad Bin Khalifa University"},{"author_name":"Meike Bartels","author_inst":"Vrije Universiteit Amsterdam"},{"author_name":"Eivind Ystrom","author_inst":"University of Oslo"},{"author_name":"Michel G Nivard","author_inst":"University of Bristol"},{"author_name":"Wonuola A Akingbuwa","author_inst":"Vrije Universiteit Amsterdam"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV","rel_doi":"10.64898\/2026.11.13.26368017","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368017","rel_abs":"Importance: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in high-risk young children during their second RSV season. Nirsevimab, a long-acting monoclonal antibody against RSV, is recommended for some children who are at increased risk for severe RSV and entering their second RSV season to prevent severe RSV disease. Because of limited eligibility criteria for second season nirsevimab, estimating its effectiveness is challenging. Objective: We evaluated nirsevimab effectiveness against RSV-associated hospitalizations among young children eligible to receive nirsevimab during their second RSV season. Design: This retrospective case control study with a test-negative design was conducted during the 2024-2025 and 2025-2026 RSV seasons. Setting: Enrollment was in 26 hospitals across 24 U.S. states. Participants: Children eligible for nirsevimab during their second RSV season (as recommended in August 2023) were included. Nirsevimab-eligible children 8-23 months old hospitalized with respiratory symptoms were enrolled. Case-patients tested positive for RSV; control-patients tested negative for RSV. Exposures: Receipt of nirsevimab before or during the second RSV season and at least 7 days before symptom onset. Outcomes and measures: RSV-associated hospitalization. We estimated nirsevimab effectiveness using multivariable logistic regression adjusted for age, month and year of hospitalization, census region, and sex comparing the odds of second season nirsevimab receipt among case- and control-patients. Results: One hundred six case-patients and 125 control-patients were analyzed. Distributions of age, sex, race and ethnicity, and region were similar in case- and control-patients. Most case- and control-patients were eligible for nirsevimab because of chronic lung disease of prematurity (84.0% and 69.6%, respectively). Overall, 21 (19.8%) of case-patients and 53 (42.4%) of control-patients received nirsevimab. Adjusted nirsevimab effectiveness against RSV-associated hospitalizations was 78.1% (95% CI, 55.2%-89.3%); the median interval from nirsevimab receipt to symptom onset was 66.5 days (IQR = 30-96 days). Effectiveness was estimated to be higher if nirsevimab was received 8-59 days before symptom onset (88.5%, 95% CI, 63.4%-96.4%). Conclusions: This analysis provides real-world estimates of substantial nirsevimab effectiveness against RSV-associated hospitalizations for high-risk U.S. children in their second RSV season These data support recommendations for nirsevimab as a preventive strategy in this population.","rel_num_authors":33,"rel_authors":[{"author_name":"Regina M Simeone","author_inst":"CDC"},{"author_name":"Margaret M Newhams","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Amanda B Payne","author_inst":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, "},{"author_name":"Amber O Orzel-Lockwood","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Jemima Calixte","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Natasha Halasa","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee"},{"author_name":"Satoshi Kamidani","author_inst":"The Center for Childhood Infections and Vaccines of Childrens Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine, Atlan"},{"author_name":"Hillary Crandall","author_inst":"Division of Pediatric Critical Care, Department of Pediatrics, University of Utah and Primary Childrens Hospital, Salt Lake City, Utah"},{"author_name":"Katherine Irby","author_inst":"Section of Pediatric Critical Care, Department of Pediatrics, Arkansas Childrens Hospital, Little Rock, Arkansas"},{"author_name":"Aline B Maddux","author_inst":"Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Childrens Hospital Colorado, Aurora, Colorado"},{"author_name":"Danielle Zerr","author_inst":"Division of Infectious Diseases, Department of Pediatrics, University of Washington, Seattle, Washington; Seattle Children's Research Institute, Seattle, Washin"},{"author_name":"Judith Guzman-Cottrill","author_inst":"Department of Pediatrics, Oregon Health and Sciences University, Portland, Oregon"},{"author_name":"Jennifer Schuster","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Childrens Mercy; University of Missouri Kansas City, Kansas City, Missouri"},{"author_name":"Kathleen Chiotos","author_inst":"Division of Critical Care Medicine, Department of Anesthesiology and Critical Care, Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"author_name":"Michele Kong","author_inst":"Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama"},{"author_name":"Mary Allen Staat","author_inst":"Department of Pediatrics, Division of Infectious Diseases, Cincinnati Childrens Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnat"},{"author_name":"Janet Hume","author_inst":"Division of Pediatric Critical Care, University of Minnesota Masonic Childrens Hospital, Minneapolis, Minnesota"},{"author_name":"Melissa  S. Stockwell","author_inst":"Division of Child and Adolescent Health, Columbia University Vagelos College of Physicians and Surgeons and Department of Population and Family Health, Columbia"},{"author_name":"Melissa Cameron","author_inst":"Division of Pediatric Hospital Medicine, UC San Diego-Rady Childrens Hospital, San Diego, California"},{"author_name":"Alexander H Hogan","author_inst":"Division of Hospital Medicine, Connecticut Childrens Medical Center, Hartford, Connecticut"},{"author_name":"Jigar Chauhan","author_inst":"Division of Critical Care, Nemours Childrens Hospital, Wilmington, Delaware"},{"author_name":"Austin Biggs","author_inst":"Department of Pediatric Critical Care, Medical University of South Carolina and Shawn Jenkins Childrens Hospital, Charleston, South Carolina"},{"author_name":"Emily R Levy","author_inst":"Divisions of Pediatric Infectious Diseases and Pediatric Critical Care Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnes"},{"author_name":"Samina Bhumbra","author_inst":"Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana"},{"author_name":"Tracie C Walker","author_inst":"Department of Pediatrics, University of North Carolina at Chapel Hill Childrens Hospital, Chapel Hill, North Carolina"},{"author_name":"Neelima K Marupudi","author_inst":"Department of Child Health, University of Arizona, Banner Childrens Hospital at Desert, Division of Pediatric Critical Care, Mesa, Arizona"},{"author_name":"Mary K Prahl","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, University of California, San Francisco, California"},{"author_name":"Kelly N Michelson","author_inst":"Division of Pediatric Critical Care Medicine, Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois"},{"author_name":"Lora Martin","author_inst":"Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi"},{"author_name":"Tamara Brandford","author_inst":"Division of Cardiology, Department of Pediatrics, Louisiana State University Health Sciences Center, Louisiana; Childrens Hospital of New Orleans, New Orleans, "},{"author_name":"Adrienne Randolph","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts; Departments of Anesthesia and Pediatrics, Harv"},{"author_name":"Angela P Campbell","author_inst":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, "},{"author_name":"- Overcoming RSV Network investigators","author_inst":""}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV","rel_doi":"10.64898\/2026.11.13.26368017","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368017","rel_abs":"Importance: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in high-risk young children during their second RSV season. Nirsevimab, a long-acting monoclonal antibody against RSV, is recommended for some children who are at increased risk for severe RSV and entering their second RSV season to prevent severe RSV disease. Because of limited eligibility criteria for second season nirsevimab, estimating its effectiveness is challenging. Objective: We evaluated nirsevimab effectiveness against RSV-associated hospitalizations among young children eligible to receive nirsevimab during their second RSV season. Design: This retrospective case control study with a test-negative design was conducted during the 2024-2025 and 2025-2026 RSV seasons. Setting: Enrollment was in 26 hospitals across 24 U.S. states. Participants: Children eligible for nirsevimab during their second RSV season (as recommended in August 2023) were included. Nirsevimab-eligible children 8-23 months old hospitalized with respiratory symptoms were enrolled. Case-patients tested positive for RSV; control-patients tested negative for RSV. Exposures: Receipt of nirsevimab before or during the second RSV season and at least 7 days before symptom onset. Outcomes and measures: RSV-associated hospitalization. We estimated nirsevimab effectiveness using multivariable logistic regression adjusted for age, month and year of hospitalization, census region, and sex comparing the odds of second season nirsevimab receipt among case- and control-patients. Results: One hundred six case-patients and 125 control-patients were analyzed. Distributions of age, sex, race and ethnicity, and region were similar in case- and control-patients. Most case- and control-patients were eligible for nirsevimab because of chronic lung disease of prematurity (84.0% and 69.6%, respectively). Overall, 21 (19.8%) of case-patients and 53 (42.4%) of control-patients received nirsevimab. Adjusted nirsevimab effectiveness against RSV-associated hospitalizations was 78.1% (95% CI, 55.2%-89.3%); the median interval from nirsevimab receipt to symptom onset was 66.5 days (IQR = 30-96 days). Effectiveness was estimated to be higher if nirsevimab was received 8-59 days before symptom onset (88.5%, 95% CI, 63.4%-96.4%). Conclusions: This analysis provides real-world estimates of substantial nirsevimab effectiveness against RSV-associated hospitalizations for high-risk U.S. children in their second RSV season These data support recommendations for nirsevimab as a preventive strategy in this population.","rel_num_authors":33,"rel_authors":[{"author_name":"Regina M Simeone","author_inst":"CDC"},{"author_name":"Margaret M Newhams","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Amanda B Payne","author_inst":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, "},{"author_name":"Amber O Orzel-Lockwood","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Jemima Calixte","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Natasha Halasa","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee"},{"author_name":"Satoshi Kamidani","author_inst":"The Center for Childhood Infections and Vaccines of Childrens Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine, Atlan"},{"author_name":"Hillary Crandall","author_inst":"Division of Pediatric Critical Care, Department of Pediatrics, University of Utah and Primary Childrens Hospital, Salt Lake City, Utah"},{"author_name":"Katherine Irby","author_inst":"Section of Pediatric Critical Care, Department of Pediatrics, Arkansas Childrens Hospital, Little Rock, Arkansas"},{"author_name":"Aline B Maddux","author_inst":"Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Childrens Hospital Colorado, Aurora, Colorado"},{"author_name":"Danielle Zerr","author_inst":"Division of Infectious Diseases, Department of Pediatrics, University of Washington, Seattle, Washington; Seattle Children's Research Institute, Seattle, Washin"},{"author_name":"Judith Guzman-Cottrill","author_inst":"Department of Pediatrics, Oregon Health and Sciences University, Portland, Oregon"},{"author_name":"Jennifer Schuster","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Childrens Mercy; University of Missouri Kansas City, Kansas City, Missouri"},{"author_name":"Kathleen Chiotos","author_inst":"Division of Critical Care Medicine, Department of Anesthesiology and Critical Care, Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"author_name":"Michele Kong","author_inst":"Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama"},{"author_name":"Mary Allen Staat","author_inst":"Department of Pediatrics, Division of Infectious Diseases, Cincinnati Childrens Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnat"},{"author_name":"Janet Hume","author_inst":"Division of Pediatric Critical Care, University of Minnesota Masonic Childrens Hospital, Minneapolis, Minnesota"},{"author_name":"Melissa  S. Stockwell","author_inst":"Division of Child and Adolescent Health, Columbia University Vagelos College of Physicians and Surgeons and Department of Population and Family Health, Columbia"},{"author_name":"Melissa Cameron","author_inst":"Division of Pediatric Hospital Medicine, UC San Diego-Rady Childrens Hospital, San Diego, California"},{"author_name":"Alexander H Hogan","author_inst":"Division of Hospital Medicine, Connecticut Childrens Medical Center, Hartford, Connecticut"},{"author_name":"Jigar Chauhan","author_inst":"Division of Critical Care, Nemours Childrens Hospital, Wilmington, Delaware"},{"author_name":"Austin Biggs","author_inst":"Department of Pediatric Critical Care, Medical University of South Carolina and Shawn Jenkins Childrens Hospital, Charleston, South Carolina"},{"author_name":"Emily R Levy","author_inst":"Divisions of Pediatric Infectious Diseases and Pediatric Critical Care Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnes"},{"author_name":"Samina Bhumbra","author_inst":"Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana"},{"author_name":"Tracie C Walker","author_inst":"Department of Pediatrics, University of North Carolina at Chapel Hill Childrens Hospital, Chapel Hill, North Carolina"},{"author_name":"Neelima K Marupudi","author_inst":"Department of Child Health, University of Arizona, Banner Childrens Hospital at Desert, Division of Pediatric Critical Care, Mesa, Arizona"},{"author_name":"Mary K Prahl","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, University of California, San Francisco, California"},{"author_name":"Kelly N Michelson","author_inst":"Division of Pediatric Critical Care Medicine, Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois"},{"author_name":"Lora Martin","author_inst":"Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi"},{"author_name":"Tamara Brandford","author_inst":"Division of Cardiology, Department of Pediatrics, Louisiana State University Health Sciences Center, Louisiana; Childrens Hospital of New Orleans, New Orleans, "},{"author_name":"Adrienne Randolph","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts; Departments of Anesthesia and Pediatrics, Harv"},{"author_name":"Angela P Campbell","author_inst":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, "},{"author_name":"- Overcoming RSV Network investigators","author_inst":""}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV","rel_doi":"10.64898\/2026.11.13.26368017","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368017","rel_abs":"Importance: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in high-risk young children during their second RSV season. Nirsevimab, a long-acting monoclonal antibody against RSV, is recommended for some children who are at increased risk for severe RSV and entering their second RSV season to prevent severe RSV disease. Because of limited eligibility criteria for second season nirsevimab, estimating its effectiveness is challenging. Objective: We evaluated nirsevimab effectiveness against RSV-associated hospitalizations among young children eligible to receive nirsevimab during their second RSV season. Design: This retrospective case control study with a test-negative design was conducted during the 2024-2025 and 2025-2026 RSV seasons. Setting: Enrollment was in 26 hospitals across 24 U.S. states. Participants: Children eligible for nirsevimab during their second RSV season (as recommended in August 2023) were included. Nirsevimab-eligible children 8-23 months old hospitalized with respiratory symptoms were enrolled. Case-patients tested positive for RSV; control-patients tested negative for RSV. Exposures: Receipt of nirsevimab before or during the second RSV season and at least 7 days before symptom onset. Outcomes and measures: RSV-associated hospitalization. We estimated nirsevimab effectiveness using multivariable logistic regression adjusted for age, month and year of hospitalization, census region, and sex comparing the odds of second season nirsevimab receipt among case- and control-patients. Results: One hundred six case-patients and 125 control-patients were analyzed. Distributions of age, sex, race and ethnicity, and region were similar in case- and control-patients. Most case- and control-patients were eligible for nirsevimab because of chronic lung disease of prematurity (84.0% and 69.6%, respectively). Overall, 21 (19.8%) of case-patients and 53 (42.4%) of control-patients received nirsevimab. Adjusted nirsevimab effectiveness against RSV-associated hospitalizations was 78.1% (95% CI, 55.2%-89.3%); the median interval from nirsevimab receipt to symptom onset was 66.5 days (IQR = 30-96 days). Effectiveness was estimated to be higher if nirsevimab was received 8-59 days before symptom onset (88.5%, 95% CI, 63.4%-96.4%). Conclusions: This analysis provides real-world estimates of substantial nirsevimab effectiveness against RSV-associated hospitalizations for high-risk U.S. children in their second RSV season These data support recommendations for nirsevimab as a preventive strategy in this population.","rel_num_authors":33,"rel_authors":[{"author_name":"Regina M Simeone","author_inst":"CDC"},{"author_name":"Margaret M Newhams","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Amanda B Payne","author_inst":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, "},{"author_name":"Amber O Orzel-Lockwood","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Jemima Calixte","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Natasha Halasa","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee"},{"author_name":"Satoshi Kamidani","author_inst":"The Center for Childhood Infections and Vaccines of Childrens Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine, Atlan"},{"author_name":"Hillary Crandall","author_inst":"Division of Pediatric Critical Care, Department of Pediatrics, University of Utah and Primary Childrens Hospital, Salt Lake City, Utah"},{"author_name":"Katherine Irby","author_inst":"Section of Pediatric Critical Care, Department of Pediatrics, Arkansas Childrens Hospital, Little Rock, Arkansas"},{"author_name":"Aline B Maddux","author_inst":"Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Childrens Hospital Colorado, Aurora, Colorado"},{"author_name":"Danielle Zerr","author_inst":"Division of Infectious Diseases, Department of Pediatrics, University of Washington, Seattle, Washington; Seattle Children's Research Institute, Seattle, Washin"},{"author_name":"Judith Guzman-Cottrill","author_inst":"Department of Pediatrics, Oregon Health and Sciences University, Portland, Oregon"},{"author_name":"Jennifer Schuster","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Childrens Mercy; University of Missouri Kansas City, Kansas City, Missouri"},{"author_name":"Kathleen Chiotos","author_inst":"Division of Critical Care Medicine, Department of Anesthesiology and Critical Care, Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"author_name":"Michele Kong","author_inst":"Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama"},{"author_name":"Mary Allen Staat","author_inst":"Department of Pediatrics, Division of Infectious Diseases, Cincinnati Childrens Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnat"},{"author_name":"Janet Hume","author_inst":"Division of Pediatric Critical Care, University of Minnesota Masonic Childrens Hospital, Minneapolis, Minnesota"},{"author_name":"Melissa  S. Stockwell","author_inst":"Division of Child and Adolescent Health, Columbia University Vagelos College of Physicians and Surgeons and Department of Population and Family Health, Columbia"},{"author_name":"Melissa Cameron","author_inst":"Division of Pediatric Hospital Medicine, UC San Diego-Rady Childrens Hospital, San Diego, California"},{"author_name":"Alexander H Hogan","author_inst":"Division of Hospital Medicine, Connecticut Childrens Medical Center, Hartford, Connecticut"},{"author_name":"Jigar Chauhan","author_inst":"Division of Critical Care, Nemours Childrens Hospital, Wilmington, Delaware"},{"author_name":"Austin Biggs","author_inst":"Department of Pediatric Critical Care, Medical University of South Carolina and Shawn Jenkins Childrens Hospital, Charleston, South Carolina"},{"author_name":"Emily R Levy","author_inst":"Divisions of Pediatric Infectious Diseases and Pediatric Critical Care Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnes"},{"author_name":"Samina Bhumbra","author_inst":"Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana"},{"author_name":"Tracie C Walker","author_inst":"Department of Pediatrics, University of North Carolina at Chapel Hill Childrens Hospital, Chapel Hill, North Carolina"},{"author_name":"Neelima K Marupudi","author_inst":"Department of Child Health, University of Arizona, Banner Childrens Hospital at Desert, Division of Pediatric Critical Care, Mesa, Arizona"},{"author_name":"Mary K Prahl","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, University of California, San Francisco, California"},{"author_name":"Kelly N Michelson","author_inst":"Division of Pediatric Critical Care Medicine, Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois"},{"author_name":"Lora Martin","author_inst":"Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi"},{"author_name":"Tamara Brandford","author_inst":"Division of Cardiology, Department of Pediatrics, Louisiana State University Health Sciences Center, Louisiana; Childrens Hospital of New Orleans, New Orleans, "},{"author_name":"Adrienne Randolph","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts; Departments of Anesthesia and Pediatrics, Harv"},{"author_name":"Angela P Campbell","author_inst":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, "},{"author_name":"- Overcoming RSV Network investigators","author_inst":""}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV","rel_doi":"10.64898\/2026.11.13.26368017","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368017","rel_abs":"Importance: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in high-risk young children during their second RSV season. Nirsevimab, a long-acting monoclonal antibody against RSV, is recommended for some children who are at increased risk for severe RSV and entering their second RSV season to prevent severe RSV disease. Because of limited eligibility criteria for second season nirsevimab, estimating its effectiveness is challenging. Objective: We evaluated nirsevimab effectiveness against RSV-associated hospitalizations among young children eligible to receive nirsevimab during their second RSV season. Design: This retrospective case control study with a test-negative design was conducted during the 2024-2025 and 2025-2026 RSV seasons. Setting: Enrollment was in 26 hospitals across 24 U.S. states. Participants: Children eligible for nirsevimab during their second RSV season (as recommended in August 2023) were included. Nirsevimab-eligible children 8-23 months old hospitalized with respiratory symptoms were enrolled. Case-patients tested positive for RSV; control-patients tested negative for RSV. Exposures: Receipt of nirsevimab before or during the second RSV season and at least 7 days before symptom onset. Outcomes and measures: RSV-associated hospitalization. We estimated nirsevimab effectiveness using multivariable logistic regression adjusted for age, month and year of hospitalization, census region, and sex comparing the odds of second season nirsevimab receipt among case- and control-patients. Results: One hundred six case-patients and 125 control-patients were analyzed. Distributions of age, sex, race and ethnicity, and region were similar in case- and control-patients. Most case- and control-patients were eligible for nirsevimab because of chronic lung disease of prematurity (84.0% and 69.6%, respectively). Overall, 21 (19.8%) of case-patients and 53 (42.4%) of control-patients received nirsevimab. Adjusted nirsevimab effectiveness against RSV-associated hospitalizations was 78.1% (95% CI, 55.2%-89.3%); the median interval from nirsevimab receipt to symptom onset was 66.5 days (IQR = 30-96 days). Effectiveness was estimated to be higher if nirsevimab was received 8-59 days before symptom onset (88.5%, 95% CI, 63.4%-96.4%). Conclusions: This analysis provides real-world estimates of substantial nirsevimab effectiveness against RSV-associated hospitalizations for high-risk U.S. children in their second RSV season These data support recommendations for nirsevimab as a preventive strategy in this population.","rel_num_authors":33,"rel_authors":[{"author_name":"Regina M Simeone","author_inst":"CDC"},{"author_name":"Margaret M Newhams","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Amanda B Payne","author_inst":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, "},{"author_name":"Amber O Orzel-Lockwood","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Jemima Calixte","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts"},{"author_name":"Natasha Halasa","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee"},{"author_name":"Satoshi Kamidani","author_inst":"The Center for Childhood Infections and Vaccines of Childrens Healthcare of Atlanta and the Department of Pediatrics, Emory University School of Medicine, Atlan"},{"author_name":"Hillary Crandall","author_inst":"Division of Pediatric Critical Care, Department of Pediatrics, University of Utah and Primary Childrens Hospital, Salt Lake City, Utah"},{"author_name":"Katherine Irby","author_inst":"Section of Pediatric Critical Care, Department of Pediatrics, Arkansas Childrens Hospital, Little Rock, Arkansas"},{"author_name":"Aline B Maddux","author_inst":"Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Childrens Hospital Colorado, Aurora, Colorado"},{"author_name":"Danielle Zerr","author_inst":"Division of Infectious Diseases, Department of Pediatrics, University of Washington, Seattle, Washington; Seattle Children's Research Institute, Seattle, Washin"},{"author_name":"Judith Guzman-Cottrill","author_inst":"Department of Pediatrics, Oregon Health and Sciences University, Portland, Oregon"},{"author_name":"Jennifer Schuster","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Childrens Mercy; University of Missouri Kansas City, Kansas City, Missouri"},{"author_name":"Kathleen Chiotos","author_inst":"Division of Critical Care Medicine, Department of Anesthesiology and Critical Care, Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"author_name":"Michele Kong","author_inst":"Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama"},{"author_name":"Mary Allen Staat","author_inst":"Department of Pediatrics, Division of Infectious Diseases, Cincinnati Childrens Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnat"},{"author_name":"Janet Hume","author_inst":"Division of Pediatric Critical Care, University of Minnesota Masonic Childrens Hospital, Minneapolis, Minnesota"},{"author_name":"Melissa  S. Stockwell","author_inst":"Division of Child and Adolescent Health, Columbia University Vagelos College of Physicians and Surgeons and Department of Population and Family Health, Columbia"},{"author_name":"Melissa Cameron","author_inst":"Division of Pediatric Hospital Medicine, UC San Diego-Rady Childrens Hospital, San Diego, California"},{"author_name":"Alexander H Hogan","author_inst":"Division of Hospital Medicine, Connecticut Childrens Medical Center, Hartford, Connecticut"},{"author_name":"Jigar Chauhan","author_inst":"Division of Critical Care, Nemours Childrens Hospital, Wilmington, Delaware"},{"author_name":"Austin Biggs","author_inst":"Department of Pediatric Critical Care, Medical University of South Carolina and Shawn Jenkins Childrens Hospital, Charleston, South Carolina"},{"author_name":"Emily R Levy","author_inst":"Divisions of Pediatric Infectious Diseases and Pediatric Critical Care Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnes"},{"author_name":"Samina Bhumbra","author_inst":"Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana"},{"author_name":"Tracie C Walker","author_inst":"Department of Pediatrics, University of North Carolina at Chapel Hill Childrens Hospital, Chapel Hill, North Carolina"},{"author_name":"Neelima K Marupudi","author_inst":"Department of Child Health, University of Arizona, Banner Childrens Hospital at Desert, Division of Pediatric Critical Care, Mesa, Arizona"},{"author_name":"Mary K Prahl","author_inst":"Division of Pediatric Infectious Diseases, Department of Pediatrics, University of California, San Francisco, California"},{"author_name":"Kelly N Michelson","author_inst":"Division of Pediatric Critical Care Medicine, Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois"},{"author_name":"Lora Martin","author_inst":"Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi"},{"author_name":"Tamara Brandford","author_inst":"Division of Cardiology, Department of Pediatrics, Louisiana State University Health Sciences Center, Louisiana; Childrens Hospital of New Orleans, New Orleans, "},{"author_name":"Adrienne Randolph","author_inst":"Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Childrens Hospital, Boston, Massachusetts; Departments of Anesthesia and Pediatrics, Harv"},{"author_name":"Angela P Campbell","author_inst":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, "},{"author_name":"- Overcoming RSV Network investigators","author_inst":""}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Fentanyl dabbing with cannabis retail equipment: an ethnographic and drug-checking study","rel_doi":"10.64898\/2026.11.13.26367858","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26367858","rel_abs":"Background: Fentanyl's entrenchment in U.S. West Coast drug markets brought a shift from injecting to smoking illicit opioids. We characterize the next transition: the rise of 'dabbing,' vaporizing fentanyl with equipment sold for cannabis concentrates. Methods: This mixed-methods study combined ethnographic interviewing and participant observation among people who use fentanyl in California and Oregon (2024-2026) with survey data from a Los Angeles drug checking program. After identifying dabbing ethnographically, we added an optional smoking-method item to the survey. Results: Of 108 participants who stated a route of administration, 104 (96%) reported smoking; of 93 who named a smoking method, 81 (87%) reported dabbing. All 11 who first named another method and returned later then reported dabbing. Dabbing was reported at 250 of 405 (62%) encounters with a stated route. We observed participants adapting cannabis equipment. They praised dabbing's discretion, reduced stigma, and convenience, and its capacity for more large hits, more quickly; the same speed led some to call it wasteful, because it went through their fentanyl faster than other methods. Participants described rapidly rising tolerance and frequent dabbing-related burns, which we also observed. Some who had injected said dabbing approximated its \"rush.\" Conclusions: Dabbing has become the dominant way to consume fentanyl among people using drug checking services in Los Angeles, and was observed in every other city where we did fieldwork. Clinicians and programs should ask people how they smoke fentanyl, not only whether they smoke or inject; dabbing may reduce some risks while increasing others.","rel_num_authors":15,"rel_authors":[{"author_name":"Morgan Godvin","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Levi Cecil","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Adam Koncsol","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Caitlin A. Molina","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Megan Grabill","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Ruby Romero","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Elham Jalayer","author_inst":"Bienestar Human Services, Los Angeles, CA, USA"},{"author_name":"Naomi Villanueva","author_inst":"Bienestar Human Services, Los Angeles, CA, USA"},{"author_name":"Oscar Arellano","author_inst":"Homeless Outreach Program Integrated Care System (HOPICS), Special Service for Groups, Los Angeles, CA, USA"},{"author_name":"Amanda Cowan","author_inst":"Community Health Project Los Angeles, Los Angeles, CA, USA"},{"author_name":"Russell G. Buhr","author_inst":"Division of Pulmonary, Critical Care, and Sleep Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Honora Englander","author_inst":"Section of Addiction Medicine, Division of General Internal Medicine & Geriatrics, Department of Medicine, Oregon Health & Science University, Portland, OR, USA"},{"author_name":"Joseph R. Friedman","author_inst":"Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA"},{"author_name":"Philippe Bourgois","author_inst":"Department of Anthropology and Center for Social Medicine and Humanities, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Chelsea L. Shover","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Fentanyl dabbing with cannabis retail equipment: an ethnographic and drug-checking study","rel_doi":"10.64898\/2026.11.13.26367858","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26367858","rel_abs":"Background: Fentanyl's entrenchment in U.S. West Coast drug markets brought a shift from injecting to smoking illicit opioids. We characterize the next transition: the rise of 'dabbing,' vaporizing fentanyl with equipment sold for cannabis concentrates. Methods: This mixed-methods study combined ethnographic interviewing and participant observation among people who use fentanyl in California and Oregon (2024-2026) with survey data from a Los Angeles drug checking program. After identifying dabbing ethnographically, we added an optional smoking-method item to the survey. Results: Of 108 participants who stated a route of administration, 104 (96%) reported smoking; of 93 who named a smoking method, 81 (87%) reported dabbing. All 11 who first named another method and returned later then reported dabbing. Dabbing was reported at 250 of 405 (62%) encounters with a stated route. We observed participants adapting cannabis equipment. They praised dabbing's discretion, reduced stigma, and convenience, and its capacity for more large hits, more quickly; the same speed led some to call it wasteful, because it went through their fentanyl faster than other methods. Participants described rapidly rising tolerance and frequent dabbing-related burns, which we also observed. Some who had injected said dabbing approximated its \"rush.\" Conclusions: Dabbing has become the dominant way to consume fentanyl among people using drug checking services in Los Angeles, and was observed in every other city where we did fieldwork. Clinicians and programs should ask people how they smoke fentanyl, not only whether they smoke or inject; dabbing may reduce some risks while increasing others.","rel_num_authors":15,"rel_authors":[{"author_name":"Morgan Godvin","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Levi Cecil","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Adam Koncsol","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Caitlin A. Molina","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Megan Grabill","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Ruby Romero","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Elham Jalayer","author_inst":"Bienestar Human Services, Los Angeles, CA, USA"},{"author_name":"Naomi Villanueva","author_inst":"Bienestar Human Services, Los Angeles, CA, USA"},{"author_name":"Oscar Arellano","author_inst":"Homeless Outreach Program Integrated Care System (HOPICS), Special Service for Groups, Los Angeles, CA, USA"},{"author_name":"Amanda Cowan","author_inst":"Community Health Project Los Angeles, Los Angeles, CA, USA"},{"author_name":"Russell G. Buhr","author_inst":"Division of Pulmonary, Critical Care, and Sleep Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Honora Englander","author_inst":"Section of Addiction Medicine, Division of General Internal Medicine & Geriatrics, Department of Medicine, Oregon Health & Science University, Portland, OR, USA"},{"author_name":"Joseph R. Friedman","author_inst":"Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA"},{"author_name":"Philippe Bourgois","author_inst":"Department of Anthropology and Center for Social Medicine and Humanities, University of California, Los Angeles, Los Angeles, CA, USA"},{"author_name":"Chelsea L. Shover","author_inst":"Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Inter-articulatory Timing of Vocalic Tongue Body and Jaw Movements across Talkers with Dysarthria due to Various Neurological Conditions","rel_doi":"10.64898\/2026.11.13.26368039","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26368039","rel_abs":"Purpose: This study compared inter-articulatory timing patterns of the tongue and jaw across talkers with Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis (MS), and neurotypical controls (CON) to identify disease-related differences. The study also explored if a talker's tongue body cycle duration, which serve as a proxy for a talker's habitual speech rate, or a talker's reliance on their jaw, as indicated by their jaw movement amplitude, could predict their inter-articulatory timing patterns. Method: Using three-dimensional electromagnetic articulography, the movements of the posterior tongue and jaw were examined in 24 talkers with PD, 19 talkers with ALS, 18 talkers with HD, 18 talkers with MS, and 34 CON during a sentence repetition task ('Buy Kaia a kite'). The tongue movement during the segment [kai] served as the reference signal (tongue body cycle) for which the phase angle of the jaw reaching the maximum opening position during [kai] was calculated. Tongue body cycle durations were measured as the time between the tongue body movement onset to the tongue body movement offset. The jaw opening amplitude was measured as the relative positional change from the jaw's maximum closing position associated with [k] to the jaw's maximal opening position at the onset of the diphthong [ai]. Results: A significant group effect was found for phase angles. Pairwise comparisons showed that talkers with ALS had significantly larger phase angles than talkers with PD, MS, HD, and CON, indicating a timing pattern where the tongue reached the target [a] earlier relative to the jaw. No significant differences were found for any other pairwise comparisons. Furthermore, no significant associations were found between tongue body cycle durations and phase angles. A significant association was found between jaw amplitudes and phase angles when considering all talkers [rS(110) = .253, p = .008] and when only considering talkers of the control group [r(34) = .361, p = .036]. Conclusions: Findings suggest that during the production of [kai], tongue-jaw timing patterns of talkers with ALS differ from those of talkers with PD, MS, HD, and CON with the tongue reaching the maximum opening position before the jaw while the opposite pattern was observed for talkers of the other groups. However, the variability in tongue body cycle duration did not significantly contribute to the variability in phase angles and the variability in jaw amplitudes only accounted for 6% of the variability in phase angles across all talkers. Future studies are needed to determine if the observed tongue-jaw timing pattern of talkers with ALS generalizes to other phonetic contexts and determine the underlying factors that contribute to the unique tongue-jaw timing patterns of talkers with ALS.","rel_num_authors":3,"rel_authors":[{"author_name":"Tabea Thies","author_inst":"Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany"},{"author_name":"Mary S Dietrich","author_inst":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA"},{"author_name":"Antje Mefferd","author_inst":"Department of Hearing and Speech Sciences, Vanderbilt University Medical Center, Nashville, TN, USA"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"The gut microbiome and incident atherosclerotic cardiovascular events: Prospective analyses in three Swedish cohorts","rel_doi":"10.64898\/2026.11.12.26367976","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.12.26367976","rel_abs":"Background: Variation in the gut microbiome composition has been associated with atherosclerotic cardiovascular disease (ASCVD) in case-control designs. We aimed to investigate associations with incident ASCVD events applying a prospective design to reduce the impact of reverse causality. Methods: We assessed associations between gut microbiome features measured by shotgun metagenomic sequencing and incident total ASCVD, ischemic heart disease (IHD) and ischemic stroke, including fatal and non-fatal events as defined by registry follow-up in 17,216 participants from three Swedish population-based cohorts (SCAPIS, SIMPLER, and MOS). Results from Cox proportional hazards regression models adjusted for demographic, and lifestyle factors, medication, and prevalent diabetes were combined across cohorts using a fixed-effect meta-analysis accounting for multiple testing. Associations were tested for replication in HUNT and FINRISK. Results: During a median of 6-8 y follow-up, 769 incident ASCVD events occurred. Species diversity was inversely associated with ASCVD and IHD, with a hazard ratio for IHD of 0.86 per SD increase in species richness (95% CI: 0.79-0.95). Sixty-eight common species (i.e., present in ?30% individuals) were associated with incident IHD after adjusting for sex and birth country, but only eight remained in fully adjusted models, including Ruminococcus_B gnavus. Among others, inverse associations were observed for SFEL01 sp004557245 and Fimadaptatus sp900553645 from Christensenellales, an order in which butyrate production has been reported. Streptococcus mutans and Limosilactobacillus fermentum, oral-associated species previously associated with coronary atherosclerosis, were associated with a higher risk of incident IHD, which remained after adjustment for dental health. Replication analysis in the HUNT study supported the finding for S. mutans. No associations were observed with ischemic stroke. Conclusions: Gut species diversity and specific species abundance were associated with incident IHD, providing evidence supporting a protective role of two Christensenellales species and an adverse role of oral species and R. gnavus in the development of IHD.","rel_num_authors":30,"rel_authors":[{"author_name":"Kamalita Pertiwi","author_inst":"Uppsala University"},{"author_name":"Ulf Hammar","author_inst":"Uppsala University"},{"author_name":"Koen Dekkers","author_inst":"Uppsala University"},{"author_name":"Eivind Coward","author_inst":"Norges teknisk-naturvitenskapelige universitet Institutt for samfunnsmedisin og sykepleie"},{"author_name":"Oleg Kambur","author_inst":"Ita-Suomen yliopisto Laaketieteen laitos"},{"author_name":"Gabriel Baldanzi","author_inst":"Uppsala University"},{"author_name":"Mario Delgado-Velandia","author_inst":"Uppsala Universitet"},{"author_name":"Sergi Sayols-Baixeras","author_inst":"Uppsala University"},{"author_name":"Shuai Yuan","author_inst":"Karolinska Institutet"},{"author_name":"Peter Persson","author_inst":"Lunds universitet Clinical Research Centre"},{"author_name":"David Gabrielsson","author_inst":"Institutet for Halso- och Sjukvardsekonomi"},{"author_name":"Mariam Miari","author_inst":"Lunds Universitet"},{"author_name":"Camila Gazolla Volpiano","author_inst":"University of Turku"},{"author_name":"Guillaume Meric","author_inst":"Baker Heart and Diabetes Institute"},{"author_name":"Daniel J\u00f6nsson","author_inst":"Department of Clinical Sciences Malm\u00f6,Lund University"},{"author_name":"Gunnar Engstr\u00f6m","author_inst":"Lund University"},{"author_name":"J. Gustav Smith","author_inst":"Goteborgs universitet"},{"author_name":"Karl Micha\u00eblsson","author_inst":"Uppsala Universitet"},{"author_name":"Olle Melander","author_inst":"Lunds Universitet"},{"author_name":"Johan \u00c4rnl\u00f6v","author_inst":"karolinska institutet"},{"author_name":"Rob Knight","author_inst":"University of California San Diego"},{"author_name":"Robin Hofmann","author_inst":"Karolinska Institutet"},{"author_name":"Teemu J. Niiranen","author_inst":"University of Turku"},{"author_name":"Aki S. Havulinna","author_inst":"Turun yliopiston Teknillinen tiedekunta"},{"author_name":"Veikko Salomaa","author_inst":"University of Turku, Department of Internal Medicine"},{"author_name":"Kristian Hveem","author_inst":"Norwegian University of Science and Technology"},{"author_name":"Claes Ohlsson","author_inst":"University of Gothenburg"},{"author_name":"Marju Orho-Melander","author_inst":"Lund University"},{"author_name":"Susanna C. Larsson","author_inst":"Karolinska Institutet"},{"author_name":"Tove Fall","author_inst":"Uppsala Universitet"}],"rel_date":"2026-11-16","rel_site":"medrxiv"},{"rel_title":"Investigating Differential Changes in Cardiovascular Mortality by Documented diabetes in the United States Before and During the COVID-19 Pandemic: A Comparative Time-Series Analysis","rel_doi":"10.64898\/2026.11.12.26367977","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.12.26367977","rel_abs":"Background: Whether diabetes modified pandemic-related changes in cardiovascular disease (CVD) mortality remains uncertain. We examined differential changes in US CVD mortality among deaths with versus without diabetes documented on the death certificate. Methods: We analyzed CDC WONDER Multiple Cause of Death data from 2005 to 2024, identifying deaths with CVD as the underlying cause among adults aged 25 years. Cohorts were CVD deaths with diabetes documented as a contributing cause (CVD+DM) and CVD deaths without documented diabetes. Because pre-2020 trajectories differed, the primary comparison of age-adjusted rates used a comparative interrupted time-series model allowing cohort-specific pre-2020 trends. Difference-in-differences estimates (2015-2019 vs 2020-2024) were descriptive. Results: CVD+DM mortality declined from 43.1 per 100,000 in 2005 to 34.3 in 2019 and was 38.4 in 2024; mortality without documented diabetes declined from 398.7 to 296.6 and was 289.8. In the primary analysis, CVD+DM mortality showed a 13.1% greater relative level increase at 2020 (95% CI, 10.4%-15.9%), with no significant differential change in slope thereafter. Descriptively, the ratio of rate ratios was 1.16, and the absolute difference-in-differences was 5.0 per 100,000. Conclusions: After accounting for cohort-specific pre-2020 trends, CVD mortality with documented diabetes showed a greater relative increase at the 2020 transition. These findings describe differential mortality patterns rather than a causal effect of diabetes or the pandemic. Keywords: Cardiovascular mortality; Diabetes; COVID-19; Difference-in-differences; Preventive Cardiology Nonstandard Abbreviations and Acronyms AAMR: age-adjusted mortality rate APC: annual percentage change CITS: comparative interrupted time-series CVD+DM: cardiovascular disease deaths with diabetes documented as contributing cause DID: differences-in-differences DM: diabetes mellitus","rel_num_authors":7,"rel_authors":[{"author_name":"Muhammad Usman Ghani","author_inst":"Central Michigan University"},{"author_name":"Haeyoon Chang","author_inst":"Albert Einstein College of Medicine"},{"author_name":"Shofikur Shuhag","author_inst":"Henry Ford St John Hospital"},{"author_name":"Sharat Kamath","author_inst":"Corewell Health Grand Rapids Hospitals - Butterworth"},{"author_name":"Shahzaib Chughtai","author_inst":"Covenant HealthCare College of Medicine at Central Michigan University"},{"author_name":"Mohammad Alfrad Nobel Bhuiyan","author_inst":"Louisiana State University Health Sciences Center at Shreveport"},{"author_name":"Carlos Jose Rodriguez","author_inst":"Albert Einstein College of Medicine and Montefiore Medical Center"}],"rel_date":"2026-11-15","rel_site":"medrxiv"},{"rel_title":"Investigating Differential Changes in Cardiovascular Mortality by Documented diabetes in the United States Before and During the COVID-19 Pandemic: A Comparative Time-Series Analysis","rel_doi":"10.64898\/2026.11.12.26367977","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.12.26367977","rel_abs":"Background: Whether diabetes modified pandemic-related changes in cardiovascular disease (CVD) mortality remains uncertain. We examined differential changes in US CVD mortality among deaths with versus without diabetes documented on the death certificate. Methods: We analyzed CDC WONDER Multiple Cause of Death data from 2005 to 2024, identifying deaths with CVD as the underlying cause among adults aged 25 years. Cohorts were CVD deaths with diabetes documented as a contributing cause (CVD+DM) and CVD deaths without documented diabetes. Because pre-2020 trajectories differed, the primary comparison of age-adjusted rates used a comparative interrupted time-series model allowing cohort-specific pre-2020 trends. Difference-in-differences estimates (2015-2019 vs 2020-2024) were descriptive. Results: CVD+DM mortality declined from 43.1 per 100,000 in 2005 to 34.3 in 2019 and was 38.4 in 2024; mortality without documented diabetes declined from 398.7 to 296.6 and was 289.8. In the primary analysis, CVD+DM mortality showed a 13.1% greater relative level increase at 2020 (95% CI, 10.4%-15.9%), with no significant differential change in slope thereafter. Descriptively, the ratio of rate ratios was 1.16, and the absolute difference-in-differences was 5.0 per 100,000. Conclusions: After accounting for cohort-specific pre-2020 trends, CVD mortality with documented diabetes showed a greater relative increase at the 2020 transition. These findings describe differential mortality patterns rather than a causal effect of diabetes or the pandemic. Keywords: Cardiovascular mortality; Diabetes; COVID-19; Difference-in-differences; Preventive Cardiology Nonstandard Abbreviations and Acronyms AAMR: age-adjusted mortality rate APC: annual percentage change CITS: comparative interrupted time-series CVD+DM: cardiovascular disease deaths with diabetes documented as contributing cause DID: differences-in-differences DM: diabetes mellitus","rel_num_authors":7,"rel_authors":[{"author_name":"Muhammad Usman Ghani","author_inst":"Central Michigan University"},{"author_name":"Haeyoon Chang","author_inst":"Albert Einstein College of Medicine"},{"author_name":"Shofikur Shuhag","author_inst":"Henry Ford St John Hospital"},{"author_name":"Sharat Kamath","author_inst":"Corewell Health Grand Rapids Hospitals - Butterworth"},{"author_name":"Shahzaib Chughtai","author_inst":"Covenant HealthCare College of Medicine at Central Michigan University"},{"author_name":"Mohammad Alfrad Nobel Bhuiyan","author_inst":"Louisiana State University Health Sciences Center at Shreveport"},{"author_name":"Carlos Jose Rodriguez","author_inst":"Albert Einstein College of Medicine and Montefiore Medical Center"}],"rel_date":"2026-11-15","rel_site":"medrxiv"},{"rel_title":"Maternal and Neonatal Outcomes Associated with Prenatal Prescription Stimulant Treatment Among Pregnant Individuals with Opioid Use Disorder","rel_doi":"10.64898\/2026.11.12.26367944","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.12.26367944","rel_abs":"IntroductionClinicians and Medicaid programs must decide whether to continue prescription stimulants in pregnancies complicated by opioid use disorder (OUD), yet no safety evidence exists for this population and stimulant coverage is frequently restricted. We evaluated maternal and neonatal outcomes associated with prescription stimulant treatment during pregnancy among individuals with OUD, including those with co-occurring stimulant use disorder (StUD) and attention-deficit\/hyperactivity disorder (ADHD)\n\nMethodsWe conducted a retrospective cohort study of Medicaidinsured pregnant individuals in Tennessee (2010-2021) with OUD. Our exposure of interest was any prescription amphetamine or methylphenidateclass stimulant overlapping pregnancy. The primary maternal outcome was overdose from delivery through 1 year postpartum; secondary outcomes included death, severe maternal morbidity and cardiovascular complications in the first 6 weeks postpartum. The primary neonatal outcome was preterm birth; secondary outcomes included low birth weight, NICU admission, neonatal opioid withdrawal syndrome (NOWS), and death. We used overlap weighting to estimate adjusted odds ratios (aORs) and predicted probabilities and evaluated effect modification by buprenorphine.\n\nResultsAmong 12,327 pregnancies with OUD, 380 (3.1%) received prescription stimulants during pregnancy; stimulant treated individuals were slightly older and more likely to have mental health comorbidities. In adjusted analyses, stimulant treatment was not associated with postpartum overdose (aOR, 1.13; 95% CI, 0.61-2.08), preterm birth (aOR, 1.04; 95% CI, 0.74-1.46), cardiovascular complications, severe maternal morbidity, low birth weight, or NOWS. Odds of NICU admission were higher among stimulant exposed infants (aOR, 1.58; 95% CI, 1.17-2.14). Maternal and infant deaths were rare. In exploratory analyses, overdose odds were elevated among pregnancies receiving both stimulants and buprenorphine (P for interaction = .03) and the cardiovascular composite was elevated within the ADHD subgroup (aOR, 2.33; 95% CI, 1.13-4.82).\n\nConclusionsThese first OUD-specific estimates do not support routine discontinuation of clinically indicated stimulant therapy in pregnancy. Higher NICU admission among stimulant-exposed infants, unaccompanied by differences in preterm birth, low birth weight, gestational age, or NOWS, is more consistent with intensified surveillance than with neonatal harm. Two exploratory signals require replication before they can inform practice.","rel_num_authors":10,"rel_authors":[{"author_name":"Thomas Reese","author_inst":"Vanderbilt University Medical Center"},{"author_name":"Ashley A Leech","author_inst":"Vanderbilt University Medical Center"},{"author_name":"Julia C Phillippi","author_inst":"Vanderbilt University"},{"author_name":"Stephen Patrick","author_inst":"Emory University"},{"author_name":"Elizabeth McNeer","author_inst":"Vanderbilt University Medical Center"},{"author_name":"Sarah Loch","author_inst":"Emory University"},{"author_name":"Jessica Young","author_inst":"Vanderbilt University Medical Center"},{"author_name":"Amanda von Horn","author_inst":"Vanderbilt University Medical Center"},{"author_name":"Mauli V Shah","author_inst":"Vanderbilt University Medical Center"},{"author_name":"Andrew D Wiese","author_inst":"Vanderbilt University Medical Center"}],"rel_date":"2026-11-15","rel_site":"medrxiv"},{"rel_title":"Shifting source hubs and the factors associated with cross-country Zika virus transmission: a phylogeographic network analysis, 2012-2025","rel_doi":"10.64898\/2026.11.12.26367925","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.12.26367925","rel_abs":"BackgroundZika virus local transmission has been reported in at least 97 countries and territories, but the sources, routes, and determinants of cross-country spread remain incompletely understood. We reconstructed a phylogeographic network, characterized source activity across epidemic phases, and examined factors associated with identified cross-country transmission events.\n\nMethodology\/Principal FindingsWe analyzed a time-scaled Nextstrain phylogeny of 1,043 Zika virus genomes collected between February 2013 and March 2026. Parent-child branches assigned to different locations were screened and consolidated into 81 source- destination-year events involving 39 locations. Network analysis characterized temporal and geographic patterns, routes, hubs, and communities. For the analysis of associated factors, 68 events with complete covariate data were compared, using mixed-effects models, with eligible year-matched control records for which no event was identified, with all 68 events retained and a new control set drawn in each of 200 iterations. Asia contributed the earliest event, from Thailand in 2012. Most events occurred within the Americas (79.0%) and were concentrated during 2014-2016, with Brazil as the principal source hub. All six events from 2019 onward originated from Thailand or India and reached destinations in Asia, Europe, and Africa. Thailands source activity spanned 2012-2025. Event identification was positively associated with high source-country incidence (odds ratio [OR], 2.66; 95% confidence interval [CI], 1.39-9.69), greater air travel (OR, 2.52; 95% CI, 1.58-5.67), and higher destination-country GNI per capita (OR, 1.70; 95% CI, 1.20-4.50). It was negatively associated with greater geographic distance (OR, 0.11; 95% CI, 0.02-0.20) and higher source-country GNI per capita (OR, 0.64; 95% CI, 0.45-0.94). Fourteen source countries showed elevated residual source propensities, with Brazil and Thailand among the highest.\n\nConclusions\/SignificanceThe transmission network showed a shift in dominant source hubs, from early activity in Asia to the Americas during the 2014-2016 epidemic and back to Asia in recent years. High source-country incidence, greater air travel, and shorter distance can help identify country pairs requiring closer surveillance, alongside established routes in the Americas and persistent or emerging Asian sources, particularly as El Nino may increase vector-borne transmission potential in 2026-2027.\n\nAuthor SummaryZika virus can spread between countries without being recognized immediately through routine surveillance. We analyzed genetic sequences from 1,043 Zika virus samples and used their evolutionary relationships and geographic information to reconstruct cross-country transmission events. After screening and consolidating records, we identified 81 events involving 39 countries and territories. Source activity changed across epidemic phases. Thailand contributed the earliest event in 2012, while transmission during the 2014-2016 epidemic occurred predominantly within the Americas, with Brazil as the principal source hub. All events identified from 2019 onward originated from Thailand or India, showing the renewed prominence of Asian sources. Cross-country events were more likely to be identified when the source country had high reported Zika incidence, air travel between the countries was greater, and geographic distance was shorter. Several countries remained unusually prominent as sources after the measured factors were taken into account, including the major network hubs Brazil and Thailand. These findings can help health agencies use historical transmission patterns and current epidemiological conditions to identify routes requiring closer surveillance, especially as El Nino may increase the potential for mosquito-borne transmission in 2026-2027.","rel_num_authors":8,"rel_authors":[{"author_name":"Mingfan Pang","author_inst":"Chinese Center for Disease Control and Prevention"},{"author_name":"Xinyan Bu","author_inst":"Sun Yat-Sen University"},{"author_name":"Qiyong Liu","author_inst":"Chinese Center for Disease Control and Prevention"},{"author_name":"Chao Li","author_inst":"Chinese Center for Disease Control and Prevention"},{"author_name":"Nimyan Chan","author_inst":"University of Hong Kong"},{"author_name":"Hanran Ji","author_inst":"Chinese Center for Disease Control and Prevention"},{"author_name":"Xiaopeng Qi","author_inst":"Chinese Center for Disease Control and Prevention"},{"author_name":"Yangmu Huang","author_inst":"Peking University Health Science Centre"}],"rel_date":"2026-11-15","rel_site":"medrxiv"},{"rel_title":"In-country cerebrospinal fluid metagenomic next generation sequencing for pathogen detection in Lima, Peru","rel_doi":"10.64898\/2026.11.13.26367457","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26367457","rel_abs":"BackgroundThe epidemiology of central nervous system (CNS) infections in low- and middle-income countries is poorly characterized due to limited access to specialized neurodiagnostic testing. Cerebrospinal fluid (CSF) metagenomic next-generation sequencing (mNGS) can detect any pathogen in a single hypothesis-free assay but has largely been confined to high-income countries due to cost and infrastructure requirements. We piloted an in-country CSF mNGS protocol in Lima, Peru to assess the feasibility of this approach in a resource-limited setting.\n\nMethodsAdults with suspected CNS infection at Hospital Nacional Dos de Mayo were enrolled. CSF mNGS (DNA and RNA) was performed in-country on a benchtop sequencer with half-volume library reactions and cloud-based analysis (CZID). Paired sequencing at a significantly higher depth was performed on a subset of samples in the United States for validation.\n\nResultsAmong 43 participants (median age 48 years; 21% living with HIV), in-country mNGS detected 20 pathogens in 18 samples (42%), of which 65% were not identified by routine clinical testing. Nine of 15 patients treated empirically for tuberculous meningitis were found to have a non-mycobacterial infection. Detected organisms included Toxoplasma gondii, Taenia solium, Treponema pallidum, herpesviruses, and, on deeper sequencing, Venezuelan equine encephalitis virus. Deep sequencing recovered four pathogens missed at shallower-depth.\n\nConclusionsIn-country CSF mNGS was feasible in Lima, Peru and recovered a clinically and epidemiologically meaningful spectrum of CNS pathogens, most missed by routine testing. By utilizing available, lower-output sequencers, we overcame a principal barrier to deploying this technology where the burden of undiagnosed CNS infection is greatest.","rel_num_authors":18,"rel_authors":[{"author_name":"Sumanth P. Reddy","author_inst":"University of California San Francisco"},{"author_name":"Antonio Chavez Neyra","author_inst":"Universidad Peruana Cayetano Heredia"},{"author_name":"Katherine Lugo","author_inst":"Universidad Peruana Cayetano Heredia"},{"author_name":"Brenda Ayzanoa","author_inst":"Universidad Peruana Cayetano Heredia"},{"author_name":"Carolina Cucho Espinoza","author_inst":"Hospital Nacional Dos de Mayo"},{"author_name":"Jarod Morgenroth-Rebin","author_inst":"University of California San Francisco"},{"author_name":"Oliver A. Bocanegra","author_inst":"University of Texas Medical Branch"},{"author_name":"Diego Cuicapuza Arteaga","author_inst":"Universidad Peruana Cayetano Heredia"},{"author_name":"Marlon Saavedra","author_inst":"Universidad Peruana Cayetano Heredia"},{"author_name":"Chloe Gerungan","author_inst":"University of California San Francisco"},{"author_name":"Kelsey C. Zorn","author_inst":"University of California San Francisco"},{"author_name":"Felicia C. Chow","author_inst":"University of California San Francisco"},{"author_name":"Felix Llanos Tejada","author_inst":"Hospital Nacional Dos de Mayo"},{"author_name":"Andres G. Lescano","author_inst":"Universidad Peruana Cayetano Heredia"},{"author_name":"Pablo Tsukayama","author_inst":"Universidad Peruana Cayetano Heredia"},{"author_name":"Meddly L. Santolalla","author_inst":"Universidad Peruana Cayetano Heredia"},{"author_name":"Michael R Wilson","author_inst":"University of California San Francisco"},{"author_name":"Renzo Villanueva-Villegas","author_inst":"Universidad Peruana Cayetano Heredia"}],"rel_date":"2026-11-15","rel_site":"medrxiv"},{"rel_title":"TALQ: A reproducible language model questionnaire for dense measurement of depressive and anxious states","rel_doi":"10.64898\/2026.11.12.26367797","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.12.26367797","rel_abs":"Depression and anxiety are often assessed weeks or months apart with brief questionnaires covering few symptoms, leaving changes between assessments unobserved. Here, we introduce TALQ, a scoring system in which a large language model rates 52 symptoms from text, and use it to score 491 members of two online mental health communities every two weeks for a year. Ratings were stable across samples, predicted human annotations of interpersonal risk factors, low self-esteem and depression severity, and agreed with inventories completed by the same model. The scores mapped into 12 replicable symptom factors, including fearful preoccupation and social strain. Sleep disturbance and self-harm content consistently preceded overwhelm and emotional pain, respectively, two weeks later. People differed mainly in the states they occupied rather than transitions between them, and 13% entered in a crisis that remitted over months. Overall, our findings suggest that TALQ can measure expressed mental states densely and quantify longitudinal dynamics.","rel_num_authors":4,"rel_authors":[{"author_name":"Maxine E Levesque","author_inst":"University of California, San Francisco"},{"author_name":"Kira E Poskanzer","author_inst":"University of California, San Francisco"},{"author_name":"Joshua Woolley","author_inst":"University of California, San Francisco"},{"author_name":"Reza Abbasi-Asl","author_inst":"University of California, San Francisco"}],"rel_date":"2026-11-15","rel_site":"medrxiv"},{"rel_title":"Age at Menopause and Dementia Risk: Blood-Based Biomarker Evidence from a US National Study","rel_doi":"10.64898\/2026.11.12.26367954","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.12.26367954","rel_abs":"ImportanceEarlier age at menopause associates with increased later life dementia risk, but the biological links that underlie this relationship remain poorly understood in population-based samples.\n\nObjectiveTo evaluate the relationship between history of menopausal timing and AD\/ADRD-related blood-based biomarkers in postmenopausal women.\n\nDesignObservational study using the U.S. Health and Retirement Study. AD\/ADRD-related biomarkers were measured from venous blood draws conducted in 2016 and released in 2025. We estimated linear and nonlinear associations between spontaneous menopause timing and biomarkers, accounting for sociodemographic and health covariates. We evaluated effect modification by APOE 4 carrier status. Secondary analyses evaluated associations with hysterectomy history.\n\nSettingPopulation-based.\n\nParticipantsCommunity-dwelling post-menopausal women aged 65 years or older.\n\nExposurePrimary: Self-reported spontaneous age of menopause among women with no history of hysterectomy. Secondary: Self-reported history of hysterectomy (oophorectomy history was not assessed).\n\nMain Outcomes and MeasuresNeurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) measured in plasma, and phosphorylated tau (p-tau181) and growth differentiation factor 15 (GDF-15), measured in serum, by Simoa or ELLA.\n\nResultsAmong 1449 women [&ge;] 65 years, 38.4% self-reported a hysterectomy. Among 893 postmenopausal women without a history of hysterectomy (mean [SD] age at biomarker collection, 75.2 [7.2] years; mean age at menopause, 50.2 [5.2] years), menopausal timing was nonlinearly associated with NfL. Between menopausal ages 45-50, menopause timing was associated with higher NfL (0.010 SD units\/year, [95% CI: -0.007, 0.027]), while from menopausal ages 50-55, the association reversed (b= -0.031, [95% CI: -0.051, -0.011]). Associations with GFAP or pTau-181 were not significant, but were directionally similar to those observed for NfL. Later menopausal timing linearly associated with lower GDF-15 (b = -0.015, [95% CI: -0.027, -0.004]). Self-reported hysterectomy was associated with higher GDF-15 (b= 0.118, [95% CI: 0.015, 0.220]), but not other biomarkers. Associations did not significantly differ by APOE {varepsilon}4 status.\n\nConclusions and RelevanceIn a nationally representative study, earlier age at menopause in midlife was associated with later life AD\/ADRDs biomarkers reflecting neuroaxonal degeneration and inflammation, underscoring the importance of understanding reproductive aging in dementia risk.\n\nKEY POINTSO_ST_ABSQuestionC_ST_ABSWhat is the association between menopausal timing and blood-based Alzheimers disease and related dementias (AD\/ADRD) biomarkers among postmenopausal women 65 years and older in the United States?\n\nFindingsMenopausal timing is associated with higher NfL in women who experienced menopause before age 50, but lower NfL in women with menopausal ages after 50. Earlier menopausal timing is linearly associated with higher GDF-15. Secondary analyses showed associations between hysterectomy history and higher GDF-15.\n\nMeaningYounger menopausal timing associates with higher AD\/ADRD-related biomarkers measured decades later in a population-based cohort, underscoring a link between reproductive aging and future neurodegenerative risk.","rel_num_authors":8,"rel_authors":[{"author_name":"Sirena Gutierrez","author_inst":"University of California San Francisco"},{"author_name":"Michelle R. Caunca","author_inst":"University of California San Francisco"},{"author_name":"Muqi Guo","author_inst":"University of Michigan"},{"author_name":"Eleanor Hayes-Larson","author_inst":"University of Southern California"},{"author_name":"Sadaf A. Milani","author_inst":"University of Texas Medical Branch"},{"author_name":"Paola Gilsanz","author_inst":"Kaiser Permanente Northern California"},{"author_name":"Jacqueline M. Torres","author_inst":"University of California San Francisco"},{"author_name":"Kaitlin B. Casaletto","author_inst":"University of California San Francisco"}],"rel_date":"2026-11-15","rel_site":"medrxiv"},{"rel_title":"Improvement in Chronic Kidney Disease (CKD) diagnosis and management after automatic loading of CKD in the electronic health record problem list","rel_doi":"10.64898\/2026.11.12.26367913","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.12.26367913","rel_abs":"BackgroundChronic kidney disease (CKD) is often underrecognized and undiagnosed. We evaluate the impact of an algorithm-based automatic loading process for CKD in the electronic health record (EHR) problem list at a large health system.\n\nMethodsStudy populations included patients receiving primary or nephrology care at Geisinger (intervention group) and 4 large health systems in the Optum Labs Data Warehouse (OLDW), a longitudinal, real-world data asset with de-identified administrative claims and electronic health record (EHR) data,(comparator group) from 2008-2023. Since 2013, an automated process has been regularly implemented at Geisinger, adding CKD to problem lists of patients meeting laboratory criteria for CKD (outpatient eGFR <60 ml\/min\/1.73m2 on 2 lab values for [&ge;] 3 months without intervening normal values). We conducted difference-in-differences (DiD) and difference-in-difference-in-differences (DiDiD) analyses comparing CKD diagnosis rates, CKD-related lab tests, use of renin-angiotensin-aldosterone system inhibitors (RAASi) and statins for those >50 years within 1 year of incident CKD (index date) at Geisinger vs. OLDW health systems before (2008-2012) and after (2013-2023) CKD auto-load implementation. Analyses relied on summary-level data and did not permit adjustment for individual-level characteristics.\n\nResultsAmong patients with incident, undiagnosed CKD (n=21,995 in Geisinger; n=208,402 in OLDW), CKD diagnosis within 1 year of index date increased from 28.4% in 2008-2012 to 65.7% in 2013-2023 at Geisinger whereas CKD diagnosis decreased from 22.6% to 20.7% at OLDW (DiD estimate 39.1%; 95% CI: 38.1%, 40.1%; p<0.001). Among CKD-related labs, DID estimates favored Geisinger for follow-up eGFR, parathyroid hormone, and phosphorus testing (all p values <0.001). CKD auto-load was associated with increased use of RAASi and statins (p values <0.05).\n\nConclusionsAn algorithm-based problem list auto-load process was associated with higher CKD diagnosis, some CKD-related labs, and use of recommended medications. This scalable strategy should be validated in other health systems.","rel_num_authors":10,"rel_authors":[{"author_name":"Waleed Zafar","author_inst":"Geisinger Medical Center"},{"author_name":"Chen Dun","author_inst":"Johns Hopkins University"},{"author_name":"Yirui Hu","author_inst":"Department of Population Health Sciences Geisinger"},{"author_name":"Lauren Brubaker","author_inst":"Geisinger Health"},{"author_name":"Celia Gray","author_inst":"Department of Population Health Sciences, Geisinger"},{"author_name":"Cory Siegrist","author_inst":"Digital Solutions Analytics, Geisinger"},{"author_name":"H. Lester Kirchner","author_inst":"Department of Population Health Sciences, Geisinger"},{"author_name":"Jamie Green","author_inst":"Geisinger Medical Center"},{"author_name":"Jung-Im Shin","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Alexander R Chang","author_inst":"Geisinger"}],"rel_date":"2026-11-15","rel_site":"medrxiv"},{"rel_title":"Sex and generation shape the genetic architecture of smoking initiation","rel_doi":"10.64898\/2026.11.11.26367842","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.11.26367842","rel_abs":"The rapidly changing cultural contexts over the past century modified the genetic factors that influence smoking initiation (SI). Using data from nearly seven million respondents, we conducted genome-wide associations study (GWAS) meta-analyses stratified by sex and generation across European, East Asian, African American, and Latino genetic ancestry populations. Sex and generation, but not genetic ancestry, moderate both the SNP-based heritability estimates and associations with individual loci. Specifically, SI is more heritable in females and younger generations. Furthermore, the impact of both discrete policy changes that target smoking and the gradual cultural redefinition of smoking norms across sex and generation are captured within the patterns of cross-trait genetic correlations between SI and extant smoking-relevant phenotypes. Robust cross-ancestry genetic correlations allowed us to meta-analyze the results across subsamples, identifying 1,717 loci associated with SI, including both main and moderated associations for either moderator. Genome-wide heterogeneity analyses identified 45 sex-specific loci and 7 generation-specific loci with distinct associations with SI. Finemapping analyses highlighted 389 and 304 loci with distinct patterns of potential causal variants by sex and generation. Accordingly, sex-and generation-specific macrosocial contexts dynamically influence the genetic architecture of SI, underscoring the need to consider gene-environment interplay for health behaviors as societal norms evolve.","rel_num_authors":22,"rel_authors":[{"author_name":"Yeongmi Jeong","author_inst":"Purdue University"},{"author_name":"Saranya Arirangan","author_inst":"Purdue University"},{"author_name":"Evelina Akimova","author_inst":"Purdue University"},{"author_name":"Katherine N. Thompson","author_inst":"University College London"},{"author_name":"Rafael Geurgas","author_inst":"Purdue University"},{"author_name":"Jiachen Liu","author_inst":"Purdue University"},{"author_name":"Aahan Bajpai","author_inst":"Purdue University"},{"author_name":"Kathryn Fiuza Malerbi","author_inst":"Purdue University"},{"author_name":"Katelyn Kukar Bond","author_inst":"23andMe Research Institute"},{"author_name":"Julie M. Granka","author_inst":"23andMe Research Institute"},{"author_name":"Barry Hicks","author_inst":"23andMe Research Institute"},{"author_name":"David A. Hinds","author_inst":"23andMe Research Institute"},{"author_name":"Robert K. Bell","author_inst":"23andMe Research Institute"},{"author_name":"- 23andMe Research Team","author_inst":"-"},{"author_name":"Geyu Zhou","author_inst":"Purdue University"},{"author_name":"Boran Gao","author_inst":"Purdue University"},{"author_name":"Meghan Zacher","author_inst":"Brown University"},{"author_name":"Andrew D. Grotzinger","author_inst":"Memorial University"},{"author_name":"Andrea Ganna","author_inst":"University of Helsinki"},{"author_name":"Michel G. Nivard","author_inst":"University of Bristol"},{"author_name":"Brad Verhulst","author_inst":"Texas A and M University"},{"author_name":"Robbee Wedow","author_inst":"Purdue University"}],"rel_date":"2026-11-13","rel_site":"medrxiv"},{"rel_title":"Sex and generation shape the genetic architecture of smoking initiation","rel_doi":"10.64898\/2026.11.11.26367842","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.11.26367842","rel_abs":"The rapidly changing cultural contexts over the past century modified the genetic factors that influence smoking initiation (SI). Using data from nearly seven million respondents, we conducted genome-wide associations study (GWAS) meta-analyses stratified by sex and generation across European, East Asian, African American, and Latino genetic ancestry populations. Sex and generation, but not genetic ancestry, moderate both the SNP-based heritability estimates and associations with individual loci. Specifically, SI is more heritable in females and younger generations. Furthermore, the impact of both discrete policy changes that target smoking and the gradual cultural redefinition of smoking norms across sex and generation are captured within the patterns of cross-trait genetic correlations between SI and extant smoking-relevant phenotypes. Robust cross-ancestry genetic correlations allowed us to meta-analyze the results across subsamples, identifying 1,717 loci associated with SI, including both main and moderated associations for either moderator. Genome-wide heterogeneity analyses identified 45 sex-specific loci and 7 generation-specific loci with distinct associations with SI. Finemapping analyses highlighted 389 and 304 loci with distinct patterns of potential causal variants by sex and generation. Accordingly, sex-and generation-specific macrosocial contexts dynamically influence the genetic architecture of SI, underscoring the need to consider gene-environment interplay for health behaviors as societal norms evolve.","rel_num_authors":22,"rel_authors":[{"author_name":"Yeongmi Jeong","author_inst":"Purdue University"},{"author_name":"Saranya Arirangan","author_inst":"Purdue University"},{"author_name":"Evelina Akimova","author_inst":"Purdue University"},{"author_name":"Katherine N. Thompson","author_inst":"University College London"},{"author_name":"Rafael Geurgas","author_inst":"Purdue University"},{"author_name":"Jiachen Liu","author_inst":"Purdue University"},{"author_name":"Aahan Bajpai","author_inst":"Purdue University"},{"author_name":"Kathryn Fiuza Malerbi","author_inst":"Purdue University"},{"author_name":"Katelyn Kukar Bond","author_inst":"23andMe Research Institute"},{"author_name":"Julie M. Granka","author_inst":"23andMe Research Institute"},{"author_name":"Barry Hicks","author_inst":"23andMe Research Institute"},{"author_name":"David A. Hinds","author_inst":"23andMe Research Institute"},{"author_name":"Robert K. Bell","author_inst":"23andMe Research Institute"},{"author_name":"- 23andMe Research Team","author_inst":"-"},{"author_name":"Geyu Zhou","author_inst":"Purdue University"},{"author_name":"Boran Gao","author_inst":"Purdue University"},{"author_name":"Meghan Zacher","author_inst":"Brown University"},{"author_name":"Andrew D. Grotzinger","author_inst":"Memorial University"},{"author_name":"Andrea Ganna","author_inst":"University of Helsinki"},{"author_name":"Michel G. Nivard","author_inst":"University of Bristol"},{"author_name":"Brad Verhulst","author_inst":"Texas A and M University"},{"author_name":"Robbee Wedow","author_inst":"Purdue University"}],"rel_date":"2026-11-13","rel_site":"medrxiv"},{"rel_title":"A multinational pharmacoepidemiology atlas of prescription medication associations with all-cause mortality across six population cohorts","rel_doi":"10.64898\/2026.11.12.26367024","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.12.26367024","rel_abs":"Observational studies sometimes report that individual medications are associated with lower mortality, but such signals are rarely compared across drugs and health systems. We screened prescription medications for associations with all-cause mortality using time-dependent Cox models in six cohorts from the UK, US, Finland, Hong Kong and Japan (8.93 million individuals aged 40 years or older; 1.49 billion prescriptions). Most medications were associated with higher mortality, reflecting confounding by indication. A few medications showed inverse associations with mortality, notably the varicella-zoster virus (VZV) vaccine, the antimalarials atovaquone-proguanil (Malarone) and mefloquine, and the hormone replacement therapy estradiol. These associations were only modestly attenuated by adjustment for comorbidity, lifestyle and socio-economic factors, and persisted within strata defined by pre-existing disease. While adjustment for self-reported health abolished the Malarone association, probably reflecting a healthy traveler profile, the VZV association was maintained. In FinnGen, deaths from external causes, which vaccination cannot prevent, were lower among VZV vaccine users, but much less so than all-cause mortality. In a target trial emulation in All of Us, the VZV association was maintained against matched unvaccinated individuals (HR 0.61, 95% CI 0.53-0.70) and pneumococcal vaccine recipients (HR 0.64, 0.55-0.74), but was attenuated against recipients of tetanus-diphtheria vaccines, a group that also has low mortality (HR 0.85, 0.70-1.03). Healthy-user selection contributes to these signals but does not appear to fully explain the VZV vaccine association, which warrants confirmation in randomized trials. This multinational atlas provides a resource for prioritizing drug-repurposing candidates in ageing research.","rel_num_authors":8,"rel_authors":[{"author_name":"Kevin Perez","author_inst":"Institute of Oncology Research (IOR), Bellinzona, Switzerland"},{"author_name":"Jonathan K. L. Mak","author_inst":"Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"},{"author_name":"Kathryn C. B. Tan","author_inst":"Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"},{"author_name":"Andrea Ganna","author_inst":"Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland"},{"author_name":"Alessandro Ceschi","author_inst":"Faculty of Biomedical Sciences, Universita della Svizzera italiana, Lugano, Switzerland"},{"author_name":"Juulia Jylhava","author_inst":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"author_name":"Ching-Lung Cheung","author_inst":"Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"},{"author_name":"Andrea Alimonti","author_inst":"Institute of Oncology Research (IOR), Bellinzona, Switzerland"}],"rel_date":"2026-11-13","rel_site":"medrxiv"},{"rel_title":"The contribution of Neanderthal ancestry to cancer risk","rel_doi":"10.64898\/2026.11.10.26367742","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.10.26367742","rel_abs":"Modern human genomes harbor DNA inherited from interbreeding with Neanderthals. Genetic variants inherited from Neanderthals associate with variation in many immune and metabolic phenotypes, two systems with direct relevance to cancer. However, the influence of Neanderthal variants on germline cancer risk has not been comprehensively evaluated.\n\nHere, we evaluated genome-wide association study (GWAS) hits for 17 cancer types for Neanderthal ancestry. Twelve cancers have multiple Neanderthal alleles significantly associated with variation in risk. Next, we fine-mapped these risk loci and identified 32 associations across seven cancers where Neanderthal variants are likely causal ([&ge;] 50% posterior inclusion probability). Fine-mapped loci include Neanderthal alleles that both increase and decrease cancer risk. Nine of the 32 Neanderthal associations, including the high frequency BNC2 Neanderthal variants, have signatures of adaptive introgression, and several suggest evidence of both mediated and antagonistic pleiotropy. Finally, we tested for enrichment of cancer heritability in genomic regions with Neanderthal ancestry. As expected, Neanderthal variants are depleted of heritability for most cancers. However, Neanderthal variants were enriched for heritability in breast cancer GWAS in both East Asian and Europeans, and this enrichment replicated using individual-level UK Biobank data.\n\nThese results suggest that Neanderthal alleles that influence germline cancer risk were largely selected against. However, introgressed Neanderthal variants implicated in many cancers persist, potentially due to adaptive pleiotropic effects. This evolutionary perspective provides new insights into the complex evolution and etiology of cancer risk among modern human populations.","rel_num_authors":3,"rel_authors":[{"author_name":"Colin M. Brand","author_inst":"University of California San Francisco"},{"author_name":"Yaen Chen","author_inst":"University of California San Francisco"},{"author_name":"John Anthony Capra","author_inst":"University of California, San Francisco"}],"rel_date":"2026-11-13","rel_site":"medrxiv"},{"rel_title":"PSEN1 loss-of-function variants do not cause early-onset Alzheimer's disease","rel_doi":"10.64898\/2026.11.13.26367865","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26367865","rel_abs":"PSEN1 variants are the most common cause of familial early-onset Alzheimers disease (EOAD), but it is debated whether they act through a loss- or gain-of-function. Following a recent report of a duo with EOAD carrying a predicted loss-of-function (LoF) stop-gain variant (p.K109*) in PSEN1, we sought to determine whether PSEN1 LoF variants, as a class, cause EOAD. We identified 45 carriers of PSEN1 LoF variants predicted to trigger nonsense-mediated decay in the Alzheimers Disease Sequencing Project, UK Biobank, and BioVU databases. None of these carriers had a recorded diagnosis of early-onset dementia, and 17 were older than 65 years at last follow-up with no dementia or AD reported. Re-analysis of the reported AD-associated variant p.K109* revealed a cryptic splice site predicted to produce an in-frame deletion of 5 amino acids (p.K109_L113del). These results suggest that PSEN1 variants must produce an altered PSEN1 protein product to cause EOAD, while true null LoF PSEN1 alleles do not cause EOAD.","rel_num_authors":7,"rel_authors":[{"author_name":"Amelia Farinas","author_inst":"Stanford University"},{"author_name":"Andr\u00e9s Pe\u00f1a-Tauber","author_inst":"Stanford University"},{"author_name":"Timothy J. Hohman","author_inst":"Vanderbilt University"},{"author_name":"Alex G. Contreras","author_inst":"Vanderbilt University"},{"author_name":"Tanner D. Jensen","author_inst":"Stanford University"},{"author_name":"Yann Le Guen","author_inst":"Stanford University"},{"author_name":"Michael D. Greicius","author_inst":"Stanford University"}],"rel_date":"2026-11-13","rel_site":"medrxiv"},{"rel_title":"Prevalence and risk factors for human papillomavirus infection among women living with HIV in Sierra Leone: A cross-sectional study","rel_doi":"10.64898\/2026.11.11.26367873","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.11.26367873","rel_abs":"BackgroundCervical cancer, a malignancy affecting the cervix, is the fourth most common cancer and cause of cancer-related mortality among women worldwide. This burden disproportionately affects low-resource regions, where approximately 90% of cases occur. HIV-positive women are at high risk of persistent Human Papillomavirus (HPV) infection and cervical cancer, but screening for this cancer is not yet integrated into HIV care in Sierra Leone. This study aimed to assess the prevalence and risk factors of high-risk HPV infection among women living with HIV (WLHIV) attending Connaught Hospital in Sierra Leone.\n\nMethodsWe conducted a cross-sectional study of women living with HIV aged 25-65 years attending the HIV clinic at Connaught Teaching Hospital in Freetown between September and December 2024. Endocervical swabs were collected for HPV DNA testing. Data was analyzed using R (v4.4.0). Logistic regression analysis was used to determine the independent risk factors for HPV positivity.\n\nResultsA total of 191 WLHIV were enrolled. The mean age was 36.8 years; 44.5% were single, and 67% were employed. High-risk HPV DNA was detected in 60 (31.4%) (95% CI 25.3%-38.3%) participants, with 50% (30\/60) having multiple serotypes. The most common genotype was HPV 52, followed by 16 and 51. Only 30% of HPV-positive women had genotypes 16 or 18, targeted by the bivalent vaccine. On multivariable analysis, former contraceptive use was independently associated with increased HPV positivity (aOR=4.86, 95% CI: 1.65-17.37, p = 0.0032).\n\nConclusionThe high prevalence of high-risk HPV infection and predominance of non 16\/18 genotypes among WLHIV in Sierra Leone underscore the need to integrate HPV screening within HIV services and consider broader HPV vaccine coverage in Sierra Leone. Former contraceptive use is an independent predictor of HPV positivity, emphasizing the need for robust screening strategies in women using contraceptives.","rel_num_authors":17,"rel_authors":[{"author_name":"Darlinda  Fatmata Jiba","author_inst":"College of Medicine and Allied Health Sciences, University of Sierra Leone"},{"author_name":"Guang Yang","author_inst":"Department of Clinical Laboratory, the Fifth Medical Center of PLA General Hospital, Beijing, China"},{"author_name":"Tian Zhang","author_inst":"Department of Clinical Laboratory, the Fifth Medical Center of PLA General Hospital, Beijing, China."},{"author_name":"Lili Zhao","author_inst":"Department of Clinical Laboratory, the Fifth Medical Center of PLA General Hospital, Beijing, China."},{"author_name":"Andrew  J Dykens","author_inst":"Department of Family and Community Medicine, University of Illinois Chicago, Chicago, Illinois, United States"},{"author_name":"Gibrilla  F Deen","author_inst":"College of Medicine and Allied Health Sciences, University of Sierra Leone, New England, Freetown, Sierra Leone"},{"author_name":"Enanga  S Namanga","author_inst":"Ministry of Health and Sanitation, Government of Sierra Leone, New England, Freetown, Sierra Leone."},{"author_name":"Matilda  N Kamara","author_inst":"Ministry of Health and Sanitation, Government of Sierra Leone, New England, Freetown, Sierra Leone."},{"author_name":"Umu Barrie","author_inst":"Infectious Disease Research Network, Freetown, Sierra Leone"},{"author_name":"Abu  Bakarr Kallon","author_inst":"Ministry of Health and Sanitation, Government of Sierra Leone, New England, Freetown, Sierra Leone"},{"author_name":"Daniel Sesay","author_inst":"Ministry of Health and Sanitation, Government of Sierra Leone, New England, Freetown, Sierra Leone"},{"author_name":"Sattu Issa","author_inst":"Ministry of Health and Sanitation, Government of Sierra Leone, New England, Freetown, Sierra Leone"},{"author_name":"Umu Sesay","author_inst":"Ministry of Health and Sanitation, Government of Sierra Leone, New England, Freetown, Sierra Leone"},{"author_name":"Miama Amy Sam-Kpakra","author_inst":"Ministry of Health and Sanitation, Government of Sierra Leone, New England, Freetown, Sierra Leone"},{"author_name":"Olukemi Adekanmbi","author_inst":"Department of Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria  \/ Department of Medicine, University College Hospital, Ibadan, Ibadan, Niger"},{"author_name":"Babatunde Duduyemi","author_inst":"College of Medicine and Allied Health Sciences, University of Sierra Leone, New England, Freetown, Sierra Leone"},{"author_name":"Sulaiman Lakoh","author_inst":"College of Medicine and Allied Health Sciences, University of Sierra Leone, New England, Freetown, Sierra Leone"}],"rel_date":"2026-11-13","rel_site":"medrxiv"},{"rel_title":"Socioeconomic Position, Kidney Outcomes, and Mortality: A Longitudinal Cohort Study from the All of Us Research Program","rel_doi":"10.64898\/2026.11.11.26367876","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.11.26367876","rel_abs":"BackgroundSocioeconomic position is associated with kidney disease, but it remains unclear whether these differences are greater for worsening kidney function than for a first recorded diagnosis. We examined how household income, education, and neighborhood deprivation relate to mortality and kidney outcomes.\n\nMethods and findingsWe conducted a retrospective cohort study involving 218,098 individuals using data from the All of Us Research Program, with follow-up to January 1, 2025. Primary outcomes involved all-cause mortality and sustained 40% estimated glomerular filtration rate decline. Secondary outcomes were incident recorded chronic kidney disease (CKD) diagnosis, incident recorded CKD category G3a or worse, and kidney failure. We also evaluated income inequalities and estimated standardized 3-year mortality risks for each baseline kidney state.\n\nMedian follow-up was 3.62 years for mortality and 2.76 years for kidney outcomes. Among 218,098 individuals, 4,777 deaths, 6,423 sustained declines, 7,870 incident recorded chronic kidney disease diagnoses, 4,716 incident category G3a-or-worse events, and 1,799 kidney failure events were observed. Adjusted hazard ratios (95% CIs) for household income below $25,000 compared with $200,000 or more were 2.68 (2.31-3.12), 3.57 (3.08-4.13), 2.13 (1.90-2.38), 2.15 (1.86-2.49), and 3.08 (2.30-4.11), respectively. Relative index of inequality estimates were approximately twice as large for sustained decline and kidney failure than for recorded CKD diagnosis. Within baseline kidney states, standardized 3-year absolute mortality differences by income did not differ significantly across states. The main limitations are the observational design, baseline creatinine measured up to a year after the survey, and outcome ascertainment from health records that may differ by income.\n\nConclusionsLower income was associated with higher mortality and greater risk of all kidney outcomes. Education and neighborhood deprivation showed different patterns of association, which supports considering individual and neighborhood circumstances together.","rel_num_authors":8,"rel_authors":[{"author_name":"Atalay Demiray","author_inst":"Yale University School of Public Health"},{"author_name":"Ibrahim Gulmaliyev","author_inst":"Koc University"},{"author_name":"Mehmet Ali Enlice","author_inst":"Koc University"},{"author_name":"Sidar Copur","author_inst":"Koc University"},{"author_name":"Metehan Berkkan","author_inst":"Koc University"},{"author_name":"Francesca Mallamaci","author_inst":"Associazione Ipertensione Nefrologia Trapianto (IPNET)"},{"author_name":"Carmine Zoccali","author_inst":"Renal Research Institute"},{"author_name":"Mehmet Kanbay","author_inst":"Koc University"}],"rel_date":"2026-11-13","rel_site":"medrxiv"},{"rel_title":"Socioeconomic Position, Kidney Outcomes, and Mortality: A Longitudinal Cohort Study from the All of Us Research Program","rel_doi":"10.64898\/2026.11.11.26367876","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.11.26367876","rel_abs":"BackgroundSocioeconomic position is associated with kidney disease, but it remains unclear whether these differences are greater for worsening kidney function than for a first recorded diagnosis. We examined how household income, education, and neighborhood deprivation relate to mortality and kidney outcomes.\n\nMethods and findingsWe conducted a retrospective cohort study involving 218,098 individuals using data from the All of Us Research Program, with follow-up to January 1, 2025. Primary outcomes involved all-cause mortality and sustained 40% estimated glomerular filtration rate decline. Secondary outcomes were incident recorded chronic kidney disease (CKD) diagnosis, incident recorded CKD category G3a or worse, and kidney failure. We also evaluated income inequalities and estimated standardized 3-year mortality risks for each baseline kidney state.\n\nMedian follow-up was 3.62 years for mortality and 2.76 years for kidney outcomes. Among 218,098 individuals, 4,777 deaths, 6,423 sustained declines, 7,870 incident recorded chronic kidney disease diagnoses, 4,716 incident category G3a-or-worse events, and 1,799 kidney failure events were observed. Adjusted hazard ratios (95% CIs) for household income below $25,000 compared with $200,000 or more were 2.68 (2.31-3.12), 3.57 (3.08-4.13), 2.13 (1.90-2.38), 2.15 (1.86-2.49), and 3.08 (2.30-4.11), respectively. Relative index of inequality estimates were approximately twice as large for sustained decline and kidney failure than for recorded CKD diagnosis. Within baseline kidney states, standardized 3-year absolute mortality differences by income did not differ significantly across states. The main limitations are the observational design, baseline creatinine measured up to a year after the survey, and outcome ascertainment from health records that may differ by income.\n\nConclusionsLower income was associated with higher mortality and greater risk of all kidney outcomes. Education and neighborhood deprivation showed different patterns of association, which supports considering individual and neighborhood circumstances together.","rel_num_authors":8,"rel_authors":[{"author_name":"Atalay Demiray","author_inst":"Yale University School of Public Health"},{"author_name":"Ibrahim Gulmaliyev","author_inst":"Koc University"},{"author_name":"Mehmet Ali Enlice","author_inst":"Koc University"},{"author_name":"Sidar Copur","author_inst":"Koc University"},{"author_name":"Metehan Berkkan","author_inst":"Koc University"},{"author_name":"Francesca Mallamaci","author_inst":"Associazione Ipertensione Nefrologia Trapianto (IPNET)"},{"author_name":"Carmine Zoccali","author_inst":"Renal Research Institute"},{"author_name":"Mehmet Kanbay","author_inst":"Koc University"}],"rel_date":"2026-11-13","rel_site":"medrxiv"},{"rel_title":"Type 2 Diabetes Mellitus and Risk of Colorectal Cancer: A Systematic Review and Meta-Analysis","rel_doi":"10.64898\/2026.11.13.26367733","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.13.26367733","rel_abs":"Epidemiologic studies suggest that type 2 diabetes mellitus (T2DM) is associated with an increased risk of colorectal cancer (CRC). However, prior meta-analyses have relied heavily on studies published more than a decade ago and have often combined distinct epidemiologic effect measures. We conducted an updated systematic review and meta-analysis of observational studies published from January 2012 through January 2026 evaluating the association between T2DM and incident CRC. PubMed, Embase, Web of Science, CENTRAL, and Scopus were searched, and eligible studies reporting associations between T2DM and CRC were included. Effect estimates were synthesized separately using random-effects models to calculate pooled estimates with 95% confidence intervals (CIs). Sex-specific and leave-one-out sensitivity analyses were also conducted. Fourteen studies were included, comprising nine cohort and five case-control studies; six reported odds ratios (ORs), seven reported hazard ratios (HRs), and one reported a standardized incidence ratio (SIR). T2DM was associated with higher odds of incident CRC (OR, 1.28; 95% CI, 1.13-1.46) and a higher hazard of incident CRC (HR, 1.27; 95% CI, 1.23-1.31). The study reporting an SIR also showed higher CRC incidence among individuals with T2DM (SIR, 1.40; 95% CI, 1.39-1.45). Sex-specific analyses generally showed positive associations in both females and males, and sensitivity analyses supported the robustness of the pooled findings. Overall, T2DM was associated with an increased risk of incident CRC, with a consistent direction of association across distinct epidemiologic effect measures. These findings provide updated evidence supporting consideration of T2DM as a marker of increased CRC risk and may inform CRC prevention strategies among individuals with T2DM.","rel_num_authors":4,"rel_authors":[{"author_name":"Shengyang Wang","author_inst":"Indiana University Bloomington"},{"author_name":"Anna Porter","author_inst":"Yale University"},{"author_name":"Nianjun Liu","author_inst":"Indiana University"},{"author_name":"Lin Ge","author_inst":"Indiana University Bloomington"}],"rel_date":"2026-11-13","rel_site":"medrxiv"},{"rel_title":"Protocol and Statistical Analysis Plan for the Hyperangulated versus Standard Geometry Laryngoscope Blade (ANGLE) Trial","rel_doi":"10.64898\/2026.11.11.26367862","rel_link":"http:\/\/medrxiv.org\/content\/10.64898\/2026.11.11.26367862","rel_abs":"BackgroundEmergency tracheal intubation is common and high risk. Although guidelines recommend using a video laryngoscope to intubate critically ill adults, whether a hyperangulated or standard-geometry blade is more likely to achieve successful intubation on the first attempt remains unknown.\n\nResearch QuestionDoes the use of a video laryngoscope with a hyperangulated blade increase the incidence of successful intubation on the first attempt among adults undergoing emergency tracheal intubation, compared to use of a video laryngoscope with a standard-geometry blade?\n\nStudy Design and MethodsThe HyperANgulated versus Standard Geometry Laryngoscope BladE (ANGLE) trial is a pragmatic, multicenter, unblinded, parallel-group, randomized trial being conducted in 28 sites (10 emergency departments and 18 intensive care units) in the United States. The trial compares use of a video laryngoscope with a hyperangulated blade versus a standard-geometry blade among 2,500 critically ill adults undergoing emergency tracheal intubation. The primary outcome is successful intubation on the first attempt. The secondary outcome is the incidence of hypoxemia during intubation. Enrollment began on December 30, 2025, and is expected to conclude in 2027.\n\nInterpretationThe ANGLE trial will provide important data on the effects of the use of a video laryngoscope with a hyperangulated blade versus standard-geometry blade on successful intubation on the first attempt and other outcomes of emergency tracheal intubation. Specifying the protocol and statistical analysis plan before the conclusion of enrollment increases the rigor, reproducibility, and transparency of the trial.\n\nTrial RegistryClinicalTrials.gov; No.: NCT07223762; URL: www.clinicaltrials.gov","rel_num_authors":65,"rel_authors":[{"author_name":"Stephanie C. DeMasi","author_inst":"Vanderbilt Health; Vanderbilt Institute for Clinical and Translational Research"},{"author_name":"Matthew W. Semler","author_inst":"Vanderbilt Health; Vanderbilt Institute for Clinical and Translational Research"},{"author_name":"Aaron E. Robinson","author_inst":"Hennepin County Medical Center"},{"author_name":"Heath D. White","author_inst":"Baylor Scott & White Medical Center Temple"},{"author_name":"Kevin G. Buell","author_inst":"Rush University Medical Center"},{"author_name":"Carolynn Lyle","author_inst":"Denver Health Medical Center"},{"author_name":"Michael Gottlieb","author_inst":"Rush University Medical Center"},{"author_name":"LuAnn H. Barnett","author_inst":"Louisiana State University Health Sciences Center New Orleans; Our Lady of the Lake Regional Medical Center"},{"author_name":"Nida Qadir","author_inst":"David Geffen School of Medicine at UCLA"},{"author_name":"Amy L. Kloosterboer","author_inst":"Stanford University School of Medicine"},{"author_name":"Daniel Resnick-Ault","author_inst":"University of Colorado Anschutz School of Medicine"},{"author_name":"Sheetal Gandotra","author_inst":"University of Maryland School of Medicine"},{"author_name":"Logan L. Beach","author_inst":"University of Alabama at Birmingham Heersink School of Medicine"},{"author_name":"Derek J. Vonderhaar","author_inst":"Ochsner Health"},{"author_name":"Taya Haas","author_inst":"Hennepin County Medical Center"},{"author_name":"Matthew J. Barraza","author_inst":"The Ohio State University"},{"author_name":"Alexandra June Gordon","author_inst":"Stanford University School of Medicine"},{"author_name":"Kevin R. Landefeld","author_inst":"David Geffen School of Medicine at UCLA"},{"author_name":"Kevin W. Gibbs","author_inst":"Wake Forest University School of Medicine"},{"author_name":"Calvin A. Brown III","author_inst":"Lahey Clinic and UMass Chan-Lahey School of Medicine"},{"author_name":"R. Gentry Wilkerson","author_inst":"University of Maryland School of Medicine"},{"author_name":"Stephen C. Lim","author_inst":"Louisiana State University Health Sciences Center New Orleans"},{"author_name":"Akram Khan","author_inst":"Oregon Health & Science University"},{"author_name":"Amelia L. Muhs","author_inst":"Louisiana State University Health Sciences Center New Orleans"},{"author_name":"Xian Qiao","author_inst":"Eastern Virginia Medical School, Macon & Joan Brock Virginia Health Sciences at Old Dominion University"},{"author_name":"Taylor Herbert","author_inst":"Duke University School of Medicine"},{"author_name":"James E. Walker","author_inst":"Our Lady of the Lake Regional Medical Center; Louisiana State University Health Sciences Center New Orleans"},{"author_name":"Jason C. Brainard","author_inst":"University of Colorado Anschutz School of Medicine"},{"author_name":"David J. Douin","author_inst":"University of Colorado Anschutz School of Medicine"},{"author_name":"Derek W. Russell","author_inst":"University of Alabama at Birmingham Heersink School of Medicine"},{"author_name":"Shekhar A. Ghamande","author_inst":"Baylor Scott & White Medical Center Temple"},{"author_name":"Karen E. Jackson","author_inst":"Rush University Medical Center"},{"author_name":"Thomas Alcorn","author_inst":"Rush University Medical Center"},{"author_name":"Shannon M. Alwood","author_inst":"Louisiana State University Health Sciences Center New Orleans; Our Lady of the Lake Regional Medical Center"},{"author_name":"Jason Kirincich","author_inst":"David Geffen School of Medicine at UCLA"},{"author_name":"Andrew P. Bartuska","author_inst":"Stanford University School of Medicine"},{"author_name":"Emily K. Bowery","author_inst":"University of Colorado Anschutz School of Medicine"},{"author_name":"Nicholas Sachs","author_inst":"University of Maryland School of Medicine"},{"author_name":"Micah R. Whitson","author_inst":"University of Alabama at Birmingham Heersink School of Medicine"},{"author_name":"Alex P. Brueder","author_inst":"Ochsner Health"},{"author_name":"Amy L. Martin","author_inst":"Hennepin County Medical Center"},{"author_name":"Jonathan C. Henricks","author_inst":"The Ohio State University"},{"author_name":"Pranjal B. Gupta","author_inst":"Stanford University School of Medicine"},{"author_name":"Oscar A. Estrada Paz","author_inst":"David Geffen School of Medicine at UCLA"},{"author_name":"Jessica A. Palakshappa","author_inst":"Wake Forest University School of Medicine"},{"author_name":"Michael S. Char","author_inst":"Lahey Clinic and UMass Chan-Lahey School of Medicine"},{"author_name":"Kami M. Hu","author_inst":"University of Maryland School of Medicine"},{"author_name":"David A. Rayburn","author_inst":"Louisiana State University Health Sciences Center New Orleans"},{"author_name":"Aaron Trimble","author_inst":"Oregon Health & Science University"},{"author_name":"Yasin A. Khan","author_inst":"Tulane University School of Medicine"},{"author_name":"Vijay Krishnamoorthy","author_inst":"Duke University School of Medicine"},{"author_name":"Nicholas Raush","author_inst":"Lady of the Lake Regional Medical Center; Louisiana State University Health Sciences Center New Orleans"},{"author_name":"Franklin L. Wright","author_inst":"University of Colorado Anschutz School of Medicine"},{"author_name":"Samuel D. Gilliland","author_inst":"University of Colorado Anschutz School of Medicine"},{"author_name":"Lauren Daley","author_inst":"University of Alabama at Birmingham Heersink School of Medicine"},{"author_name":"Adit A. Ginde","author_inst":"University of Colorado Anschutz School of Medicine"},{"author_name":"Ariel A. Lewis","author_inst":"Vanderbilt Institute for Clinical and Translational Research"},{"author_name":"Todd W. Rice","author_inst":"Vanderbilt Institute for Clinical and Translational Research; Vanderbilt Health"},{"author_name":"Wesley H. Self","author_inst":"Vanderbilt Health; Vanderbilt Institute for Clinical and Translational Research"},{"author_name":"Brant Imhoff","author_inst":"Vanderbilt Health"},{"author_name":"Li Wang","author_inst":"Vanderbilt Health"},{"author_name":"Matthew E. Prekker","author_inst":"Hennepin County Medical Center"},{"author_name":"Brian E. Driver","author_inst":"Hennepin County Medical Center"},{"author_name":"Jonathan D. Casey","author_inst":"Vanderbilt Health; Vanderbilt Institute for Clinical and Translational Research"},{"author_name":"Stacy A. Trent","author_inst":"Denver Health Medical Center; University of Colorado Anschutz School of Medicine"}],"rel_date":"2026-11-13","rel_site":"medrxiv"}]}